INVACARE (IVCRQ) 10-K 3 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 01, 2016	Jun. 30, 2015
Entity Information [Line Items]
Entity Registrant Name	INVACARE CORPORATION
Entity Central Index Key	742,112
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 660,426,735
Common Stock
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		31,834,488
Class B Common Shares
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		733,309

Consolidated Statement Of Compr

Consolidated Statement Of Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net sales		$ 1,142,338	$ 1,270,163	$ 1,334,505
Cost of products sold		829,514	922,775	967,079
Gross Profit		312,824	347,388	367,426
Selling, general and administrative expenses		319,847	383,913	397,332
Charges related to restructuring activities		1,971	11,112	9,336
Asset write-downs to intangible assets		0	13,041	1,523
Interest expense		2,911	3,039	3,078
Interest income		(165)	(507)	(384)
Loss from Continuing Operations Before Income Taxes		(11,740)	(63,210)	(43,459)
Income taxes		14,710	5,550	10,875
Net Loss from Continuing Operations		(26,450)	(68,760)	(54,334)
Net earnings from discontinued operations (net of tax of $0; $1,200 and $2,235)		0	1,596	6,442
Gain on sale (net of tax of $140; $5,975 and $1,220)		260	11,094	80,943
Total Net Earnings from Discontinued Operations		260	12,690	87,385
Net Earnings (loss)		$ (26,190)	$ (56,070)	$ 33,051
Net Earnings (loss) per Share—Basic:
Net loss from continuing operations - Basic (in dollars per share)		$ (0.82)	$ (2.15)	$ (1.70)
Net earnings (loss) from discontinued operations - Basic (in dollars per share		0.01	0.40	2.74
Net Earnings (loss) per Share - Basic (in dollars per share)		$ (0.81)	$ (1.75)	$ 1.04
Weighted Average Shares Outstanding - Basic (in shares)		32,171	32,009	31,915
Net Earnings (loss) per Share—Assuming Dilution:
Net loss from continuing operations assuming dilution (in dollars per share)	[1]	$ (0.82)	$ (2.15)	$ (1.70)
Net earnings (loss) from discontinued operations assuming dilution (in dollars per share)		0.01	0.39	2.73
Net Earnings (loss) per Share - Assuming Dilution (in dollars per share)	[1]	$ (0.81)	$ (1.75)	$ 1.03
Weighted Average Shares Outstanding - Assuming Dilution (in shares)		32,683	32,197	32,043
Other comprehensive income (loss):
Foreign currency translation adjustments		$ (81,404)	$ (51,508)	$ 10,969
Defined benefit plans:
Amortization of prior service costs and unrecognized gains (losses)		(1,375)	(2,178)	1,771
Amounts arising during the year, primarily addition of new participants		(784)	0	(320)
Deferred tax adjustment resulting from defined benefit plan activity		(44)	213	(355)
Valuation reserve (reversal) associated with defined benefit plan activity		47	(222)	275
Current period gain (loss) on cash flow hedges		2,731	244	83
Deferred tax benefit (loss) related to gain (loss) on cash flow hedges		(177)	(86)	(10)
Other Comprehensive Income (Loss)		(81,006)	(53,537)	12,413
Comprehensive Income (Loss)		$ (107,196)	$ (109,607)	$ 45,464
[1]	Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss.

Consolidated Statement of Comp3

Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Income Tax Expense (Benefit), Discontinued Operations	$ 0	$ 1,200	$ 2,235
Income Tax Expense (Benefit) on Gain (Loss), Discontinued Operations	$ 140	$ 5,975	$ 1,220

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 60,055	$ 38,931
Trade receivables, net	133,655	154,207
Installment receivables, net	1,145	1,054
Inventories, net	132,807	155,561
Deferred income taxes	0	2,048
Other current assets	34,459	36,798
Disposal Group, Including Discontinued Operation, Assets, Current	0	17,388
Total Current Assets	362,121	405,987
Other Assets	4,659	19,053
Intangibles	31,000	38,013
Property and Equipment, net	78,683	79,659
Goodwill	361,680	421,019
Total Assets	838,143	963,731
Current Liabilities
Accounts payable	105,608	119,927
Accrued expenses	122,420	155,699
Current taxes, payable and deferred	17,588	12,634
Short-term debt and current maturities of long-term obligations	2,028	959
Disposal Group, Including Discontinued Operation, Liabilities	0	1,013
Total Current Liabilities	247,644	290,232
Long-Term Debt	45,092	19,372
Other Long-Term Obligations	82,589	88,805
Shareholders’ Equity
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	247,022	240,743
Retained earnings	310,583	338,362
Accumulated other comprehensive earnings	(9,387)	71,619
Treasury shares (3,194 and 3,187 shares in 2015 and 2014, respectively)	(94,399)	(94,265)
Total Shareholders’ Equity	462,818	565,322
Total Liabilities and Shareholders’ Equity	838,143	963,731
Common Shares (Authorized 100,000 shares; 35,024 and 34,219 issued in 2015 and 2014, respectively)—no par
Shareholders’ Equity
Common shares	8,815	8,591
Class B Common Shares (Authorized 12,000 shares; 734 and 1,085 issued and outstanding in 2015 and 2014)—no par
Shareholders’ Equity
Common shares	184	272
Total Shareholders’ Equity	$ 184	$ 272

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands	Dec. 31, 2015	Dec. 31, 2014
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	3,194	3,187
Common Stock
Common Stock, Shares Authorized	100,000	100,000
Common Stock, Shares, Issued	35,024	34,219
Class B Common Shares
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	734	1,085

Consolidated Statement Of Cash

Consolidated Statement Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Activities
Net earnings (loss)	$ (26,190)	$ (56,070)	$ 33,051
Adjustments to reconcile net earnings to net cash provided by operating activities:
Gain on sale of business (pre-tax)	(424)	(17,069)	(82,163)
Depreciation and amortization	19,430	32,789	36,789
Provision for losses on trade and installment receivables	754	1,775	3,689
Provision (benefit) for deferred income taxes	3,588	(2,387)	2,017
Provision (benefit) for other deferred liabilities	266	1,393	(146)
Provision for stock-based compensation	4,013	5,626	5,957
Loss on disposals of property and equipment	5,135	1,074	666
Asset write-downs to intangible assets	0	13,041	1,523
Asset write-downs related to restructuring activities	0	1,163	0
Amortization of convertible debt discount	796	710	633
Changes in operating assets and liabilities:
Trade receivables	9,164	17,211	9,706
Installment sales contracts, net	283	15	(3,773)
Inventories	11,610	(9,527)	23,797
Other current assets	5,283	1,950	(2,070)
Accounts payable	(7,240)	8,329	(19,013)
Accrued expenses	(22,003)	34,113	1,396
Other long-term liabilities	(9,843)	(25,244)	(2,005)
Net Cash (Used) Provided by Operating Activities	(5,378)	8,892	10,054
Investing Activities
Purchases of property and equipment	(7,522)	(12,327)	(14,158)
Proceeds from sale of property and equipment	23,117	2,521	885
Proceeds from sale of businesses	13,700	21,870	187,552
Decrease in other long-term assets	15,003	20,949	1,001
Other	78	569	65
Net Cash Provided for Investing Activities	44,376	33,582	175,345
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	219,603	255,658	352,455
Payments on revolving lines of credit and long-term borrowings	(232,808)	(286,712)	(545,874)
Proceeds from exercise of equity awards	2,402	480	512
Payment of financing costs	(1,954)	0	0
Payment of dividends	(1,589)	(1,584)	(1,581)
Net Cash Used by Financing Activities	(14,346)	(32,158)	(194,488)
Effect of exchange rate changes on cash	(3,528)	(1,170)	83
Increase (decrease) in cash and cash equivalents	21,124	9,146	(9,006)
Cash and cash equivalents at beginning of year	38,931	29,785	38,791
Cash and cash equivalents at end of year	$ 60,055	$ 38,931	$ 29,785

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Class B Common Stock	Additional Paid-in- Capital	Retained Earnings	Accumulated Other Comprehensive Earnings	Treasury Stock	Class B Common Shares
Beginning Balance at Dec. 31, 2012	$ 620,989	$ 8,503		$ 228,187	$ 364,546	$ 112,743	$ (93,262)	$ 272
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	512	7		505
Non-qualified stock option expense	3,925			3,925
Restricted stock awards	1,500	29		2,003			(532)
Net earnings (loss)	33,051				33,051
Foreign currency translation adjustments	10,969					10,969
Unrealized gain on cash flow hedges	73					73
Defined benefit plans:
Amortization of prior service costs and unrecognized losses and credits	1,691					1,691
Amounts arising during the year, primarily due to the addition of new participants	(320)					(320)
Comprehensive Income (Loss)	45,464
Dividends	(1,581)				(1,581)
Ending Balance at Dec. 31, 2013	670,809	8,539		234,620	396,016	125,156	(93,794)	272
Stock Issued During Period, Deferred Equity Compensation	69
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	480	8		472
Non-qualified stock option expense	3,356			3,356
Restricted stock awards	1,799	44		2,226			(471)
Net earnings (loss)	(56,070)				(56,070)
Foreign currency translation adjustments	(51,508)					(51,508)
Unrealized gain on cash flow hedges	158					158
Defined benefit plans:
Amortization of prior service costs and unrecognized losses and credits	(2,187)					(2,187)
Comprehensive Income (Loss)	(109,607)
Dividends	(1,584)				(1,584)
Ending Balance at Dec. 31, 2014	565,322	8,591		240,743	338,362	71,619	(94,265)	272
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	2,402	43		2,359
Non-qualified stock option expense	1,228			1,228
Restricted stock awards	2,651	93		2,692			(134)
Conversion from Class B Stock to Common Stock	0	88	$ (88)
Net earnings (loss)	(26,190)				(26,190)
Foreign currency translation adjustments	(81,404)					(81,404)
Unrealized gain on cash flow hedges	2,554					2,554
Defined benefit plans:
Amortization of prior service costs and unrecognized losses and credits	(1,372)					(1,372)
Amounts arising during the year, primarily due to the addition of new participants	(784)					(784)
Comprehensive Income (Loss)	(107,196)
Dividends	(1,589)				(1,589)
Ending Balance at Dec. 31, 2015	$ 462,818	$ 8,815		$ 247,022	$ 310,583	$ (9,387)	$ (94,399)	$ 184

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Accounting Policies	Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home based upon the company’s distribution channels, breadth of product line and net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and continuing care markets. Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of December 31, 2015 and the results of its operations and changes in its cash flow for the years ended December 31, 2015 , 2014 and 2013 , respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a November 30 fiscal year end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company’s financial statements. All significant intercompany transactions are eliminated. Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates. Accounts Receivable: The company records accounts receivable when product ships or services are provided to its unaffiliated customers, risk of loss is passed and title is transferred. The estimated allowance for uncollectible amounts is based primarily on management's evaluation of the financial condition of specific customers. The company records accounts receivable reserves for amounts that may become uncollectible in the future. The company writes off accounts receivable when it becomes apparent, based upon customer circumstances, that such amounts will not be collected and legal remedies are exhausted. Inventories: Inventories are stated at the lower of cost or market with cost determined by the first-in, first-out method. Market values are based on the lower of replacement cost or estimated net realizable value. Finished goods and work in process inventories include material, labor and manufacturing overhead costs. Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management’s review of inventories on hand compared to estimated future usage and sales. Property and Equipment: Property and equipment are stated on the basis of cost. The company principally uses the straight-line method of depreciation for financial reporting purposes based on annual rates sufficient to amortize the cost of the assets over their estimated useful lives. Machinery and equipment as well as furniture and fixtures are generally depreciated using lives of 3 to 10 years, while buildings and improvements are depreciated using lives of 5 to 40 years. Accelerated methods of depreciation are used for federal income tax purposes. Expenditures for maintenance and repairs are charged to expense as incurred. Amortization of assets under capital leases is included in depreciation expense. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An asset would be considered impaired when the future net undiscounted cash flows generated by the asset are less than its carrying value. An impairment loss would be recognized based on the amount by which the carrying value of the asset exceeds its fair value. Goodwill and Other Intangibles: In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill and indefinite lived intangibles are subject to annual impairment testing. For purposes of the goodwill impairment test, the fair value of each reporting unit is estimated by forecasting cash flows and discounting those cash flows using appropriate discount rates. The fair values are then compared to the carrying value of the net assets of each reporting unit. Intangibles assets are also reviewed for impairment by estimating forecasted cash flows and discounting those cash flows as needed to calculate impairment amounts. During 2014, the company recognized intangible write-down charges of $13,041,000 comprised of a customer list impairment of $12,826,000 and a non-compete agreement impairment of $215,000 each recorded in the IPG segment. During 2013, the company recognized intangible write-down charges of $1,523,000 comprised of: trademarks with indefinite lives impairment of $568,000 , a trademark with a definite life impairment of $123,000 , customer list impairment of $442,000 and a developed technology impairment of $223,000 each recorded in the IPG segment and a customer list impairment of $167,000 recorded in the North America/HME segment. Accrued Warranty Cost: Generally, the company’s products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sale to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company’s warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. See Current Liabilities in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual. Product Liability Cost: The company is self-insured in North America for product liability exposures through its captive insurance company, Invatection Insurance Company, which currently has a policy year that runs from September 1 to August 31 and insures annual policy losses up to $10,000,000 per occurrence and $13,000,000 in the aggregate. The company also has additional layers of external insurance coverage, related to all lines of insurance coverage, insuring up to $75,000,000 in aggregate losses per policy year arising from individual claims anywhere in the world that exceed the captive insurance company policy limits or the limits of the company’s per country foreign liability limits, as applicable. There can be no assurance that Invacare’s current insurance levels will continue to be adequate or available at affordable rates. Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and other indicators. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the company in estimating the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, that the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate. Estimates made are adjusted on a regular basis and can be impacted by actual loss awards and settlements on claims. While actuarial analysis is used to help determine adequate reserves, the company is responsible for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices. Revenue Recognition: Invacare’s revenues are recognized when products are shipped or service provided to unaffiliated customers, risk of loss is passed and title is transferred. Revenue Recognition , ASC 605, provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. Shipping and handling costs are included in cost of goods sold. Sales are made only to customers with whom the company believes collection is reasonably assured based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts. The company offers discounts and rebates, which are accounted for as reductions to revenue in the period in which the sale is recognized. Discounts offered include: cash discounts for prompt payment, base and trade discounts based on contract level for specific classes of customers. Volume discounts and rebates are given based on large purchases and the achievement of certain sales volumes. Product returns are accounted for as a reduction to reported sales with estimates recorded for anticipated returns at the time of sale. The company does not sell any goods on consignment. Distributed products sold by the company are accounted for in accordance with the revenue recognition guidance in ASC 605-45-05 . The company records distributed product sales gross as a principal since the company takes title to the products and has the risks of loss for collections, delivery and returns. Product sales that give rise to installment receivables are recorded at the time of sale when the risks and rewards of ownership are transferred. As such, interest income is recognized based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments, interest income is no longer recognized. All installment accounts are accounted for using the same methodology, regardless of duration of the installment agreements. The company has entered into an agreement with De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to Invacare customers. Research and Development: Research and development costs are expensed as incurred and included in cost of products sold. The company’s annual expenditures for product development and engineering were approximately $18,677,000 , $23,149,000 and $24,075,000 for 2015 , 2014 and 2013 , respectively. Advertising: Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising expenses amounted to $9,203,000 , $13,463,000 and $15,026,000 for 2015 , 2014 and 2013 , respectively, the majority of which is incurred for advertising in the United States and Europe. Income Taxes: The company uses the liability method in measuring the provision for income taxes and recognizing deferred tax assets and liabilities on the balance sheet. The liability method requires that deferred income taxes reflect the tax consequences of currently enacted rates for differences between the tax and financial reporting bases of assets and liabilities. With the exception of two subsidiaries, foreign subsidiaries with undistributed earnings are considered to have such earnings indefinitely reinvested and, accordingly with the exception of the two subsidiaries, no deferred tax liability has been provided for future repatriation of $24,100,000 of unremitted earnings of these foreign subsidiaries. The amount of the unrecognized deferred tax liability for temporary differences related to investments in foreign subsidiaries that are permanently reinvested is not practically determinable. The company has recorded the deferred tax impact of the unremitted earnings of the two subsidiaries for which the earnings are not permanently reinvested. Value Added Taxes: The company operates internationally and is required to comply with value added tax (VAT) or goods and service tax (GST) regulations, particularly in Europe and Asia/Pacific. VAT and GST are taxes on consumption in which the company pays tax on its purchases of goods and services and charges customers on the sale of product. The difference between billings to customers and payments on purchases is then remitted or received from the government as filings are due. The company records tax assets and liabilities related to these taxes and the balances in these accounts can vary significantly from period to period based on the timing of the underlying transactions. Derivative Instruments: Derivatives and Hedging, ASC 815, requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. Foreign Currency Translation: The functional currency of the company’s subsidiaries outside the United States is the applicable local currency. The assets and liabilities of the company’s foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Revenues and expenses are translated at monthly average exchange rates. Gains and losses resulting from translation of balance sheet items are included in accumulated other comprehensive earnings. Net Earnings Per Share: Basic earnings per share are computed based on the weighted-average number of Common Shares and Class B Common Shares outstanding during the year. Diluted earnings per share are computed based on the weighted-average number of Common Shares and Class B Common Shares outstanding plus the effects of dilutive stock options and awards outstanding during the year. Diluted earnings per share can potentially be impacted by the convertible notes issued in 2007 should the conditions be met to make the notes convertible or if average market price of company stock for the period exceeds the conversion price of $24.79 . For periods in which there was a net loss, loss per share assuming dilution utilized weighted average shares-basic. Defined Benefit Plans: The company’s benefit plans are accounted for in accordance with Compensation-Retirement Benefits , ASC 715 which requires plan sponsors to recognize the funded status of their defined benefit postretirement benefit plans in the consolidated balance sheet, measure the fair value of plan assets and benefit obligations as of the balance sheet date and to recognize changes in that funded status in the year in which the changes occur through comprehensive income. Reclassifications: In May 2015, the company's board of directors authorized the sale of the company's former rentals businesses. Accordingly, the rentals businesses were treated as held for sale. The company's December 31, 2014 Balance Sheet was restated to reflect this treatment. See Operations Held for Sale in the Notes to the Consolidated Financial Statements for a description of the impact on the consolidated balance sheet. Recent Accounting Pronouncements: In April 2014, the FASB issued ASU 2014-08 changing the presentation of discontinued operations on the statements of income and other requirements for reporting discontinued operations. Under the new standard, a disposal of a component or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the component meets the criteria to be classified as held for sale or is disposed. The amendments in this update also require additional disclosures about discontinued operations and disposal of an individually significant component of an entity that does not qualify for discontinued operations. This standard must be prospectively applied to all reporting periods presented in financial reports issued after the effective date. Early adoption was permitted for disposals that were not reported in financial statements previously issued or available for issuance. The new accounting guidance was effective for interim and annual periods beginning after December 15, 2014. This standard can impact the presentation of the company's financial statements but does not affect the calculation of net income, comprehensive income or earnings per share. The company adopted ASU 2014-08 effective January 1, 2015 which impacted the company’s Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets and Statement of Cash Flows. Specifically, the disposal of the United States Rentals businesses, in the third quarter of 2015, was not deemed to be a discontinued operation. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers." ASU 2014-09 requires a company to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. The guidance requires five steps to be applied: 1) identify the contract(s) with customers, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligation in the contract and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also requires both quantitative and qualitative disclosures, which are more comprehensive than existing revenue standards. The disclosures are intended to enable financial statement users to understand the nature, timing and uncertainty of revenue and the related cash flow. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospective with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new accounting guidance is effective for annual periods beginning after December 15, 2017, due to an approved one-year deferral, and early adoption is not permitted. The company is currently reviewing the impact of the adoption of ASU 2014-09 on the company's financial statements. In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 requires debt issuance costs to be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability, which is similar presentation of debt discounts or premiums. Debt issuance costs are currently reported on the balance sheet as assets and amortized as interest expense. ASU 2015-03 does not change the recognition and measurement guidance for debt issuance costs and requires retrospective application to all periods presented upon adoption. The new accounting guidance is effective for fiscal periods beginning after December 15, 2015 and early adoption is permitted. The company has determined the adoption of ASU 2015-03 will not have a material impact on the company's financial statements. In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory,” to simplify the subsequent measurement of inventory. Entities are now required to subsequently measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market. This update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, and early adoption is permitted. The company is currently reviewing the impact of the adoption of ASU 2015-11 on the company's financial statements. In November 2015, the FASB issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes." ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent amounts on the balance sheet. The new accounting guidance is effective for fiscal periods beginning after December 15, 2016 and early adoption is permitted. The company adopted ASU 2015-17, on a prospective basis, effective October 1, 2015 and thus the company's deferred tax assets and liabilities have been classified as long-term in its Balance Sheet as of December 31, 2015. No prior periods were retrospectively adjusted. In February 2016, the FASB issued ASU 2016-02, "Leases." ASU 2016-02 requires lessees to put most leases on their balance sheet while recognizing expense in a manner similar to existing accounting. The new accounting guidance is effective for fiscal periods beginning after December 15, 2018 and early adoption is permitted. The company is currently reviewing the impact of the adoption of ASU 2016-02 on the company's financial statements.

Operations Held for Sale (Notes

Operations Held for Sale (Notes)	12 Months Ended
	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operations	Operations Held for Sale On May 14, 2015 , the company's board of directors authorized the company and Invacare Continuing Care, Inc., a Missouri Corporation and wholly-owned subsidiary of the company ("ICC") to enter into an agreement to sell all the issued and outstanding membership interests of Dynamic Medical Systems, LLC, a Nevada limited liability company, and Invacare Outcomes Management, LLC, a Delaware limited liability company, each a wholly-owned subsidiary of ICC (“collectively the rentals businesses”). The company determined on that date that the "held for sale" criteria of ASC 360-10-45-9 were met, and accordingly, the assets and liabilities of the rentals businesses (long-lived asset disposal group) were shown at their carrying amounts, which approximate their fair values. The rentals businesses had been operated on a stand-alone basis and reported as part of the Institutional Products Group (IPG) segment of the company. On July 2, 2015 , ICC completed the sale (the "Transaction") of all the issued and outstanding membership interests in the rentals businesses, pursuant to a Membership Interest Purchase Agreement (the “Purchase Agreement”) among the company, ICC and Joerns Healthcare Parent, LLC, a Delaware limited liability company. The price paid to ICC for the rentals businesses was approximately $15,500,000 in cash, which was subject to certain post-closing adjustments required by the Purchase Agreement. Net proceeds from the Transaction were approximately $13,700,000 , net of taxes and expenses. The company recorded a pre-tax gain of approximately $24,000 in the third quarter of 2015, which represents the excess of the net sales price over the book value of the assets and liabilities of the rentals businesses, as of the date of completion of the disposition. The company recorded expenses related to the sale of the rentals businesses totaling $1,792,000 , of which $1,244,000 have been paid as of December 31, 2015 . The sale of the rentals businesses was not dilutive to the company's results. The company utilized the net proceeds from the sale to reduce debt outstanding under its credit agreement. The company determined that the sale of the rentals businesses did not meet the criteria for classification as a discontinued operation in accordance with ASU 2014-08. The rentals businesses were treated as held for sale as of June 30, 2015 until sold on July 2, 2015 . As a result, the December 31, 2014 Balance Sheet was restated to reflect this treatment. The assets and liabilities of the rentals businesses that were sold and shown as held for sale in the company's Consolidated Balance Sheets were comprised of the following (in thousands): July 2, December 31, Trade receivables, net $ 5,834 $ 6,207 Inventories, net 412 315 Other current assets 212 221 Property and equipment, net 4,126 5,896 Goodwill 4,518 4,692 Intangibles 40 57 Assets sold $ 15,142 $ 17,388 Accounts payable $ 410 $ 225 Accrued expenses and other short-term obligations 1,056 788 Liabilities sold $ 1,466 $ 1,013

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On December 21, 2012 , in order to focus on its core equipment product lines, the company entered into an agreement to sell ISG and determined on that date that the "held for sale" criteria of ASC 360-10-45-9 were met. On January 18, 2013 , the company completed the sale of the ISG medical supplies business to AssuraMed, Inc. for a purchase price of $150,800,000 in cash. ISG had been operated on a stand-alone basis and reported as a reportable segment of the company. The company recorded a gain of $59,402,000 pre-tax in 2013 which represented the excess of the net sales price over the book value of the assets and liabilities of ISG, excluding cash. The sale of this business is dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the first quarter of 2013. In 2013, the net sales of the discontinued operation of ISG were $18,498,000 and earnings before income taxes were $402,000 , On August 6, 2013 , the company sold Champion, its domestic medical recliner business for dialysis clinics, to Champion Equity Holdings, LLC for $45,000,000 in cash, which was subject to final post-closing adjustments. Champion had been operated on a stand-alone basis and reported as part of the IPG segment of the company. The company recorded a gain of $22,761,000 pre-tax in the third quarter of 2013, which represented the excess of the net sales price over the book value of the assets and liabilities of Champion. The sale of this business was dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the third quarter of 2013. The gain recorded by the company reflects the company's estimated final purchase adjustments. In 2013, the net sales of the discontinued operation of Champion were $15,857,000 and earnings before income taxes were $3,156,000 . Results for Champion include an interest expense allocation from continuing operations to discontinued operations of $449,000 in 2013, as proceeds from the sale were required to be utilized to pay down debt. The interest allocation was based on the net proceeds assumed to pay down debt applying the company's average interest rates for the periods presented. In addition, in accordance with ASC 350, when a portion of a reporting entity that constitutes a business is disposed of, goodwill associated with that business should be included in the carrying amount of the net assets of the business sold in determining the gain or loss on the disposal. As such, the company allocated additional goodwill of $16,205,000 to Champion from the continuing operations of the IPG segment based on the relative fair value of Champion as compared to the remaining IPG reporting unit. On August 29, 2014 , the company sold Altimate Medical, Inc. (Altimate), its manufacturer of stationary standing assistive devices for use in patient rehabilitation, to REP Acquisition Corporation for $23,000,000 in cash, which was subject to final post-closing adjustments. Altimate had been operated on a stand-alone basis and reported as part of the North America/HME segment of the company. The company recorded a gain of $17,069,000 pre-tax in the third quarter of 2014, which represented the excess of the net sales price over the book value of the assets and liabilities of Altimate. The sale of this business was dilutive to the company's results. The company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the third quarter of 2014. The gain recorded by the company reflects the company's estimated final purchase adjustments. The assets and liabilities of Altimate were the following as of the date of the sale, August 29, 2014 , and as of December 31, 2013 (in thousands): August 29, Trade receivables, net $ 2,019 Inventories, net 1,954 Other current assets 246 Property and equipment, net 176 Other Intangibles 1,047 Assets sold $ 5,442 Accounts payable $ 425 Accrued expenses 316 Liabilities sold $ 741 The net sales of the Altimate discontinued operations were $11,778,000 and $17,854,000 for 2014 and 2013, respectively, and earnings before income taxes were $2,796,000 and $5,118,000 , respectively for the same periods. Results for Altimate include an interest expense allocation from continuing operations to discontinued operations of $202,000 and $323,000 for 2014 and 2013, respectively, as proceeds from the sale were required to be utilized to pay down debt. The interest allocation was based on the net proceeds assumed to pay down debt applying the company's average interest rates for the periods presented. The company recorded total expenses related to the discontinued operations noted above of $8,801,000 , of which $8,405,000 were paid as of December 31, 2015 . The company recorded an incremental intra-period tax allocation expense to discontinued operations for 2015, 2014 and 2013 representing the cumulative intra-period allocation expense to discontinued operations based on the company's domestic taxable loss related to continuing operations for 2015, 2014 and 2013. The company has classified ISG, Champion and Altimate as a discontinued operations for all periods presented.

Receivables

Receivables	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Receivables	Receivables Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand, China and Europe. A significant portion of products sold to providers, both foreign and domestic, are ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts ($ 10,487,000 in 2015 and $11,970,000 in 2014 ) is based primarily on management’s evaluation of the financial condition of specific customers. In addition, as a result of the company's financing arrangement with DLL, a third party financing company which the company has worked with since 2000, management monitors the collection status of these contracts in accordance with the company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet. The company’s U.S. customers electing to finance their purchases can do so using DLL. In addition, the company often provides financing directly for its Canadian customers for which DLL is not an option, as DLL typically provides financing to Canadian customers only on a limited basis. The installment receivables recorded on the books of the company represent a single portfolio segment of finance receivables to the independent provider channel and long-term care customers. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by 3 payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by the company because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for twelve months and historically have had a very low risk of default. The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the company’s ability to enforce judgments, liens, etc. For purposes of granting or extending credit, the company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for most customers desiring credit greater than $250,000 , which generally includes a detailed review of the customer’s financials as well as consideration of other factors such as exposure to changing reimbursement laws. Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the company goes through a legal process for pursuing collection of outstanding amounts, the length of which typically approximates eighteen months . Any write-offs are made after the legal process has been completed. The company has not made any changes to either its accounting policies or methodology to estimate allowances for doubtful accounts in the last twelve months. Installment receivables as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Current Long- Term Total Current Long- Term Total Installment receivables $ 2,309 $ 2,318 $ 4,627 $ 2,692 $ 5,117 $ 7,809 Less: Unearned interest (42 ) — (42 ) (46 ) — (46 ) 2,267 2,318 4,585 2,646 5,117 7,763 Allowance for doubtful accounts (1,122 ) (1,670 ) (2,792 ) (1,592 ) (4,260 ) (5,852 ) $ 1,145 $ 648 $ 1,793 $ 1,054 $ 857 $ 1,911 Installment receivables purchased from DLL during the twelve months ended December 31, 2015 increased the gross installment receivables balance by $936,000 during the year compared to $2,123,000 in 2014 . No sales of installment receivables were made by the company during the year. The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): 2015 2014 Balance as of January 1 $ 5,852 $ 6,039 Current period (benefit) provision (332 ) 796 Direct write-offs charged against the allowance (2,728 ) (983 ) Balance as of December 31 $ 2,792 $ 5,852 Installment receivables by class as of December 31, 2015 consist of the following (in thousands): Total Installment Receivables Unpaid Principal Balance Related Allowance for Doubtful Accounts Interest Income Recognized U.S. Impaired installment receivables with a related allowance recorded $ 3,618 $ 3,618 $ 2,729 $ — Canada Non-Impaired installment receivables with no related allowance recorded 946 904 — 52 Impaired installment receivables with a related allowance recorded 63 63 63 — Total Canadian installment receivables $ 1,009 $ 967 $ 63 $ 52 Total Non-Impaired installment receivables with no related allowance recorded 946 904 — 52 Impaired installment receivables with a related allowance recorded 3,681 3,681 2,792 — Total installment receivables $ 4,627 $ 4,585 $ 2,792 $ 52 Installment receivables by class as of December 31, 2014 consist of the following (in thousands): Total Installment Receivables Unpaid Principal Balance Related Allowance for Doubtful Accounts Interest Income Recognized U.S. Impaired installment receivables with a related allowance recorded $ 6,735 $ 6,735 $ 5,786 $ — Canada Non-Impaired installment receivables with no related allowance recorded 1,008 962 — 82 Impaired installment receivables with a related allowance recorded 66 66 66 — Total Canadian installment receivables $ 1,074 $ 1,028 $ 66 $ 82 Total Non-Impaired installment receivables with no related allowance recorded 1,008 962 — 82 Impaired installment receivables with a related allowance recorded 6,801 6,801 5,852 — Total installment receivables $ 7,809 $ 7,763 $ 5,852 $ 82 Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of December 31, 2015 , the company had no U.S. installment receivables past due of 90 days or more for which the company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement. In Canada, the company had an immaterial amount of installment receivables which were past due of 90 days or more as of December 31, 2015 and December 31, 2014 for which the company is still accruing interest. The aging of the company’s installment receivables was as follows as of December 31, 2015 and 2014 (in thousands): December 31, 2015 December 31, 2014 Total U.S. Canada Total U.S. Canada Current $ 908 $ — $ 908 $ 976 $ — $ 976 0-30 days past due 16 — 16 15 — 15 31-60 days past due 12 — 12 2 — 2 61-90 days past due 1 — 1 — — — 90+ days past due 3,690 3,618 72 6,816 6,735 81 $ 4,627 $ 3,618 $ 1,009 $ 7,809 $ 6,735 $ 1,074

Inventories

Inventories	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories, net of reserves, as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Finished goods $ 67,207 $ 85,828 Raw materials 54,005 57,509 Work in process 11,595 12,224 $ 132,807 $ 155,561

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Current Assets	Other Current Assets Other current assets as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Value added tax receivables $ 18,031 $ 21,273 Recoverable income taxes 367 261 Derivatives (foreign currency forward contracts) 4,143 520 Prepaid insurance 2,538 2,713 Prepaid and other current assets 9,380 12,031 $ 34,459 $ 36,798

Other Long-Term Assets

Other Long-Term Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Long-Term Assets	Other Long-Term Assets Other long-term assets as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Cash surrender value of life insurance policies $ 1,674 $ 15,765 Deferred financing fees 1,088 408 Investments 160 249 Long-term installment receivables 648 857 Long-term deferred taxes 908 613 Other 181 1,161 $ 4,659 $ 19,053 The company sold life insurance policies of $11,902,000 and $21,338,000 in 2015 and 2014, respectively, to fund payments as the result of the retirement of certain executive officers of the company.

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property And Equipment	Property and Equipment Property and equipment as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Machinery and equipment $ 299,721 $ 318,286 Land, buildings and improvements 73,830 81,219 Furniture and fixtures 10,031 11,738 Leasehold improvements 11,966 14,517 395,548 425,760 Less allowance for depreciation (316,865 ) (346,101 ) $ 78,683 $ 79,659

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The carrying amount of goodwill by operating segment is as follows (in thousands): Institutional Products Group Europe Consolidated Balance at January 1, 2014 $ 31,615 $ 425,919 $ 457,534 Foreign currency translation adjustments (1,696 ) (34,819 ) (36,515 ) Balance at December 31, 2014 29,919 391,100 421,019 Foreign currency translation adjustments (2,763 ) (56,576 ) (59,339 ) Balance at December 31, 2015 $ 27,156 $ 334,524 $ 361,680 In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill is reviewed annually for impairment. The company first estimates the fair value of each reporting unit and compares the calculated fair value to the carrying value of each reporting unit. A reporting unit is defined as an operating segment or one level below. The company has determined that its reporting units are the same as its operating segments. The company completes its annual impairment tests in the fourth quarter of each year or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To estimate the fair values of the reporting units, the company utilizes a discounted cash flow method model in which the company forecasts income statement and balance sheet amounts based on assumptions regarding future sales growth, profitability, inventory turns, days' sales outstanding, etc. to forecast future cash flows. The cash flows are discounted using a weighted average cost of capital discount rate where the cost of debt is based on quoted rates for 20 -year debt of companies of similar credit risk and the cost of equity is based upon the 20 -year treasury rate for the risk free rate, a market risk premium, the industry average beta and a small cap stock adjustment. The discount rates used have a significant impact upon the discounted cash flow methodology utilized in the company's annual impairment testing as higher discount rates decrease the fair value estimates. The assumptions used are based on a market participant's point of view and yielded a discount rate of 9.41% in 2015 for the company's initial impairment analysis compared to 9.89% in 2014 and 10.00% in 2013 . The company also utilizes an Enterprise Value (EV) to Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) Method to compute the fair value of its reporting units which considers potential acquirers and their EV to EBITDA multiples adjusted by an estimated premium. While more weight is given to the discounted cash flow method, the EV to EBITDA Method does provide corroborative evidence of the reasonableness of the discounted cash flow method results. While there was no indication of impairment in 2015 related to goodwill for the Europe or IPG segments, a future potential impairment is possible for these segments should actual results differ materially from forecasted results used in the valuation analysis. Furthermore, the company's annual valuation of goodwill can differ materially if the market inputs used to determine the discount rate change significantly. For instance, higher interest rates or greater stock price volatility would increase the discount rate and thus increase the chance of impairment. In consideration of this potential, the company reviewed the results if the discount rate used were 100 basis points higher for the 2015 impairment analysis and determined that there still would not be an indicator of potential impairment for the Europe or IPG segments. As part of the company's review of goodwill for impairment, the company also considers the potential for impairment of any other assets. In 2015 , 2014 and 2013 , the company performed a review for potential impairments of any other assets, including the company's Taylor Street facility which is subject to the FDA consent decree that limits the company's manufacture and distribution of custom power and manual wheelchairs, wheelchair components and wheelchair subassemblies at the Taylor Street facility. The company determined there was no impairment of the property, plant and equipment of the Taylor Street facility based on a comparison of the forecasted undiscounted cash flows to the carrying value of the net assets in accordance with ASC 360. In addition, the company determined there was no impairment of net inventory associated with the facility.

Intangibles

Intangibles	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles	Intangibles All of the company’s other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $24,524,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2014 to December 31, 2015 were the result of foreign currency translation and amortization. The company’s intangibles consist of the following (in thousands): December 31, 2015 December 31, 2014 Historical Cost Accumulated Amortization Historical Cost Accumulated Amortization Customer lists $ 49,858 $ 45,019 $ 78,693 $ 71,343 Trademarks 24,524 — 28,314 — License agreements 1,098 1,098 1,290 1,290 Developed technology 7,405 5,921 8,297 6,340 Patents 5,959 5,843 6,102 5,804 Other 1,161 1,124 2,548 2,454 $ 90,005 $ 59,005 $ 125,244 $ 87,231 Amortization expense related to other intangibles was $1,907,000 , $20,358,000 and $10,567,000 for 2015 , 2014 and 2013 , respectively. Estimated amortization expense for each of the next five years is expected to be $1,626,000 for 2016 , $1,549,000 in 2017 , $1,530,000 in 2018 , $992,000 in 2019 and $184,000 in 2020 . Amortized intangibles are being amortized on a straight-line basis over remaining lives from 1 to 10 years with the majority of the intangibles being amortized over an average remaining life of approximately 5 years. In accordance with ASC 350, Intangibles—Goodwill and Other , the company reviews intangibles for impairment. The company's intangible assets consist of intangible assets with defined lives as well as intangible assets with indefinite lives. Defined-lived intangible assets consist principally of customer lists, developed technology, license agreements, patents and other miscellaneous intangibles such as non-compete agreements. The company's indefinite lived intangible assets consist entirely of trademarks. The company evaluates the carrying value of definite-lived assets whenever events or circumstances indicate possible impairment. Definite-lived assets are determined to be impaired if the future un-discounted cash flows expected to be generated by the asset are less than the carrying value. Actual impairment amounts for definite-lived assets are then calculated using a discounted cash flow calculation. The company reviews indefinite-lived assets for impairment annually in the fourth quarter of each year and whenever events or circumstances indicate possible impairment. Any impairment amounts for indefinite-lived assets are calculated as the difference between the future discounted cash flows expected to be generated by the asset less than the carrying value for the asset. During 2014, the company recognized intangible write-down charges in the IPG segment of $13,041,000 comprised of a customer list impairment of $12,826,000 and a non-compete agreement of $215,000 as the actual and remaining cash flows associated with the intangibles were less than the cash flows originally used to value the intangibles, primarily driven by reduced net sales. The after-tax and pre-tax impairment amounts were the same for each of the above impairments. During 2013, the company recognized intangible write-down charges of $1,523,000 comprised of: trademarks with indefinite lives impairment of $568,000 , a trademark with a definite life impairment of $123,000 , customer list impairment of $442,000 and developed technology impairment of $223,000 all recorded in the IPG segment and a customer list impairment of $167,000 recorded in the North America/HME segment. The after-tax and pre-tax impairment amounts were the same for each of the above impairments except for the indefinite-lived trademark impairment in the IPG segment, which was $496,000 after-tax. The fair values of the customer lists were calculated using an excess earnings method, using a discounted cash flow model. Estimated cash flow returns to the customer relationship were reduced by the cash flows required to satisfy the return requirements of each of the assets employed with the residual cash flow then discounted to value the customer list. The fair values of the trademarks and developed technology were calculated using a relief from royalty payment methodology which requires applying an estimated market royalty rate to forecasted net sales and discounting the resulting cash flows to determine fair value. The patent was impaired as the related product was discontinued.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued expenses as of December 31, 2015 and 2014 consisted of accruals for the following (in thousands): 2015 2014 Salaries and wages $ 41,305 $ 40,850 Taxes other than income taxes, primarily Value Added Taxes 21,424 24,743 Warranty cost 22,820 30,738 Supplemental Executive Retirement Plan (SERP) 1,279 21,517 Freight 6,153 6,202 Professional 5,774 6,613 Product liability, current portion 3,127 4,334 Rebates 1,791 1,722 Insurance 695 1,266 Interest 872 1,068 Derivatives (foreign currency forward exchange contracts) 2,014 2,526 Severance 2,477 4,209 Other items, principally trade accruals 12,689 9,911 $ 122,420 $ 155,699 As a result of the retirement of certain executives of the company during 2015, Supplemental Executive Retirement Program (SERP) and deferred compensation payments of $21,126,000 and $3,525,000 , respectively, were made in 2015. Accrued rebates relate to several volume incentive programs the company offers its customers. The company accounts for these rebates as a reduction of revenue when the products are sold in accordance with the guidance in ASC 605-50, C ustomer Payments and Incentives . Generally, the company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sales to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product field action and recalls, which could warrant additional warranty reserve provision. Changes in accrued warranty costs were as follows (in thousands): 2015 2014 Balance as of January 1 $ 30,738 $ 27,393 Warranties provided during the period 11,561 21,472 Settlements made during the period (17,817 ) (22,752 ) Changes in liability for pre-existing warranties during the period, including expirations (1,662 ) 4,625 Balance as of December 31 $ 22,820 $ 30,738 The company's warranty expense for 2015 includes reversals of $2,325,000 principally driven by a $2,000,000 reversal as a result of changes in the company's estimate of costs related to a recall for a component in a stationary oxygen concentrator that was manufactured in the company’s facility in Suzhou, China, and sold globally, which is no longer used in production. The company's warranty expense for 2014 includes $11,493,000 for three specific product issues. First, an expense of $6,559,000 for a recall related to a component in a stationary oxygen concentrator that was manufactured in the company’s facility in Suzhou, China, and sold globally, which is no longer used in production. This expense was recorded in the European segment ( $3,395,000 ) and North America/HME segment ( $3,164,000 ). Second, an expense of $2,057,000 for the recall of a sieve bed component used within stationary oxygen concentrators manufactured during August 2014, which was recorded in the North America/HME segment. Third, an incremental expense of $2,877,000 related to the company's joystick recall as a result of higher than previously anticipated response rates from larger customers in the U.S. and Canada and a shift in the product mix toward higher cost joysticks, which was recorded in the North America/HME segment ( $1,612,000 ) and the Asia/Pacific segment ( $1,265,000 ). These warranty reserves are subject to adjustment in future periods as new developments change the company's estimate of the total cost of these matters.

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Debt as of December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Senior secured revolving credit facility, due in October 2015 $ — $ 4,000 Convertible senior subordinated debentures at 4.125%, due in February 2027 12,147 11,351 Other notes and lease obligations 34,973 4,980 47,120 20,331 Less current maturities of long-term debt (2,028 ) (959 ) $ 45,092 $ 19,372 The company had outstanding letters of credit of $3,230,000 and $7,063,000 as of December 31, 2015 and 2014 , respectively. On September 30, 2015 the company entered into an Amended and Restated Revolving Credit and Security Agreement (the “Amended and Restated Credit Agreement”), amending and restating the company’s existing Revolving Credit and Security Agreement which was originally entered into on January 16, 2015 and amended on April 22, 2015 (the “Prior Credit Agreement”) and which matures in January 2018 . The Amended and Restated Credit Agreement was entered into by and among the company, certain of the company’s direct and indirect U.S. and Canadian subsidiaries and certain of the company’s European subsidiaries (together with the company, the “Borrowers”), certain other of the company’s direct and indirect U.S., Canadian and European subsidiaries (the “Guarantors”), and PNC Bank, National Association (“PNC”), JPMorgan Chase Bank, N.A., J.P. Morgan Europe Limited, KeyBank National Association, and Citizens Bank, National Association (the “Lenders”). PNC is the administrative agent (the “Administrative Agent”) and J.P. Morgan Europe Limited is the European agent (the “European Agent”) under the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement contains customary representations, warranties and covenants. Exceptions to the operating covenants in the Amended and Restated Credit Agreement provide the company with flexibility to, among other things, enter into or undertake certain sale and leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement also contains a covenant requiring the company to maintain minimum availability under the U.S. and Canadian Credit Facility of not less than the greater of (i) 11.25% of the maximum amount that may be drawn under the U.S. and Canadian Credit Facility for five ( 5 ) consecutive business days, or (ii) $10,000,000 on any business day (which amount was reduced to $5,000,000 pursuant to an amendment in February 2016 -- see “Subsequent Events”). The company also is subject to dominion triggers under the U.S. and Canadian Credit Facility (as defined below) requiring the company to maintain borrowing capacity of not less than $11,250,000 on any business day or $12,500,000 for five consecutive days in order to avoid triggering full control by an agent for the lenders of the company's cash receipts for application to the company’s obligations under the agreement. The Amended and Restated Credit Agreement contains customary default provisions, with certain grace periods and exceptions, which provide that events of default that include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption of any material manufacturing facilities for more than 10 consecutive days. The initial borrowings under the U.S. and Canadian Credit Facility were used to repay and terminate the company’s previous credit agreement, which was scheduled to mature in October 2015 . The Prior Credit Agreement was amended on April 22, 2015 to provide for certain technical amendments, including: (1) revising various provisions of the Prior Credit Agreement to allow the company to issue letters of credit denominated in foreign currencies other than those originally contemplated under the Prior Credit Agreement; and (2) amending certain covenants in the Prior Credit Agreement to permit the company (i) to make a single acquisition of assets of a third-party for cash consideration not to exceed $500,000 on or before September 30, 2015 and (ii) to accept surrenders of company shares by employees to facilitate the payment of tax withholding obligations in connection with employee equity compensation. In connection with entering into the Prior Credit Agreement and subsequent Amended and Restated Credit Agreement, the company incurred $1,954,000 in fees which were capitalized and are being amortized through January 2018. In addition, as a result of terminating the previous credit agreement, which was scheduled to mature in October 2015, the company wrote-off $668,000 in previously capitalized fees in the first quarter of 2015, which is reflected in the expense of the North America / HME segment. In comparison, the company wrote-off $1,070,000 in fees previously capitalized in the first quarter of 2014 as a result of a reduction in the borrowing capacity under the company's previous credit agreement, which was scheduled to mature in October 2015. U.S. and Canadian Borrowers Credit Facility For the company's U.S. and Canadian Borrowers, the Amended and Restated Credit Agreement provides for an asset-based-lending senior secured revolving credit facility which is secured by substantially all of the company’s U.S. and Canadian assets, other than real estate. The Amended and Restated Credit Agreement provides the company and the other Borrowers with a credit facility in an aggregate principal amount of $100,000,000 , subject to availability based on a borrowing base formula, under a senior secured revolving credit, letter of credit and swing line loan facility (the “U.S. and Canadian Credit Facility”). Up to $25,000,000 of the U.S. and Canadian Credit Facility will be available for issuance of letters of credit. The aggregate principal amount of the U.S. and Canadian Credit Facility may be increased by up to $25,000,000 to the extent requested by the company and agreed to by any Lender or new financial institution approved by the Administrative Agent. The aggregate borrowing availability under the U.S. and Canadian Credit Facility is determined based on a borrowing base formula set forth in the Amended and Restated Credit Agreement and summarized below. Under the Amended and Restated Credit Agreement, the aggregate usage under the U.S. and Canadian Credit Facility may not exceed an amount equal to the sum of (a) 85% of eligible U.S. accounts receivable plus (b) the lesser of (i) 70% of eligible U.S. inventory and eligible foreign in-transit inventory and (ii) 85% of the net orderly liquidation value of eligible U.S. inventory and eligible foreign in-transit inventory (not to exceed $4,000,000 ), plus (c) the lesser of (i) 85% of the net orderly liquidation value of U.S. eligible machinery and equipment and (ii) $2,485,000 (subject to reduction as provided in the Amended and Restated Credit Agreement), plus (d) 85% of eligible Canadian accounts receivable, plus (e) the lesser of (i) 70% of eligible Canadian inventory and (ii) 85% of the net orderly liquidation value of eligible Canadian inventory, less (f) swing loans outstanding under the U.S. and Canadian Credit Facility, less (g) letters of credit issued and undrawn under the U.S. and Canadian Credit Facility, less (h) a $10,000,000 minimum availability reserve, less (i) other reserves required by the Administrative Agent, and in each case subject to the definitions and limitations in the Amended and Restated Credit Agreement. As of December 31, 2015 , the company was in compliance with all covenant requirements and had borrowing capacity on the U.S. and Canadian Credit Facility under the Amended and Restated Credit Agreement of $38,230,000 , taking into account the $10,000,000 minimum availability reserve (which amount was reduced to $5,000,000 pursuant to an amendment in February 2016 - see "Subsequent Events"), then-outstanding letters of credit, other reserves and the $11,250,000 dominion trigger amount noted above. Interest will accrue on outstanding indebtedness under the Amended and Restated Credit Agreement at the LIBOR rate, plus a margin ranging from 2.25% to 2.75% , or at the alternate base rate, plus a margin ranging from 1.25% to 1.75% , as selected by the company. Borrowings under the U.S. and Canadian Credit Facility are subject to commitment fees of 0.25% or 0.375% per year, depending on utilization. European Credit Facility The Amended and Restated Credit Agreement retains the existing asset-based lending senior secured revolving credit facility provided for the company and the U.S. and Canadian Borrowers under the Prior Credit Agreement (the “Existing Credit Facility”) and provides for a new revolving credit, letter of credit and swing line loan facility which gives the European Borrowers the ability to borrow up to an aggregate principal amount of $30,000,000 , with a $5,000,000 sublimit for letters of credit and a $2,000,000 sublimit for swing line loans (the “European Credit Facility”). Up to $15,000,000 of the European Credit Facility will be available to each of Invacare Limited (the “UK Borrower”) and Invacare Poirier SAS (the “French Borrower” and, together with the UK Borrower, the “European Borrowers”). The European Credit Facility matures in January 2018, together with the Existing Credit Facility. The aggregate borrowing availability for each European Borrower under the European Credit Facility is determined based on a borrowing base formula set forth in the Amended and Restated Credit Agreement and summarized below. Under the Amended and Restated Credit Agreement, the aggregate borrowings of each of the European Borrowers under the European Credit Facility may not exceed an amount equal to (a) 85% of the European Borrower’s eligible accounts receivable, less (b) the European Borrower’s borrowings and swing line loans outstanding under the European Credit Facility, less (c) the European Borrower’s letters of credit issued and undrawn under the European Credit Facility, less (d) a $3,000,000 minimum availability reserve, less (e) other reserves required by the European Agent, and in each case subject to the definitions and limitations in the Amended and Restated Credit Agreement. As of December 31, 2015 , as determined pursuant to the borrowing base formula, the aggregate borrowing base available to the European Borrowers under the European Credit Facility was approximately $21,528,000 , with aggregate borrowing availability of approximately $15,153,000 , taking into account the $3,000,000 minimum availability reserve and a $3,375,000 dominion trigger amount described below. The aggregate principal amount of the European Credit Facility may be increased by up to $10,000,000 to the extent requested by the company and agreed to by any Lender or Lenders that wish to increase their lending participation or, if not agreed to by any Lender, a new financial institution that agrees to join the European Credit Facility and that is approved by the Administrative Agent and the European Agent. Interest will accrue on outstanding indebtedness under the European Credit Facility at an adjusted LIBOR rate, plus a margin ranging from 2.50% to 3.00% , or for swing line loans, at the overnight LIBOR rate, plus a margin ranging from 2.50% to 3.00% . The margin will be adjusted quarterly based on utilization. Borrowings under the European Credit Facility are subject to commitment fees of between 0.25% and 0.375% per year, depending on utilization. The European Credit Facility is secured by substantially all of the personal property assets of the UK Borrower and its in-country subsidiaries, and all of the receivables of the French Borrower and its in-country subsidiaries. The UK and French facilities (which comprise the European Credit Facility) are cross collateralized, and the US personal property assets previously pledged under the Existing Credit Facility also serve as collateral for the European Credit Facility. The European Credit Facility is subject to customary representations, warranties and covenants generally consistent with those applicable to the Existing Credit Facility. Exceptions to the operating covenants in the Amended and Restated Credit Agreement provide the company with flexibility to, among other things, enter into or undertake certain sale/leaseback transactions, dispositions of assets, additional credit facilities, sales of receivables, additional indebtedness and intercompany indebtedness, all subject to limitations set forth in the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement also contains a covenant requiring the European Borrowers to maintain undrawn availability under the European Credit Facility of not less than the greater of (i) 11.25% of the maximum amount that may be drawn under the European Credit Facility for five ( 5 ) consecutive business days, or (ii) $3,000,000 on any business day. The European Borrowers also are subject to cash dominion triggers under the European Credit Facility requiring the European Borrower to maintain borrowing capacity of not less than $3,375,000 on any business day or 12.50% of the maximum amount that may be drawn under the European Credit Facility for five ( 5 ) consecutive business days in order to avoid triggering full control by an agent for the Lenders of the European Borrower’s cash receipts for application to its obligations under the European Credit Facility. The European Credit Facility is subject to customary default provisions, with certain grace periods and exceptions, consistent with those applicable to the Existing Credit Facility, which provide that events of default include, among other things, failure to pay amounts due, breach of covenants, representations or warranties, cross-default, bankruptcy, the occurrence of a material adverse effect, exclusion from any medical reimbursement program, and an interruption in the operations of any material manufacturing facility for more than 10 consecutive days. The proceeds of the European Credit Facility will be used to finance the working capital and other business needs of the company. Convertible senior subordinated debentures In 2007 , the company issued $135,000,000 principal amount of Convertible Senior Subordinated Debentures due 2027 . The debentures are unsecured senior subordinated obligations of the company guaranteed by substantially all of the company’s domestic subsidiaries (which guarantees were released effective February 16, 2016 , see "Subsequent Events"), pay interest at 4.125% per annum on each February 1 and August 1 , and are convertible upon satisfaction of certain conditions into cash, common shares of the company, or a combination of cash and common shares of the company, subject to certain conditions. The debentures allow the company to satisfy the conversion using any combination of cash or stock, and at the company’s discretion. In the event of such a conversion, the company intends to satisfy the accreted value of the debentures using cash. Assuming adequate cash on hand at the time of conversion, the company also intends to satisfy the conversion spread using cash, as opposed to stock. As of December 31, 2015 , the principal amount of the company’s Convertible Notes exceeded the if-converted value of those notes by $3,379,000 . The company includes the dilutive effect of shares necessary to settle the conversion spread in the Net Earnings per Share- Assuming Dilution calculation unless such amounts are anti-dilutive as was the case in 2015, 2014 and 2013. The initial conversion rate is 40.3323 shares per $1,000 principal amount of debentures, which represents an initial conversion price of approximately $24.79 per share. Holders of the debentures can convert the debt to common stock if the company’s common stock price is at a level in excess of $32.23 , a 30% premium to the initial conversion price for at least 20 trading days during a period of thirty consecutive trading days preceding the date on which the notice of conversion is given. At a conversion price of $32.23 ( 30% premium over $24.79 ), the full conversion of the convertible debt equates to 539,000 shares. The debentures are redeemable at the company’s option, subject to specified conditions, on or after February 6, 2012 through and including February 1, 2017 . The company may redeem some or all of the debentures for cash on or after February 1, 2017 . Holders have the right to require the company to repurchase all or some of their debentures upon the occurrence of certain circumstances on February 1, 2017 and 2022 . The company evaluated the terms of the call, redemption and conversion features under the applicable accounting literature, including Derivatives and Hedging, ASC 815, and determined that the features did not require separate accounting as derivatives. The notes, debentures and common shares issuable upon conversion of the debentures have been registered under the Securities Act. The components of the company’s convertible debt as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Carrying amount of equity component $ 25,381 $ 25,381 Principal amount of liability component $ 13,350 $ 13,350 Unamortized discount (1,203 ) (1,999 ) Net carrying amount of liability component $ 12,147 $ 11,351 The unamortized discount of $1,203,000 is to be amortized through February 2017 . The effective interest rate on the liability component was 11.5% for 2007 through 2014 . Non-cash interest expense of $796,000 , $710,000 and $633,000 was recognized in 2015 , 2014 and 2013 , respectively, in comparison to actual interest expense paid of $551,000 , $551,000 and $551,000 based on the stated coupon rate of 4.125% , for each of the same periods. The convertible debt was not convertible as of December 31, 2015 nor was the convertible debt conversion price threshold of $32.23 met during 2015 . There were no borrowings denominated in foreign currencies as of December 31, 2015 or December 31, 2014 . For 2015 and 2014 , the weighted average interest rate on all borrowings, excluding capital leases, was 3.83% and 2.87% , respectively. The aggregate minimum maturities of long-term debt for each of the next five years are as follows: $2,028,000 in 2016 , $2,169,000 in 2017 , $1,784,000 in 2018 , $1,632,000 in 2019 , and $1,703,000 in 2020 . Interest paid on all borrowings was $2,753,000 , $3,302,000 and $4,046,000 in 2015 , 2014 and 2013 , respectively.

Other Long-Term Obligations

Other Long-Term Obligations	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Other Liabilities Disclosure	Other Long-Term Obligations Other long-term obligations as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Supplemental Executive Retirement Plan liability $ 4,930 $ 6,067 Product liability 14,582 18,860 Deferred income taxes 32,115 30,423 Deferred gain on sale leaseback 6,978 — Deferred compensation 4,167 5,667 Uncertain tax obligation including interest 4,467 15,160 Other 15,350 12,628 Total long-term obligations $ 82,589 $ 88,805 On April 23, 2015, the company entered into a real estate sales leaseback transaction which resulted in the recording of an initial deferred gain of $7,414,000 , the majority of which is included in Other Long-Term Obligations and will be recognized over the 20-year life of the leases. The gain realized in 2015 was $171,000 . The decrease in the uncertain tax obligation was driven primarily by a reclassification from long term obligations to current taxes payable based on the amount expected be paid in the next twelve months.

Leases and Commitments

Leases and Commitments	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Leases and Commitments	Leases and Commitments The company leases a portion of its facilities, transportation equipment, data processing equipment and certain other equipment. These leases have terms from 1 to 20 years and provide for renewal options. Generally, the company is required to pay taxes and normal expenses of operating the facilities and equipment. As of December 31, 2015 , the company is committed under non-cancelable operating leases, which have initial or remaining terms in excess of one year and expire on various dates through 2024 . Lease expenses were approximately $20,360,000 in 2015 , $23,568,000 in 2014 and $24,726,000 in 2013 . On April 23, 2015 , the company sold and leased back, under four separate lease agreements, four properties located in Ohio and one property in Florida for net proceeds of $23,000,000 , which were used to reduce debt under the U.S. and Canadian Credit Facility . The total annual rent for the properties will be $2,275,000 for the first year, which can increase annually over the 20 year term of the leases based on the applicable geographical consumer price index (CPI). Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is permitted to sublet the properties; however, the properties are currently being utilized exclusively by the company and there is no current subletting. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives. In connection with the transaction, the requirements for sale lease-back accounting were met. Accordingly, the company recorded the sale of the properties, removed the related property and equipment from the company's balance sheet, recognized an initial deferred gain of $7,414,000 and an immediate loss of $257,000 related to one property and recorded new lease liabilities. Specifically, the company recorded four capital leases totaling $32,339,000 and one operating lease related to leased land, which was not a material component of the transaction. The gains on the sales of the properties are required to be deferred and recognized over the life of the leases as the property sold is being leased back. The deferred gain is classified under Other Long-Term Obligations on the Condensed Consolidated Balance Sheet. The amount of buildings and equipment capitalized in connection with capital leases was $42,640,000 and $12,123,000 at December 31, 2015 and 2014 , respectively. At December 31, 2015 and 2014 , accumulated amortization was $7,667,000 and $7,143,000 , respectively, which is included in depreciation expense. Future minimum operating and capital lease commitments, as of December 31, 2015 , are as follows (in thousands): Capital Leases Operating Leases 2016 $ 3,375 $ 15,067 2017 3,375 8,804 2018 2,848 5,005 2019 2,671 2,378 2020 2,671 1,101 Thereafter 32,872 268 Total future minimum lease payments 47,812 $ 32,623 Amounts representing interest (12,839 ) Present value of minimum lease payments $ 34,973

Retirement and Benefit Plans

Retirement and Benefit Plans	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement and Benefit Plans	Retirement and Benefit Plans Substantially all full-time salaried and hourly domestic employees are included in the Invacare Retirement Savings Plan sponsored by the company. The company makes matching cash contributions up to 66.7% of employees’ contributions up to 3% of compensation. The company also makes quarterly contributions to this Plan equal to a percentage of qualified wages. In 2015 , quarterly contributions were made at 1% of qualified wages. The company may make discretionary contributions to the domestic plans based on an annual resolution of the Board of Directors. Contribution expense for the Invacare Retirement Savings Plan in 2015 , 2014 and 2013 was $2,573,000 , $2,698,000 and $3,126,000 , respectively. The company sponsors a Deferred Compensation Plus Plan covering certain employees, which provides for elective deferrals and the company retirement deferrals so that the total retirement deferrals equal amounts that would have contributed to the company’s principal retirement plans if it were not for limitations imposed by income tax regulations. The company sponsors a non-qualified defined benefit Supplemental Executive Retirement Plan (SERP) for certain key executives. Effective December 31, 2008 , the SERP was amended, in part to comply with IRS Section 409A. As a result of the amendment, the plan became a defined benefit cash balance plan for the non-retired participants and thus, future payments by the company will be made based upon a cash balance formula with interest credited at a rate determined annually by the Compensation and Management Development Committee of the Board of Directors. In 2015 interest was credited at 0% for active participants in the SERP in accordance with a July 1, 2011 resolution of the Compensation and Management Development Committee of the Board of Directors. The plan continues to be unfunded with individual hypothetical accounts maintained for each participant. The SERP projected benefit obligation related to this unfunded plan was $6,209,000 and $27,548,000 at December 31, 2015 and 2014 , respectively, and the accumulated benefit obligation was $6,209,000 and $27,548,000 at December 31, 2015 and 2014 , respectively. The projected benefit obligations were calculated using an assumed future salary increase of 4% at both December 31, 2015 and 2014 . The assumed discount rate, relevant for three participants unaffected by the plan conversion was 4.34% and 3.95% for 2015 and 2014 , respectively, based upon the discount rate on high-quality fixed-income investments without adjustment. The retirement age was 67 for 2015 and 67 for 2014 . Expense for the plan in 2015 was $142,000 compared to expense of $539,000 in 2014 and income of $14,000 in 2013 . The expense was comprised of interest income of $42,000 in 2015 , interest expense of $377,000 in 2014 and income of $236,000 in 2013 with the remaining portion related to service costs, prior service costs and other gains/losses. Benefit payments in 2015 , 2014 and 2013 were $21,517,000 , $394,000 and $398,000 , respectively. The company also sponsors a Death Benefit Only Plan (DBO) for certain key executives that provides a benefit equal to three times the participant’s final target earnings should the participant’s death occur while an employee and a benefit equal to one times the participant’s final earnings upon the participant’s death after normal retirement or if a participant dies after his or her employment with the company is terminated following a change in control of the company. Expense for the plan in 2015 was $103,000 compared to expense of $808,000 and income of $259,000 in 2014 and 2013 , respectively. The expense was comprised of service and accrual adjustment expense of $28,000 in 2015 , expense of $692,000 in 2014 and income of $364,000 in 2013 with the remaining portion related to interest costs in each year, respectively. There were no benefit payments in 2015 , 2014 or 2013 . In conjunction with these non-qualified and unfunded U.S. defined benefit plans, the company has invested in life insurance policies related to certain employees to help satisfy these obligations of which $11,902,000 and $21,338,000 in life insurance policies were sold during 2015 and 2014, respectively, to fund payments related to the retirement of certain executive officers of the company. In Europe, the company maintains two defined benefit plans in Switzerland. In Switzerland, a statutory pension plan is maintained with a private insurance company and, in accordance with Swiss law, the plan functions as a defined contribution plan whereby employee and employer contributions are defined as a percentage of individual salary depending on the age of the employee and a guaranteed interest rate, which is annually defined by the Swiss Pension Fund. Under U.S. GAAP, the plans are treated as a defined benefit plans. During 2014, the company terminated its plan in the Netherlands which contained benefits and provisions for an Old Age Pension benefit that started at age 65 and were payable until death and a Survivors Pension that started immediately after the death of the insured and is payable until the death of the surviving spouse. Under U.S. GAAP the plan was treated as a defined benefit plan. Income for both the Switzerland and Netherlands plans was $19,000 , $220,000 and $205,000 in 2015 , 2014 and 2013 , respectively. Accumulated other comprehensive income associated with the SERP, DBO, Swiss and Netherlands pension plans combined was $9,757,000 and $7,601,000 as of December 31, 2015 and 2014 , respectively for a net change of $2,156,000 with $226,000 in net periodic benefit income recognized during the year.

Equity Compensation

Equity Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Compensation	Equity Compensation The company’s Common Shares have a $.25 stated value. The Common Shares and the Class B Common Shares generally have identical rights, terms and conditions and vote together as a single class on most issues, except that the Class B Common Shares have ten votes per share, carry a 10% lower cash dividend rate and, in general, can only be transferred to family members. Holders of Class B Common Shares are entitled to convert their shares into Common Shares at any time on a share-for-share basis. On May 16, 2013 shareholders approved the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”), which was adopted on March 27, 2013 by the company's Board of Directors (the “Board”). The Board adopted the 2013 Plan to replace the company's prior equity plan, the Invacare Corporation Amended and Restated 2003 Performance Plan (the “2003 Plan”), which expired on May 21, 2013 . Due to its expiration, no new awards may be granted under the 2003 Plan; however, awards granted prior to its expiration will remain in effect under their original terms. The 2013 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or stock appreciation rights ("SAR") will count against the number of total shares available under the 2013 Plan as one share; and each common share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2013 Plan as two shares. Any common shares that are added back to the 2013 Plan as the result of the cancellation or forfeiture of an award granted under the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2013 Plan. Each common share that is added back to the 2013 Plan due to a cancellation or forfeiture of an award granted under the 2003 Plan will be added back as one common share. The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2013 Plan to any director or employee of the company or an affiliate. The 2013 Plan initially allows the Compensation Committee to grant up to 4,460,337 common shares in connection with the following types of awards with respect to shares of the company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Compensation Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards. The 2013 Plan provides that shares granted come from the company’s authorized but unissued common shares or treasury shares. In addition, the company’s stock-based compensation plans allow participants to exchange mature shares for minimum withholding taxes, which results in the company acquiring treasury shares. Under these provisions, the company acquired approximately 7,000 treasury shares for $134,000 in 2015 , 29,000 shares for $471,000 in 2014 and 23,000 shares for $532,000 in 2013 . The amounts of equity-based compensation expense recognized as part of selling, general and administrative expenses were as follows (in thousands): 2015 2014 2013 Non-Qualified stock options $ 1,228 $ 3,356 $ 3,926 Restricted stock and restricted stock units 2,785 2,270 2,031 Performance shares and performance share units — — — Total stock-based compensation expense $ 4,013 $ 5,626 $ 5,957 As of December 31, 2015 , unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2013 Plan and previous plans, which is related to non-vested options and shares, was as follows (in thousands): 2015 2014 2013 Non-Qualified stock options $ 1,059 $ 2,600 $ 8,270 Restricted stock and restricted stock units 9,476 4,461 3,705 Performance shares and performance share units — — — Total stock-based compensation expense $ 10,535 $ 7,061 $ 11,975 Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (see "Performance Shares and Performance Share Units" below). No tax benefit for share-based compensation was realized during 2015 , 2014 and 2013 as a result of a valuation allowance against deferred tax assets. In accordance with ASC 718, any tax benefits resulting from tax deductions in excess of the compensation expense recognized is classified as a component of financing cash flows. Stock Options Generally, non-qualified stock option awards typically have a term of ten years and are granted at the fair market value of the company’s common shares on the date of grant. The company expects the compensation expense to be recognized over a weighted-average period of approximately 2 years . The following table summarizes information about stock option activity for the three years ended 2015 , 2014 and 2013 : 2015 Weighted Average Exercise Price 2014 Weighted Average Exercise Price 2013 Weighted Average Exercise Price Options outstanding at January 1 3,600,132 $ 22.74 4,533,782 $ 23.86 4,664,634 $ 26.21 Granted — 0.00 8,977 16.71 756,700 14.47 Exercised (172,218 ) 13.95 (33,810 ) 14.16 (30,166 ) 16.94 Canceled (485,131 ) 34.98 (908,817 ) 28.57 (857,386 ) 28.63 Options outstanding at December 31 2,942,783 $ 21.22 3,600,132 $ 22.74 4,533,782 $ 23.86 Options exercise price range at December 31 $ 13.37 to $ 13.37 to $ 13.35 to $ 33.36 $ 47.80 $ 47.80 Options exercisable at December 31 2,656,983 2,954,082 2,985,175 Shares available for grant at December 31* 2,659,562 3,654,426 4,460,337 ________________________ * Shares available for grant as of December 31, 2015 reduced by net restricted stock / unit and performance share / unit award activity of 1,110,740 shares and 681,058 shares, respectively. The following table summarizes information about stock options outstanding at December 31, 2015 : Options Outstanding Options Exercisable Exercise Prices Number Outstanding At 12/31/15 Weighted Average Remaining Contractual Life Years Weighted Average Exercise Price Number Exercisable At 12/31/15 Weighted Average Exercise Price $ 13.37 – $20.00 778,159 6.7 $ 14.12 493,671 $ 14.11 $ 20.01 – $25.00 1,353,578 3.3 22.59 1,353,578 22.59 $ 25.01 – $30.00 783,738 3.7 25.55 783,738 25.55 $ 30.01 – $33.36 27,308 1.0 31.74 25,996 31.73 Total 2,942,783 4.3 $ 21.22 2,656,983 $ 21.98 Pursuant to the Plans, the Committee has established that grants may not be exercised within one year from the date granted and options must be exercised within ten years from the date granted. Accordingly, for the stock options issued in 2014 and 2013 , 25% of such options vested in the year following issuance. The stock options awarded during such years provided a four -year vesting period whereby options vest equally in each year. Options granted with graded vesting are accounted for as single options. The 2015 , 2014 and 2013 expense has been adjusted for estimated forfeitures of awards that will not vest because service or employment requirements have not been met. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for awards granted in 2014 and 2013 as no options were granted in 2015: 2014 2013 Expected dividend yield 0.3 % 0.4 % Expected stock price volatility 36.8 % 38.2 % Risk-free interest rate 1.76 % 0.82 % Expected life in years 6.1 6.1 Forfeiture percentage 13.0 % 9.2 % Expected dividend yields are based on historical dividends as the company has no current intention of changing its dividend policy. Expected stock price volatility percentages are calculated at each date of grant based on historical stock prices for a period of time commensurate with the expected life of the option. The assumed expected lives and forfeiture percentages are based on the company's historical analysis of option history. The weighted-average fair value of options granted during 2014 and 2013 was $6.23 and $5.33 , respectively. The weighted-average remaining contractual life of options outstanding at December 31, 2015 , 2014 and 2013 was 4.3 , 5.0 and 5.8 years, respectively. The weighted-average contractual life of options exercisable at December 31, 2015 was 4.0 years. The total intrinsic value of stock awards exercised in 2015 , 2014 and 2013 was $1,107,000 , $101,000 and $158,000 , respectively. As of December 31, 2015 , the intrinsic value of all options outstanding and of all options exercisable was $2,562,000 and $1,636,000 , respectively. The exercise of stock awards in 2015 , 2014 and 2013 resulted in cash received by the company totaling $2,413,000 , $480,000 and $512,000 for each period, respectively with no tax benefits for any period. The total fair value of awards vested during 2015 , 2014 and 2013 was $1,867,000 , $3,436,000 and $3,778,000 , respectively. Restricted Stock and Restricted Stock Units The following table summarizes information about restricted shares and restricted share units (for non-U.S. recipients): 2015 Weighted Average Fair Value 2014 Weighted Average Fair Value 2013 Weighted Average Fair Value Stock / Units unvested at January 1 312,423 $ 17.91 264,878 $ 16.69 260,548 $ 19.15 Granted 480,839 19.09 218,276 19.36 114,700 14.49 Vested (56,976 ) 16.47 (93,140 ) 17.62 (97,445 ) 20.33 Canceled (94,781 ) 18.11 (77,591 ) 17.58 (12,925 ) 19.23 Stock / Units unvested at December 31 641,505 $ 18.89 312,423 $ 17.91 264,878 $ 16.69 The restricted stock awards vest ratably over the three years after the award date, except for those awards granted in 2014, which vest after a three -year period. Unearned restricted stock compensation, determined as the market value of the shares at the date of grant, is being amortized on a straight-line basis over the vesting period. Performance Shares and Performance Share Units The following table summarizes information about performance shares and performance share units (for non-U.S. recipients): 2015 Weighted Average Fair Value 2014 Weighted Average Fair Value Shares / Units unvested at January 1 121,644 $ 20.05 — $ — Granted 114,257 18.95 152,800 20.05 Vested — — — — Canceled (37,500 ) 19.62 (31,156 ) 20.05 Shares / Units unvested at December 31 198,401 $ 19.50 121,644 $ 20.05 During 2015 and 2014, the performance shares and performance share units (for non-U.S. recipients) were granted as performance awards with a 3 year performance period with payouts based on achievement of certain performance goals. The awards are classified as equity awards as they will be settled in common shares upon vesting. The number of shares earned will be determined at the end of the performance period based on achievement of performance criteria for January 1, 2016 through December 31, 2016 established by the Compensation Committee at the time of grant. Recipients will be entitled to receive a number of common shares equal to the number of performance shares that vest based upon the levels of achievement which may range between 0% and 150% of the target number of shares with the target being 100% of the initial grant. The fair value of the performance awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The company assesses the probability that the performance targets will be met with expense recognized whenever it is probable that at least the minimum performance criteria will be achieved. Depending upon the company's assessment of the probability of achievement of the goals, the company may not recognize any expense associated with performance awards in a given period, may reverse prior expense recorded or record additional expense to make up for expense not recorded in a prior period. Performance award compensation expense is generally expected to be recognized over 3 years. However, for the years ended December 31, 2015 and December 31, 2014, the company concluded that it was not probable that the performance goals, as defined in the agreements, would be achieved and thus no performance award expense was recognized in 2015 or 2014. Rights Agreement Effective July 8, 2005 , the company adopted a Rights Agreement to replace the company’s previous shareholder rights plan, which expired on July 7, 2005 . In order to implement the new Rights Agreement, the Board of Directors declared a dividend of one Right for each outstanding share of the company’s Common Shares and Class B Common Shares to shareholders of record at the close of business on July 19, 2005 . Each Right entitled the registered holder to purchase from the company one one-thousandth of a Series A Participating Serial Preferred Share, without par value, at a Purchase Price of $180.00 in cash, subject to adjustment. The Rights were not exercisable until after a person (an “Acquiring ”) has acquired, or obtained the right to acquire, or commences a tender offer to acquire, shares representing 30% or more of the company’s outstanding voting power, subject to deferral by the Board of Directors. If the Rights became exercisable, under certain circumstances, the Rights may have been exercisable to purchase Common Shares of the company, or common shares of an acquiring company, at a price equal to the exercise price of the Right divided by 50% of the then current market price per Common Share or acquiring company common share, as the case may be. The Rights expired on July 18, 2015 and were not redeemed or exchanged by the company. The company could have redeemed and terminated the Rights in whole, but not in part, at a price of $0.001 per Right at any time prior to 10 days following a public announcement that an Acquiring Party has acquired beneficial ownership of shares representing 30% or more of the company’s outstanding voting power, and in certain other circumstances described in the Rights Agreement. The company's Board of Directors did not renew the Rights Agreement which expired on July 18, 2015 .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss) by Component	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss) by Component	Accumulated Other Comprehensive Income (Loss) by Component Changes in accumulated other comprehensive income ("OCI") during the year ended December 31, 2015 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2014 $ 86,236 $ (6,465 ) $ (7,601 ) $ (551 ) $ 71,619 OCI before reclassifications (91,980 ) 10,576 (2,292 ) 3,545 (80,151 ) Amount reclassified from accumulated OCI — — 136 (991 ) (855 ) Net current-period OCI (91,980 ) 10,576 (2,156 ) 2,554 (81,006 ) December 31, 2015 $ (5,744 ) $ 4,111 $ (9,757 ) $ 2,003 $ (9,387 ) Changes in OCI during the year ended December 31, 2014 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2013 $ 143,845 $ (12,566 ) $ (5,414 ) $ (709 ) $ 125,156 OCI before reclassifications (57,609 ) 6,101 (3,223 ) 562 (54,169 ) Amount reclassified from accumulated OCI — — 1,036 (404 ) 632 Net current-period OCI (57,609 ) 6,101 (2,187 ) 158 (53,537 ) December 31, 2014 $ 86,236 $ (6,465 ) $ (7,601 ) $ (551 ) $ 71,619 OCI activity related to Long-Term Notes represents currency translation on notes that are long-term in nature and not intended to be settled. Reclassifications out of accumulated OCI for the year ended December 31, 2015 and December 31, 2014 were as follows (in thousands): Amount reclassified from OCI Affected Statement of Comprehensive (Income) Loss line 2015 2014 Defined Benefit Plans Service and interest costs $ 133 $ 1,045 Selling, General and Administrative Tax 3 (9 ) Income Taxes Total after tax $ 136 $ 1,036 Derivatives Foreign currency forward contracts hedging sales $ 2,778 $ 657 Net Sales Foreign currency forward contracts hedging purchases (3,890 ) (995 ) Cost of Products Sold Interest rate swaps — 12 Interest Expense Total before tax (1,112 ) (326 ) Tax 121 (78 ) Income Taxes Total after tax $ (991 ) $ (404 )

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Capital Stock	Capital Stock Capital stock activity for 2015 , 2014 and 2013 consisted of the following (in thousands of shares): Common Stock Shares Class B Shares Treasury Shares January 1, 2013 Balance 33,952 1,085 (3,135 ) Exercise of stock options 30 — — Restricted stock awards 102 — (23 ) December 31, 2013 Balance 34,084 1,085 (3,158 ) Exercise of stock options 34 — — Restricted stock awards 101 — (29 ) December 31, 2014 Balance 34,219 1,085 (3,187 ) Conversion of Class B to Common 351 (351 ) — Exercise of stock options 172 — — Restricted stock awards 282 — (7 ) December 31, 2015 Balance 35,024 734 (3,194 ) Stock awards for 94,781 , 77,591 and 12,925 shares were canceled in 2015 , 2014 and 2013 , respectively. In 2015 , 2014 and 2013 , dividends of $0.05 per Common Share and $0.045 per Class B Common Share were declared and paid, respectively.

Charges Related To Restructurin

Charges Related To Restructuring Activities	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Charges Related To Restructuring Activities	Charges Related to Restructuring Activities The company's restructuring charges recorded since 2011 were necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affect the company's customers (e.g. home health care providers) and continued pricing pressures faced by the company as a result of outsourcing by competitors to lower cost locations. In addition, restructuring decisions were also the result of reduced profitability in the North America/HME and Asia/Pacific segments. While the company's restructuring efforts have been executed on a timely basis resulting in operating cost savings, the savings have been more than offset by continued margin decline, principally as a result of product mix, reduced volumes and regulatory and compliance costs related to quality system improvements which are unrelated to the restructuring actions. The company expects any near-term cost savings from restructuring will be offset by other costs as a result of pressures on the business. The company's restructuring commenced in the second quarter of 2011 with the company's decision to close the Hong, Denmark assembly facility as part of the company's ongoing globalization initiative to reduce complexity in the company's supply chain which is intended to reduce expenses to help offset pricing pressures. In the third quarter of 2011, the company continued to execute on the closure of the Hong, Denmark assembly facility and initiated the closure of a smaller facility in the U.S. Charges for the quarter ended December 31, 2011 were primarily incurred at the company's corporate headquarters for severance, with additional costs incurred as a result of the closure of the Hong, Denmark facility. The facility closures were completed in 2012 in addition to the elimination of various positions principally in the North America/Home Medical Equipment (HME) and Asia/Pacific segments. Charges for the year ended December 31, 2011 totaled $10,534,000 including charges for severance ( $8,352,000 ), contract exit costs primarily related to the closure of the Hong, Denmark assembly facility ( $1,788,000 ) and inventory write-offs ( $277,000 ), recorded in cost of products sold, and miscellaneous costs ( $117,000 ). The majority of the 2011 North America/HME charges were incurred for severance, primarily at the corporate headquarters as the result of the elimination of various positions principally in sales and administration in Elyria, Ohio. These eliminations were permanent reductions in workforce which primarily resulted in reduced selling, general and administrative expenses. In Europe, the charges were the result of the closure of the company's Hong, Denmark facility. The assembly activities were transferred to other company facilities or outsourced to third parties. This closure enabled the company to reduce fixed operating costs related to the facility and reduce headcount with the transfer of a portion of the production to other company facilities. The 2011 charges have now been paid out and were funded with operating cash flows. Charges for the year ended December 31, 2012 totaled $11,395,000 including charges for severance ( $6,775,000 ), lease termination costs ( $1,725,000 ), building and asset write-downs, primarily related to the closure of the Hong, Denmark assembly facility, and other miscellaneous charges in Europe and Asia/Pacific ( $2,404,000 ) and inventory write-offs ( $491,000 ) in Asia/Pacific recorded in cost of products sold. Severance charges were primarily incurred in the North America/HME segment ( $4,242,000 ), Asia/Pacific segment ( $1,681,000 ) and Europe segment ( $817,000 ). In addition, a portion of the North America/HME segment severance was related to positions eliminated, principally in sales and marketing as well as manufacturing, at the company's Taylor Street facility as a result of the FDA consent decree. The savings from these charges will be reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the company. In Europe, positions were eliminated as a result of finalizing the exit from the manufacturing facility in Denmark and an elimination of a senior management position in Switzerland. In Asia/Pacific, at the end of October 2012, the company's management approved a plan to restructure the company's operations in this segment. In Australia, the company consolidated offices / warehouses, decreased staffing and exited various activities while returning to a focus on distribution. At the company's subsidiary, which produces microprocessor controllers, the company decided to cease the contract manufacturing business for companies outside of the healthcare industry. Payments for the year ended December 31, 2012 were $9,381,000 and were funded with operating cash flows. The 2012 charges have been paid out. Charges for the year ended December 31, 2013 totaled $9,336,000 including charges for severance ( $8,282,000 ), lease termination costs ( $698,000 ) and other miscellaneous charges principally in North America/HME ( $356,000 ). Severance charges were primarily incurred in the North America/HME segment ( $5,405,000 ), Europe segment ( $1,640,000 ) and Asia/Pacific segment ( $970,000 ). The charges were incurred as a result of the elimination of various positions as part of the company's globalization initiatives. North America/HME segment severance was principally related to positions eliminated due to lost sales volumes resulting from the impact of the FDA consent decree. The savings from these charges will be reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the company. In Europe, severance incurred for elimination of certain sales and supply chain positions. In Asia/Pacific, severance principally incurred at the company's subsidiary, which produces microprocessor controllers, as a result of the company's decision in 2012 to cease the contract manufacturing business for companies outside of the healthcare industry. The lease termination costs were principally related to Australia as a result of the restructuring announced in 2012. Payments for the year ended December 31, 2013 were $11,844,000 and were funded with operating cash flows and cash on hand. The 2013 charges have been paid out. Charges for the year ended December 31, 2014 totaled $11,112,000 including charges for severance ( $9,841,000 ), other charges in IPG and Europe ( $1,286,000 ) principally related to building write-downs and lease termination cost reversals ( $15,000 ). Severance charges were incurred in the North America/HME segment ( $4,404,000 ), Other ( $2,978,000 ), IPG segment ( $1,163,000 ), Asia/Pacific segment ( $769,000 ) and Europe segment ( $527,000 ). The North America/HME segment severance was principally related to additional positions eliminated due to lost sales volumes resulting from the continued impact of the FDA consent decree. The Other severance related to the elimination of two senior corporate executive positions. IPG segment severance related principally to the closure of the London, Canada facility. Europe and Asia/Pacific severance related to the elimination of certain positions as a result of general restructuring efforts. The savings from these charges will be reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the company. Payments for the year ended December 31, 2014 were $11,131,000 and were funded with operating cash flows and cash on hand. The majority of the 2014 charges have been paid out other than certain executive charge payments which will be paid out over next few years. Charges for the year ended December 31, 2015 totaled $1,971,000 including charges for severance ( $1,678,000 ) and charges primarily in the North America/HME segment ( $293,000 ) principally related to a building lease termination. Severance charges were incurred in the North America/HME segment ( $1,069,000 ), Europe segment ( $510,000 ), IPG segment ( $73,000 ) and Asia/Pacific segment ( $26,000 ) related to the elimination of certain positions as a result of general restructuring efforts. The savings from these charges will be reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the company. Payments for the year ended December 31, 2015 were $3,723,000 and were funded with operating cash flows and cash on hand. The majority of the 2015 charges are expected to be paid out within the next 12 months . To date, the company's liquidity has not been materially impacted. There have been no material changes in accrued balances related to the charges, either as a result of revisions in the plans or changes in estimates. In addition, the savings anticipated as a result of the company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting Selling, General and Administrative expenses, and to a lesser extent, Costs of Products Sold. However, these savings have been more than offset by continued margin decline, principally as a result of product mix, and higher regulatory and compliance costs related to quality system improvements as well as reduced net sales volumes. A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands): Severance Inventory Lease Terminations Other Total December 31, 2010 Balance $ — $ — $ — $ — $ — Charges North America/HME 4,755 — — 4 4,759 IPG 123 — — — 123 Europe 3,288 277 1,788 113 5,466 Asia/Pacific 186 — — — 186 Total 8,352 277 1,788 117 10,534 Payments North America/HME (1,663 ) — — (4 ) (1,667 ) IPG (52 ) — — — (52 ) Europe (1,546 ) (277 ) (1,714 ) (113 ) (3,650 ) Asia/Pacific (186 ) — — — (186 ) Total (3,447 ) (277 ) (1,714 ) (117 ) (5,555 ) December 31, 2011 Balance North America/HME 3,092 — — — 3,092 IPG 71 — — — 71 Europe 1,742 — 74 — 1,816 Asia/Pacific — — — — — Total 4,905 — 74 — 4,979 Charges North America/HME 4,242 — 5 — 4,247 IPG 35 — — — 35 Europe 817 — 53 1,223 2,093 Asia/Pacific 1,681 491 1,667 1,181 5,020 Total 6,775 491 1,725 2,404 11,395 Payments North America/HME (3,587 ) — (5 ) — (3,592 ) IPG (106 ) — — — (106 ) Europe (1,964 ) — (127 ) (1,223 ) (3,314 ) Asia/Pacific (812 ) (340 ) (42 ) (1,175 ) (2,369 ) Total (6,469 ) (340 ) (174 ) (2,398 ) (9,381 ) December 31, 2012 Balance North America/HME 3,747 — — — 3,747 Europe 595 — — — 595 Asia/Pacific 869 151 1,625 6 2,651 Total 5,211 151 1,625 6 6,993 Charges North America/HME 5,405 — 164 353 5,922 IPG 267 — — — 267 Europe 1,640 — — — 1,640 Asia/Pacific 970 — 534 3 1,507 Total 8,282 — 698 356 9,336 Payments North America/HME (6,347 ) — (164 ) (353 ) (6,864 ) IPG (175 ) — — — (175 ) Europe (1,146 ) — — — (1,146 ) Asia/Pacific (1,839 ) (151 ) (1,660 ) (9 ) (3,659 ) Total $ (9,507 ) $ (151 ) $ (1,824 ) $ (362 ) $ (11,844 ) Severance Inventory Lease Terminations Other Total December 31, 2013 Balance North America/HME $ 2,805 $ — $ — $ — $ 2,805 IPG 92 — — — 92 Europe 1,089 — — — 1,089 Asia/Pacific — — 499 — 499 Total 3,986 — 499 — 4,485 Charges North America/HME 4,404 — — — 4,404 IPG 1,163 — — 761 1,924 Europe 527 — — 525 1,052 Asia/Pacific 769 — (15 ) — 754 Other 2,978 — — — 2,978 Total 9,841 — (15 ) 1,286 11,112 Payments North America/HME (6,547 ) — — — (6,547 ) IPG (1,107 ) — — (761 ) (1,868 ) Europe (1,195 ) — — (525 ) (1,720 ) Asia/Pacific (769 ) — (227 ) — (996 ) Total (9,618 ) — (227 ) (1,286 ) (11,131 ) December 31, 2014 Balance North America/HME 662 — — — 662 IPG 148 — — — 148 Europe 421 — — — 421 Asia/Pacific — — 257 — 257 Other 2,978 — — — 2,978 Total 4,209 — 257 — 4,466 Charges North America/HME 1,069 — 292 — 1,361 IPG 73 — — — 73 Europe 510 — — — 510 Asia/Pacific 26 — 1 — 27 Total 1,678 — 293 — 1,971 Payments North America/HME (1,069 ) — (55 ) — (1,124 ) IPG (221 ) — — — (221 ) Europe (619 ) — — — (619 ) Asia/Pacific (26 ) — (258 ) — (284 ) Other (1,475 ) — — — (1,475 ) Total (3,410 ) — (313 ) — (3,723 ) December 31, 2015 Balance North America/HME 662 — 237 — 899 Europe 312 — — — 312 Other 1,503 — — — 1,503 Total $ 2,477 $ — $ 237 $ — $ 2,714

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Earnings (loss) from continuing operations before income taxes consist of the following (in thousands): 2015 2014 2013 Domestic $ (54,812 ) $ (104,776 ) $ (73,529 ) Foreign 43,072 41,566 30,070 $ (11,740 ) $ (63,210 ) $ (43,459 ) The company has provided for income taxes (benefits) from continuing operations as follows (in thousands): 2015 2014 2013 Current: Federal $ (167 ) $ (7,105 ) $ (2,485 ) State (150 ) (63 ) 300 Foreign 11,439 15,105 11,043 11,122 7,937 8,858 Deferred: Federal 3,222 100 3,011 State 318 — — Foreign 48 (2,487 ) (994 ) 3,588 (2,387 ) 2,017 Income Taxes $ 14,710 $ 5,550 $ 10,875 Included in the 2015, 2014 and 2013 Federal current tax benefit is a benefit of $140,000 , $7,175,000 and $3,455,000 , respectively, related to an intra-period allocation to continuing operations. A charge in an equal amount is in discontinued operations. A reconciliation to the effective income tax rate from the federal statutory rate is as follows: 2015 2014 2013 Statutory federal income tax rate (35.0 )% (35.0 )% (35.0 )% State and local income taxes, net of federal income tax benefit 0.9 (0.1 ) 0.5 Tax credits (61.8 ) (5.1 ) (22.8 ) Foreign taxes at less than the federal statutory rate (including tax holidays) (46.1 ) (10.7 ) (10.6 ) Federal and foreign valuation allowance 168.0 52.5 35.8 Withholding taxes 3.0 0.6 0.7 Compensation 0.6 0.1 0.5 Dividends 100.1 12.3 54.6 Life insurance (2.7 ) 4.1 (1.5 ) Foreign branch activity (8.1 ) (1.8 ) (1.8 ) Uncertain tax positions 6.7 1.2 1.3 Other, net (0.3 ) (9.3 ) 3.3 125.3 % 8.8 % 25.0 % Effective October 1, 2015, the company adopted ASU 2015-17, "Balance Sheet Classification of Deferred Taxes", on a prospective basis, and thus the company's deferred tax assets and liabilities have been classified as long-term in its Balance Sheet as of December 31, 2015. No prior periods were retrospectively adjusted. At December 31, 2015 , total deferred tax assets were $154,401,000 , total deferred tax liabilities were $33,636,000 and the tax valuation allowance total was $151,972,000 for a net deferred income tax liability of $31,207,000 compared to total deferred tax assets of $137,511,000 , total deferred tax liabilities of $33,778,000 and a tax valuation allowance total of $133,912,000 for a net deferred income tax liability of $30,179,000 at December 31, 2014 . Significant components of deferred income tax assets and liabilities at December 31, 2015 and 2014 are as follows (in thousands): 2015 2014 Current deferred income tax assets (liabilities), net: Bad debt $ — $ 5,364 Warranty — 7,092 State and local taxes — 2,240 Other accrued expenses and reserves — 1,852 Inventory — 3,096 Compensation and benefits — 2,209 Product liability — 594 Valuation allowance — (22,084 ) Other, net — (732 ) $ — $ (369 ) Long-term deferred income tax assets (liabilities), net: Bad Debt $ 3,670 $ — Warranty 5,357 — Other accrued expenses and reserves 4,355 — Inventory 2,395 — Goodwill and intangibles (25,008 ) (21,915 ) Convertible debt (421 ) (700 ) Fixed assets (8,207 ) (10,431 ) Compensation and benefits 7,136 14,630 Loss and credit carryforwards 102,194 65,123 Product liability 4,107 4,919 State and local taxes 19,932 17,745 Valuation allowance (151,972 ) (111,828 ) Other, net 5,255 12,647 $ (31,207 ) $ (29,810 ) Net Deferred Income Taxes $ (31,207 ) $ (30,179 ) The company recorded a valuation allowance for its U.S. and certain foreign country net deferred tax assets where it is in a three year cumulative loss. The company made net payments for income taxes of $7,966,000 , $6,384,000 , and $6,349,000 during the years ended December 31, 2015 , 2014 and 2013 , respectively. At December 31, 2015 , the company had foreign tax loss carryforwards of approximately $61,330,000 which are non-expiring, of which $61,330,000 are offset by valuation allowances. At December 31, 2015 , the company also had $563,000,000 of domestic state and local tax loss carryforwards, of which $206,000,000 expire between 2016 and 2019 , $191,000,000 expire between 2020 and 2029 and $166,000,000 expire after 2029 . The company has a federal domestic net operating loss carryforward of $131,130,000 which expires in 2034 and 2035 and federal tax credit carryforwards of $38,520,000 of which $4,169,000 expire between 2016 and 2018 and $32,522,000 expire between 2019 and 2025 , $1,582,000 expire between 2031 and 2035 , and $247,000 are indefinite. As of December 31, 2015 and 2014 , the company had a liability for uncertain tax positions, excluding interest and penalties of $8,366,000 and $10,030,000 , respectively. The company expects payments over the next twelve months of $9,100,000 pursuant to a payment plan entered in a foreign country for an item being contested in the courts and an anticipated settlement of an audit. The total liabilities associated with unrecognized tax benefits that, if recognized, would impact the effective tax rates were $8,366,000 and $10,030,000 at December 31, 2015 and 2014 , respectively. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2015 2014 Balance at beginning of year $ 11,019 $ 10,833 Additions to: Positions taken during the current year 227 348 Positions taken during a prior year 270 418 Deductions due to: Exchange rate impact (1,197 ) (362 ) Positions taken during a prior year (527 ) — Lapse of statute of limitations (239 ) (218 ) Balance at end of year $ 9,553 $ 11,019 The company recognizes interest and penalties associated with uncertain tax positions in income tax expense. During 2015 , 2014 and 2013 the (expense) benefit for interest and penalties was $(315,000) , $(500,000) and $(676,000) , respectively. The company had approximately $5,440,000 and $5,130,000 of accrued interest and penalties as of December 31, 2015 and 2014 , respectively. The company and its subsidiaries file income tax returns in the U.S. and certain foreign jurisdictions. The company is subject to U.S. federal income tax examinations for calendar years 2012 to 2015 , and is subject to various U.S. state income tax examinations for 2011 to 2015 . With regards to foreign income tax jurisdictions, the company is generally subject to examinations for the periods 2009 to 2015 .

Net Earnings (Loss) Per Common

Net Earnings (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Earnings (Loss) Per Common Share	Net Earnings (Loss) Per Common Share The following table sets forth the computation of basic and diluted net earnings (loss) per common share. 2015 2014 2013 (In thousands except per share data) Basic Average common shares outstanding 32,171 32,009 31,915 Net loss from continuing operations $ (26,450 ) $ (68,760 ) $ (54,334 ) Net earnings from discontinued operations $ 260 $ 12,690 $ 87,385 Net earnings (loss) $ (26,190 ) $ (56,070 ) $ 33,051 Net loss per common share from continuing operations $ (0.82 ) $ (2.15 ) $ (1.70 ) Net earnings per common share from discontinued operations $ 0.01 $ 0.40 $ 2.74 Net earnings (loss) per common share $ (0.81 ) $ (1.75 ) $ 1.04 Diluted Average common shares outstanding 32,171 32,009 31,915 Stock options and awards 512 188 128 Average common shares assuming dilution 32,683 32,197 32,043 Net loss from continuing operations $ (26,450 ) $ (68,760 ) $ (54,334 ) Net earnings from discontinued operations $ 260 $ 12,690 $ 87,385 Net earnings (loss) $ (26,190 ) $ (56,070 ) $ 33,051 Net loss per common share from continuing operations * $ (0.82 ) $ (2.15 ) $ (1.70 ) Net earnings per common share from discontinued operations $ 0.01 $ 0.39 $ 2.73 Net earnings (loss) per common share * $ (0.81 ) $ (1.75 ) $ 1.03 * Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss. At December 31, 2015 , 2014 and 2013 , shares associated with stock options of 1,479,912 , 2,857,590 and 4,307,458 , respectively, were excluded from the average common shares assuming dilution, as they were anti-dilutive. At December 31, 2015 , the majority of the anti-dilutive shares were granted at an exercise price of $18.51 , which was lower than the average fair market value price of $25.24 for 2015 . For the 2015 , 2014 and 2013 net loss per share from continuing operations calculation, all of the shares associated with stock options were anti-dilutive because of the company's loss. In 2014 , the majority of the anti-dilutive shares were granted at an exercise price of $41.87 , which was higher than the average fair market value price of $16.95 for 2014 . In 2013 , the majority of the anti-dilutive shares were granted at an exercise price of $41.87 , which was higher than the average fair market value price of $16.48 for 2013 . Shares necessary to settle a conversion spread on the convertible notes issued in 2007 were not included in the common shares assuming dilution as the average market price of the company stock in 2015 , 2014 and 2013 did not exceed the conversion price.

Concentration Of Credit Risk

Concentration Of Credit Risk	12 Months Ended
	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Of Credit Risk	Concentration of Credit Risk The company manufactures and distributes durable medical equipment and supplies to the home health care, retail and extended care markets. The company performs credit evaluations of its customers’ financial condition. The company utilizes De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to Invacare’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The company retains a recourse obligation of $6,089,000 at December 31, 2015 to DLL for events of default under the contracts, which total $39,510,000 at December 31, 2015 . Guarantees, ASC 460, requires the company to record a guarantee liability as it relates to the limited recourse obligation. As such, the company has recorded a liability of $109,000 for this guarantee obligation within accrued expenses. The company's recourse is re-evaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables purchased by the company from DLL. The company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4 . Credit losses are provided for in the financial statements. Substantially all of the company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. The company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the company’s customers. The company’s top 10 customers accounted for approximately 16.4% of 2015 net sales. The loss of business of one or more of these customers may have a significant impact on the company, although no single customer accounted for more than 3.3% of the company’s 2015 net sales. Providers who are part of a buying group generally make individual purchasing decisions and are invoiced directly by the company.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. Cash Flow Hedging Strategy The company uses derivative instruments in an attempt to manage its exposure to transactional foreign currency exchange risk and interest rate risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the company’s fixed and floating-rate borrowings. The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change. During a portion of 2014 and all of 2013, the company was a party to interest rate swap agreements that qualified as cash flow hedges and effectively converted floating-rate debt to fixed-rate debt, so the company could avoid the risk of changes in market interest rates. The gains or losses on interest rate swaps are reflected in interest expense on the consolidated statement of comprehensive income (loss). To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months. The company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the company generally limits its hedges to between 50% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $136,818,000 and $157,121,000 matured during the twelve months ended December 31, 2015 and 2014 , respectively. Foreign exchange forward contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): December 31, 2015 December 31, 2014 Notional Amount Unrealized Net Gain (Loss) Notional Amount Unrealized Net Gain (Loss) USD / AUD $ 2,910 $ (83 ) $ 1,250 $ 65 USD / CAD 3,893 181 3,570 (63 ) USD / CHF — — 111 — USD / CNY 16,786 (282 ) — — USD / EUR 72,758 2,681 25,524 — USD / GBP 3,862 22 1,199 3 USD / NZD 4,893 37 7,018 (55 ) USD / SEK 5,128 39 594 1 USD / MXP 8,494 (284 ) 10,297 (657 ) EUR / AUD 669 (10 ) 452 5 EUR / CAD 1,283 (17 ) 580 (1 ) EUR / CHF 1,944 (17 ) 505 (2 ) EUR / DKK — — 643 (3 ) EUR / GBP 36,567 (424 ) 11,906 23 EUR / NOK 3,375 (55 ) 1,490 43 EUR / SEK 2,464 (42 ) 2,917 (9 ) EUR / NZD 3,609 476 7,074 60 GBP / AUD 830 (46 ) 656 22 GBP / CHF 463 (7 ) 331 (1 ) GBP / SEK 2,067 (1 ) 1,035 (2 ) AUD / CAD — — 1,538 30 AUD / CHF — — 93 1 AUD / NZD 352 8 537 19 AUD / SEK — — 61 (1 ) CAD / SEK — — 182 (1 ) CHF / DKK — — 269 (2 ) DKK / SEK 37,293 46 2,497 (44 ) NOK / CHF — — 66 2 NOK / SEK 3,524 (39 ) 1,547 19 $ 213,164 $ 2,183 $ 83,942 $ (548 ) Derivatives Not Qualifying or Designated for Hedge Accounting Treatment The company utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the company in 2015 or 2014 related to these contracts and the associated short-term intercompany trading receivables and payables. Foreign exchange forward contracts not qualifying or designated for hedge accounting treatment entered into in 2015 and 2014 , respectively, and outstanding were as follows (in thousands USD): December 31, 2015 December 31, 2014 Notional Amount Gain (Loss) Notional Amount Gain (Loss) AUD / USD $ 8,051 $ 337 $ 7,300 $ 117 CAD / USD 5,762 (4 ) 6,016 $ (6 ) CNY / USD 9,943 (441 ) 3,200 (14 ) EUR / USD 2,118 53 53,365 (1,585 ) DKK / USD 7,927 125 — — GBP / USD 4,526 (106 ) 5,592 18 NZD / USD — — 4,500 12 NOK / USD 1,838 (18 ) — — $ 40,165 $ (54 ) $ 79,973 $ (1,458 ) The fair values of the company’s derivative instruments were as follows (in thousands): December 31, 2015 December 31, 2014 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ 3,626 $ 1,443 $ 373 $ 921 Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 517 571 147 1,605 Total derivatives $ 4,143 $ 2,014 $ 520 $ 2,526 The fair values of the company’s foreign currency forward assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets. The effect of derivative instruments on the Statement of Operations and Other Comprehensive Income (OCI) was as follows, net of tax (in thousands): Derivatives in ASC 815 cash flow hedge relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Loss Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing) Year ended December 31, 2015 Foreign currency forward exchange contracts $ 3,545 $ 991 $ (11 ) Year ended December 31, 2014 Foreign currency forward exchange contracts $ 562 $ 416 $ (11 ) Interest rate swap contracts — (12 ) — $ 562 $ 404 $ (11 ) Derivatives not designated as hedging instruments under ASC 815 Amount of Gain (Loss) Recognized in Income on Derivatives Year ended December 31, 2015 Foreign currency forward contracts $ (54 ) Year ended December 31, 2014 Foreign currency forward contracts $ (1,458 ) The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales or cost of product sold for hedges of inventory purchases. In 2015 , net sales were decreased by $2,778,000 and cost of product sold was decreased by $3,890,000 for a net realized gain of $1,112,000 . In 2014 , net sales were decreased by $657,000 and cost of product sold was decreased by $995,000 for a net realized gain of $338,000 compared to a net loss of $271,000 in 2013 . The company recognized incremental expense of $12,000 and $337,000 in 2014 and 2013 , respectively, related to interest rate swap agreements which are reflected in interest expense on the consolidated statement of comprehensive income (loss). Losses of $54,000 and $1,458,000 in 2015 and 2014 , respectively, and a gain $370,000 in 2013 were recognized in selling, general and administrative (SG&A) expenses on ineffective foreign currency forward contracts as well as foreign currency forward contracts not designated as hedging instruments that are entered into to offset gains/losses on intercompany trade receivables or payables. The gains/losses on the non-designated hedging instruments were substantially offset by gains/losses also recorded in SG&A expenses on intercompany trade receivables or payables. The company has entered into foreign currency forward exchange contracts and, at times, interest rate swap contracts (the “agreements”) with various bank counterparties, each of which are subject to provisions which are similar to a master netting agreement. The agreements provide for a net settlement payment in a single currency upon a default by the company. Furthermore, the agreements provide the counterparty with a right of set off in the event of a default that would enable the counterparty to offset any net payment due by the counterparty to the company under the applicable agreement by any amount due by the company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the company's Amended and Restated Credit Agreement to reduce any derivative settlement amounts owed to the company under the derivative contract by any amounts owed to the counterparty by the company under the Amended and Restated Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the company under the agreement in the event of a default by the company under another agreement with the same counterparty. The company does not present any derivatives on a net basis in its financial statements and all derivative balances presented are subject to provisions that are similar to master netting agreements.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Values of Financial Instruments Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable. The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands). Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Markets for Identical Assets / (Liabilities) Significant Other Observable Inputs Significant Other Unobservable Inputs Total Level I Level II Level III December 31, 2015 : Forward Exchange Contracts—net $ 2,129 — $ 2,129 — December 31, 2014 : Forward Exchange Contracts—net $ (2,006 ) — $ (2,006 ) — Forward Contracts: The company operates internationally, and as a result, is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge the following currencies: AUD, CAD, CHF, CNY, DKK, EUR, GBP, MXP, NOK, NZD, SEK and USD. The company does not use derivative financial instruments for speculative purposes. Fair values for the company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities. The gains and losses that result from the majority of the forward contracts are deferred and recognized when the offsetting gains and losses for the identified transactions are recognized. The company recognized a net gain of $1,112,000 in 2015 , a net gain of $338,000 in 2014 and a net loss of $271,000 in 2013 related to ASC 815 designated derivatives. Gains or losses recognized as the result of the settlement of forward contracts are recognized in cost of products sold for hedges of inventory transactions, sales for hedges of forecasted sales or selling, general and administrative expenses for other hedged transactions. The company’s forward contracts are included in Other Current Assets or Accrued Expenses in the Consolidated Balance Sheets. The carrying amounts and fair values of the company’s financial instruments at December 31, 2015 and 2014 are as follows (in thousands): 2015 2014 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 60,055 $ 60,055 $ 38,931 $ 38,931 Other investments 160 160 249 249 Installment receivables, net of reserves 1,793 1,793 1,911 1,911 Long-term debt (including current maturities of long-term debt) (47,120 ) (47,369 ) (20,331 ) (20,248 ) Forward contracts in other current assets 4,143 4,143 520 520 Forward contracts in accrued expenses (2,014 ) (2,014 ) (2,526 ) (2,526 ) The company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions: Cash, cash equivalents: The carrying amount reported in the balance sheet for cash, cash equivalents equals its fair value. Other investments: The company has made other investments in limited partnerships and non-marketable equity securities, which are accounted for using the cost method, adjusted for any estimated declines in value. These investments were acquired in private placements and there are no quoted market prices or stated rates of return. The company does not have the ability to easily sell these investments. The company completes an evaluation of the residual value related to these investments in the fourth quarter of each year. No impairment was recognized in 2015 , 2014 or 2013 . Installment receivables: The carrying amount reported in the balance sheet for installment receivables approximates its fair value. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value. Long-term debt: Fair value for the company’s convertible debt is based on quoted market-based estimates as of the end of the year, while the revolving credit facility fair values are based upon the company’s estimate of the market for similar borrowing arrangements. These fair values are deemed to be categorized as Level 2 in the fair value hierarchy. Intangibles and Goodwill: Under Intangibles—Goodwill and Other , ASC 350, goodwill and intangible assets deemed to have indefinite lives are subject to annual impairment tests. Furthermore, goodwill and other long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. To review goodwill for impairment in accordance with ASC 350, the company first estimates the fair value of each reporting unit and compares the calculated fair value to the carrying value of the each reporting unit. A reporting unit is defined as an operating segment or one level below. The company has determined that its reporting units are the same as its operating segments. The company completes its annual impairment tests in the fourth quarter of each year. To estimate the fair values of the reporting units, the company utilizes a discounted cash flow method model in which the company forecasts income statement and balance sheet amounts based on assumptions regarding future sales growth, profitability, inventory turns, days' sales outstanding, etc. to forecast future cash flows. The cash flows are discounted using a weighted average cost of capital discount rate where the cost of debt is based on quoted rates for 20 -year debt of companies of similar credit risk and the cost of equity is based upon the 20 -year treasury rate for the risk free rate, a market risk premium, the industry average beta and a small cap stock adjustment. The discount rates used have a significant impact upon the discounted cash flow methodology utilized in the company's annual impairment testing as higher discount rates decrease the fair value estimates. The assumptions used are based on a market participant view and yielded a discount rate of 9.41% in 2015 for the company's impairment analysis compared to 9.89% in 2014 and 10.00% in 2013 . The company also utilizes an Enterprise Value (EV) to EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) Method to compute the fair value of its reporting units which considers potential acquirers and their EV to EBITDA multiples adjusted by an estimated premium. While more weight is given to the discounted cash flow method, the EV to EBITDA Method does provide corroborative evidence of the reasonableness of the discounted cash flow method results. While there was no indication of impairment in 2015 related to goodwill for the Europe or IPG segments, a future potential impairment is possible for any of the company's segments should actual results differ materially from forecasted results used in the valuation analysis. Furthermore, the company's annual valuation of goodwill can differ materially if the market inputs used to determine the discount rate change significantly. For instance, higher interest rates or greater stock price volatility would increase the discount rate and thus increase the chance of impairment. In consideration of this potential, the company reviewed the results if the discount rate used were 100 basis points higher for the 2015 impairment analysis and determined that there still would not be any indicator of potential impairment for the segments with goodwill, which are Europe and IPG. During 2014, the company recognized intangible write-down charges in the IPG segment of $13,041,000 comprised of a customer list impairment of $12,826,000 and a non-compete agreement of $215,000 all recorded in the IPG segment as the actual and remaining cash flows associated with the intangibles were less than the cash flow originally used to value the intangibles, primarily driven by reduced net sales. The after-tax and pre-tax impairment amounts were the same for each of the above impairments. In the fourth quarter of 2013, the company recognized intangible write-down charges of $1,523,000 comprised of: trademarks with indefinite lives of $568,000 , a trademark with a definite life of $123,000 , a customer lists impairment of $442,000 and a developed technology of $223,000 all recorded in the IPG segment and a customer list intangible write-down charge of $167,000 recorded in the North America/HME segment. The after-tax and pre-tax impairment amounts were the same for each of the above impairments except for the indefinite-lived trademark impairments in the IPG segment, which were $496,000 after-tax. The fair values of the trademarks and developed technology were calculated using a relief from royalty payment methodology which requires applying an estimated market royalty rate to forecasted net sales and discounting the resulting cash flows to determine fair value. The fair value of the customer lists were calculated using an excess earnings method, using a discounted cash flow model. Estimated cash flow returns to the customer relationship were reduced by the cash flows required to satisfy the return requirements of each of the assets employed with the residual cash flow then discounted to value the customer relationship. The write-down charges were the result of decisions to exit certain businesses as well as lower than anticipated sales. The fair values of the company's intangible assets were calculated using inputs that are not observable in the market and included management’s own estimates regarding the assumptions that market participants would use and thus these inputs are deemed Level III inputs in regards to the fair value hierarchy.

Business Segments

Business Segments	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Business Segments	Business Segments The company operates in four primary business segments: North America/Home Medical Equipment (North America/HME), Institutional Products Group (IPG), Europe and Asia/Pacific. The North America/HME segment sells each of the three primary product lines, which includes: lifestyle, mobility and seating and respiratory therapy products. IPG sells, and rented prior to the disposition of the rentals businesses, long-term care medical equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell product lines similar to North America/HME and IPG. The company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance except for Asia/Pacific due to its significant intercompany sales volume relative to the segment. The information by segment is as follows (in thousands): 2015 2014 2013 Revenues from external customers North America/HME $ 474,196 $ 507,867 $ 589,240 Institutional Products Group 87,137 102,796 112,290 Europe 536,463 610,555 583,143 Asia/Pacific 44,542 48,945 49,832 Consolidated $ 1,142,338 $ 1,270,163 $ 1,334,505 Intersegment revenues North America/HME $ 111,321 $ 84,247 $ 77,553 Institutional Products Group 997 6,711 5,304 Europe 9,958 8,938 8,272 Asia/Pacific 20,661 26,173 24,941 Consolidated $ 142,937 $ 126,069 $ 116,070 Depreciation and amortization North America/HME $ 8,775 $ 10,925 $ 12,149 Institutional Products Group 1,980 7,656 8,310 Europe 7,183 11,111 12,123 Asia/Pacific 1,463 2,406 3,073 All Other (1) 29 173 275 Discontinued Operations — 518 859 Consolidated $ 19,430 $ 32,789 $ 36,789 2015 2014 2013 Net interest expense (income) North America/HME $ 2,080 $ 348 $ (1,869 ) Institutional Products Group 1,028 2,244 3,656 Europe (444 ) (209 ) (53 ) Asia/Pacific 82 149 960 Consolidated $ 2,746 $ 2,532 $ 2,694 Earnings (loss) before income taxes from continuing operations North America/HME $ (32,866 ) $ (63,601 ) $ (50,506 ) Institutional Products Group 6,757 (10,961 ) 1,418 Europe 38,644 48,088 40,468 Asia/Pacific (3,521 ) (9,485 ) (13,258 ) All Other (1) (20,754 ) (27,251 ) (21,581 ) Consolidated $ (11,740 ) $ (63,210 ) $ (43,459 ) Assets North America/HME (2) $ 215,500 $ 218,877 $ 250,239 Institutional Products Group (3) 38,730 42,692 45,933 Europe 557,740 638,896 693,790 Asia/Pacific 24,421 30,231 31,034 All Other (1) 1,752 15,647 37,142 Assets Held for Sale (4) — 17,388 38,296 Consolidated $ 838,143 $ 963,731 $ 1,096,434 Long-lived assets North America/HME (2) $ 49,319 $ 44,727 $ 60,309 Institutional Products Group (3) 30,278 33,487 38,342 Europe 391,533 459,957 506,329 Asia/Pacific 3,140 4,046 5,238 All Other (1) 1,752 15,527 36,830 Consolidated $ 476,022 $ 557,744 $ 647,048 Expenditures for assets North America/HME $ 1,232 $ 2,960 $ 5,017 Institutional Products Group 212 1,232 3,308 Europe 5,058 6,708 4,809 Asia/Pacific 969 1,417 830 All Other (1) 51 — 50 Discontinued Operations — 10 144 Consolidated $ 7,522 $ 12,327 $ 14,158 ________________________ (1) Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. (2) The 2013 North America/HME assets and long-lived assets include a decrease of $167,000 due to an intangible asset impairment write-off. (3) Restated 2014 and 2013 for rentals businesses sold in July 2015 and classified as assets held for sale. (4) Assets held for sale includes decreases of $13,041,000 and $1,356,000 in 2014 and 2013, respectively, due to intangible asset impairment write-offs. Net sales by product, are as follows (in thousands): 2015 2014 2013 North America/HME Lifestyle Products $ 222,944 $ 239,625 $ 267,934 Mobility and Seating 117,232 115,776 134,995 Respiratory Therapy 130,349 149,063 178,065 Other(1) 3,671 3,403 8,246 $ 474,196 $ 507,867 $ 589,240 Institutional Products Group Continuing Care $ 87,137 $ 102,796 $ 112,290 Europe Lifestyle Products $ 275,932 $ 322,370 $ 303,225 Mobility and Seating 208,730 228,163 216,152 Respiratory Therapy 36,373 40,661 40,885 Other(1) 15,428 19,361 22,881 $ 536,463 $ 610,555 $ 583,143 Asia/Pacific Mobility and Seating $ 25,655 $ 28,174 $ 26,737 Lifestyle Products 10,277 11,772 12,023 Continuing Care 3,115 3,956 2,785 Respiratory Therapy 807 1,286 1,290 Other(1) 4,688 3,757 6,997 $ 44,542 $ 48,945 $ 49,832 Total Consolidated $ 1,142,338 $ 1,270,163 $ 1,334,505 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting. No single customer accounted for more than 3.3% of the company’s sales.

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies General In the ordinary course of its business, the company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits that the company faces in the United States have been referred to the company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures. As a medical device manufacturer, the company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting, developing, testing, manufacturing, labeling, promoting, distributing and other practices of health care suppliers and medical device manufacturers are all subject to government scrutiny. Most of the company's facilities are subject to inspection at any time by the FDA or similar medical device regulatory agencies in other jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, which could have a material adverse effect on the company's business. On November 15, 2013, an amended complaint, in a lawsuit originally instituted on May 24, 2013, was filed against Invacare Corporation, former officer and director Gerald B. Blouch and former officer and director A. Malachi Mixon III in the U.S. District Court for the Northern District of Ohio, alleging that the defendants violated federal securities laws by failing to properly disclose the issues that the company has faced with the FDA. The lawsuit sought class certification and unspecified damages and attorneys' fees for purchasers of the company's common shares between February 27, 2009 and December 7, 2011. After mediation, the parties agreed to settle the matter, which agreement was fully and finally approved by the Court on November 19, 2015, and the case was dismissed. The settlement was paid entirely by the company’s insurance carriers. On September 12, 2014, a second amended complaint, in a lawsuit originally instituted on August 26, 2013, was filed against Invacare Corporation, former officer and director Gerald B. Blouch, former officer and director A. Malachi Mixon III and the Company's senior Vice President, Human Resources, Patricia Stumpp, as well as outside directors Dale C. LaPorte and Michael F. Delaney and former outside director Charles S. Robb, in the U.S. District Court for the Northern District of Ohio, alleging that the defendants breached their fiduciary duties and violated the Employee Retirement Income Security Act (ERISA) in the administration and maintenance of the company stock fund in the company’s Retirement Savings Plan (401(k) Plan). The lawsuit seeks class certification and unspecified damages and attorneys' fees for participants in the company's stock fund of the 401(k) Plan between July 22, 2010 and the present. On August 28, 2015, the Court limited plaintiff’s claim to the time period between July 22, 2010 and December 8, 2011. This lawsuit has been referred to the company's insurance carriers. The company intends to vigorously defend this lawsuit. Medical Device Regulatory Matters The FDA in the United States and comparable medical device regulatory authorities in other jurisdictions regulate virtually all aspects of the marketing, invoicing, documenting, development, testing, manufacturing, labeling, promotion, distribution and other practices regarding medical devices. The company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the company's products are manufactured or sold. The company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the company to administrative or judicially imposed sanctions or enforcement actions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production. In December 2012, the company reached agreement with the FDA on the terms of the consent decree of injunction with respect to the company's Corporate facility and its Taylor Street wheelchair manufacturing facility in Elyria, Ohio. A complaint and consent decree were filed in the U.S. District Court for the Northern District of Ohio, and on December 21, 2012 , the Court approved the consent decree and it became effective. The consent decree limits the company's manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility. The decree also initially limited design activities related to wheelchairs and power beds that take place at the impacted Elyria, Ohio facilities. The company is entitled to continue to produce from the Taylor Street manufacturing facility certain medically necessary wheelchairs provided that documentation and record-keeping requirements are followed, as well as ongoing replacement, service and repair of products already in use, under terms delineated in the consent decree. Under the terms of the consent decree, in order to resume full operations at the impacted facilities, the company must successfully complete a third-party expert certification audit at the impacted Elyria facilities, which is comprised of three distinct reports that must be submitted to, and accepted by, the FDA. During 2013, the company completed the first two of the third-party expert certification audits, and the FDA found the results of both to be acceptable. In these reports, the third-party expert certified that the company's equipment and process validation procedures and its design control systems are compliant with the FDA's QSR. As a result of the FDA's acceptance of the first certification report on May 13, 2013, the Taylor Street facility was able to resume supplying parts and components for the further manufacturing of medical devices at other company facilities. The company's receipt of the FDA's acceptance of the second certification report on July 15, 2013, resulted in the company being able to resume design activities at the impacted facilities related to power wheelchairs and power beds. In February, 2016, the independent expert auditor issued its certification report for the third phase of the consent decree indicating substantial compliance to the FDA's QSR, and the report has been submitted to the FDA. Per the terms of the consent decree, the company must submit its own report to the FDA regarding its compliance status together with its written responses to any observations in the independent expert's report. Both the independent expert auditor's third certification report as well as the company's own report must be accepted by the FDA before the agency reinspects the impacted Elyria facilities. If the FDA is satisfied with the company's compliance, the FDA will provide written notification that the company is permitted to resume full operations at the impacted facilities. The company cannot predict the acceptance of these reports by the FDA, nor any remaining work that may be needed to meet the FDA's requirements. The FDA has the authority to inspect any FDA registered facility at any time. After resumption of full operations, the company must undergo five years of audits by a third-party expert auditor to determine whether the facilities are in continuous compliance with FDA's QSR and the consent decree. The auditor will inspect the Corporate and Taylor Street facilities’ activities every six months during the first year following the resumption of full operations and then every 12 months for the next four years thereafter. As described above, because the limitations on production are not expected to be permanent in nature, and partial production is allowed, the company does not anticipate any major repair, replacement or scrapping of its fixed assets at the Taylor Street manufacturing facility. Based on the company's expectations at the time of filing of this Annual Report on Form 10-K with respect to the utilization of such raw material and with respect to expected future cash flows from production at the Taylor Street manufacturing facility, the company concluded that there is no impairment in the value of the fixed assets related to the Taylor Street manufacturing facility at December 31, 2015 . The majority of the production from the Taylor Street facility is "made to order" custom wheelchairs for customers and, as a result, there was not a significant amount of finished goods inventory on hand at December 31, 2015 , and the inventory is expected to be fully utilized. Accordingly, the company concluded that there was not an impairment of the work in process and finished goods at the Taylor Street facility at December 31, 2015 . Further, based on its analysis of the raw material inventory at the Taylor Street facility and the company's expectations at the time of filing of this Annual Report on Form 10-K with respect to the time frame for FDA's acceptance of the third-party expert certification audit and FDA inspection, the company concluded that the value of the inventory was not excessive nor impaired at December 31, 2015 . However, if the company's expectations regarding the impacts of the limitations in the consent decree or the time frame for acceptance of the third-party expert certification audit and FDA inspection were to change, the company may, in future periods, conclude that an impairment exists with respect to its fixed assets or inventory at the Taylor Street facility. Although the North America/HME segment is the segment primarily impacted by the limitations in the FDA consent decree, the Asia/Pacific segment also is negatively affected as a result of the consent decree due to the lower sales volume of microprocessor controllers. During 2012, before the effective date of the consent decree, the company started to experience decreases in net sales in the North America/HME and Asia/Pacific segments. The company believes that those decreases, which continued beyond 2012, were driven in large part by the consent decree which led to delays in new product introductions and to uncertainty regarding the timing of exiting the consent decree, which limited the company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders. Separately, net sales in the North America/HME segment were likely impacted by uncertainty on the part of the company's customers as they coped with prepayment reviews and post-payment audits by the Centers for Medicare and Medicaid Services ("CMS") and contemplated their participation in the National Competitive Bidding ("NCB") process. The negative effect of the consent decree on customer orders and net sales in these segments has been considerable, and the company expects to continue to experience low levels of net sales in the North America/HME and Asia/Pacific segments at least until it has successfully completed the previously-described FDA re-inspection and has received written notification from the FDA that the company may resume full operations at the Corporate and Taylor Street facilities. Even after the company is permitted to resume full operations at the affected facilities, it is uncertain as to whether, or how quickly, the company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the company's 2010 results, the limitations in the consent decree had, and likely will continue to have, a material adverse effect on the company's business, financial condition and results of operations. For additional information regarding the consent decree, please see the following sections of this Annual Report on Form 10-K: Item 1. Business - Government Regulation and Item 1A. Risk Factors; Item 3. Legal Proceedings; and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations - Outlook and - Liquidity and Capital Resources. The company's warranty reserves are subject to adjustment in future periods as new developments change the company's estimate of the total cost of these matters. In 2015 , the company's warranty expense includes reversals of $2,325,000 comprised of $2,000,000 related the company's stationary oxygen concentrator recall, $250,000 related to the recall of a sieve bed component and $75,000 related to the company's joystick recall, all of which impacted the North America/HME segment. The company' recorded incremental warranty expense in 2014 totaling $11,493,000 for three specific product recalls. First, an expense of $6,559,000 for a recall related to a component in a stationary oxygen concentrator that was manufactured in the company’s facility in Suzhou, China, and sold globally. This expense was recorded in the European segment ( $3,395,000 ) and North America/HME segment ( $3,164,000 ). Second, an expense of $2,057,000 for the recall of a sieve bed component used within stationary oxygen concentrators manufactured in the company's Sanford, Florida facility during August 2014, which was recorded in the North America/HME segment. Third, an incremental expense of $2,877,000 related to the company's joystick recall as a result of higher than previously anticipated response rates from large customers in the U.S. and Canada and a product mix toward higher cost joysticks, which was recorded in the North America/HME segment ( $1,612,000 ) and the Asia/Pacific segment ( $1,265,000 ). In 2013, the company recorded an incremental warranty reserve of $7,264,000 , which primarily impacted the Asia/Pacific ( $4,639,000 ) and the North America/HME ( $2,625,000 ) segments. The warranty accrual related to the power wheelchair joystick recall which was increased during the fourth quarter of 2013 principally as a result of the commencement of the recall in the quarter and the realization that the number of replacement units required was trending higher than the company's original estimates, which were based on historical experience related to previous recalls. See Current Liabilities in the Notes to the Consolidated Financial Statements for the total provision amounts and a reconciliation of the changes in the warranty accrual. In December 2010, the company received a warning letter from the FDA related to quality system processes and procedures at the company's Sanford, Florida facility. In January 2014, the FDA conducted inspections at the company’s manufacturing facility in Suzhou, China and at the company’s electronic components subsidiary in Christchurch, New Zealand, covering quality systems and current Good Manufacturing Practice regulations. In August 2014, the FDA inspected Alber GmbH in Albstadt, Germany. The FDA issued its inspectional observations on Forms 483 to the company after these inspections, and the company submitted its responses to the agency in a timely manner. In October 2014, the FDA conducted an inspection at the Sanford facility and, at the conclusion, issued its Form 483 observations. In December 2015, the FDA issued Form 483 observations following a 2015 inspection of approximately 5 months at the Corporate and Taylor Street facilities in Elyria, Ohio which included a review of the company’s compliance with terms of the consent decree and the matters covered by the first and second expert certification reports previously accepted in 2013. The company has timely filed its responses to these Form 483 with the FDA and continues to work on addressing the FDA's observations. The results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA warning letter or other FDA enforcement related to the Sanford or other company facilities could materially and adversely affect the company's business, financial condition, and results of operations. Any of the above contingencies could have an adverse impact on the company's financial condition or results of operations.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On February 16, 2016 , in connection with the commencement of the company's offering of 5.00% convertible senior notes due 2021 described below, the company entered into a First Amendment to Amended and Restated Revolving Credit and Security Agreement (the “Credit Agreement Amendment”), which amended the Amended and Restated Revolving Credit and Security Agreement (the “Credit Agreement”), dated as of September 30, 2015 , by and among the company, certain of the company’s direct and indirect domestic, Canadian and European subsidiaries, the lenders party thereto, PNC Bank, National Association, as the administrative agent, and J.P. Morgan Europe Limited, as the European agent. The Credit Agreement Amendment provides for, among other things: • the amendment of the negative covenant regarding indebtedness to permit the issuance of new convertible notes ; • the amendment of various negative covenants to permit convertible bond hedge and warrant transactions to be entered into by the company in connection with the issuance of new convertible notes; • the amendment of the mandatory prepayment provision to eliminate the prepayment requirement that would otherwise be required upon the receipt of proceeds from the issuance of the convertible notes and the sale of the warrants and the negative covenant regarding dividends to permit the issuance of certain equity interests, payment of interest on the notes and certain payments to be made upon conversion of the convertible notes, as well as upon the exercise, settlement or termination of the convertible bond hedge and warrant transactions, so long as the company is not, and would not after giving pro-forma effect to any such transaction be, in default under the Credit Agreement and has had undrawn availability equal to at least 20% of the maximum revolving advance amount under its North American-based credit facility (which maximum amount is currently $100,000,000 ) for the 30 consecutive days ending delivered by the company under the Credit Agreement; • the amendment of the negative covenant to permit the repurchase by the company of up to $5,000,000 of its common shares, including any such shares that may be repurchased in connection with the issuance of the convertible notes so long as the company is not, and would not after giving pro-forma effect to any such repurchase be, in default under the Credit Agreement and has had undrawn availability equal to at least 20% of the maximum revolving advance amount under its North American-based credit facility (which maximum amount is currently $100,000,000 ) for the 30 consecutive days ending as of the date of the most recent North American borrowing base certificate delivered by the company under the Credit Agreement; • the amendment of the negative covenant regarding capital expenditures to increase the aggregate amount of permitted expenditures from $20,000,000 to $35,000,000 ; • the amendment of the negative covenant regarding investments to permit certain qualifying acquisitions for total aggregate consideration of up to $30,000,000 ; • the amendment of the negative covenant regarding sales of assets to increase the aggregate amount of permitted dispositions from $20,000,000 to $25,000,000 (calculated as of the date of the Credit Agreement Amendment), so long as the company is not, and would not after giving pro-forma effect to any such disposition be, in default under the Credit Agreement and has had undrawn availability equal to at least 20% of the maximum revolving advance amount under its North American-based credit facility (which maximum amount is currently $100,000,000 ) for the 30 consecutive days ending as of the date of the most recent North American borrowing base certificate delivered by the company under the Credit Agreement; and • the amendment of the availability block (which affects the company’s borrowing base) by reducing the block from $10,000,000 to $5,000,000 , the effect of which is to increase borrowing capacity. Also on February 16, 2016 , the company executed a release, acknowledged by Wells Fargo Bank, N.A., as trustee, effecting the release as guarantors of all of the company’s subsidiaries that were guarantors of the company’s 4.125% Convertible Senior Subordinated Debentures due 2027, issued pursuant to the terms of the indenture, dated as of February 12, 2007 , between the company and the trustee. See “Supplemental Guarantor Information”. On February 23, 2016 , the company issued $130,000,000 aggregate principal amount of 5.00% convertible senior notes due 2021 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. In connection with the offering, the company granted the initial purchasers an option to purchase (solely to cover over-allotments, if any) up to an additional $20,000,000 aggregate principal amount of notes, for which notice of exercise shall be delivered to the company within a 13-day period beginning on, and including, the date the Company first issues the notes. The notes bear interest at a rate of 5.00% per year payable semi-annually in arrears on February 15 and August 15 of each year, beginning August 15, 2016 . The notes will mature on February 15, 2021 , unless repurchased or converted in accordance with their terms prior to such date. Prior to August 15, 2020 , the notes will be convertible only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Unless and until the company obtains shareholder approval under applicable New York Stock Exchange rules, the notes will be convertible, subject to certain conditions, into cash. If the company obtains such shareholder approval, the notes may be settled in cash, the company’s common shares or a combination of cash and the company’s common shares, at the company’s election. Holders of the notes will have the right to require the company to repurchase all or some of their notes at 100% of their principal, plus any accrued and unpaid interest, upon the occurrence of certain fundamental changes. The conversion rate will initially be 60.0492 common shares per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $16.65 per common share). In connection with the offering of the notes, the company entered into privately negotiated convertible note hedge transactions with two financial institutions (the “option counterparties”). These transactions cover, subject to customary anti-dilution adjustments, the number of the company’s common shares that will initially underlie the notes, and are expected generally to reduce the potential equity dilution, and/or offset any cash payments in excess of the principal amount due, as the case may be, upon conversion of the notes. The company entered into separate, privately negotiated warrant transactions with the option counterparties at a higher strike price relating to the same number of the company’s common shares, subject to customary anti-dilution adjustments, pursuant to which the company will sell warrants to the option counterparties. The warrants could have a dilutive effect on the company’s outstanding common shares and the company’s earnings per share to the extent that the price of the company’s common shares exceeds the strike price of those warrants. The strike price of the warrants will initially be $22.4175 per share and is subject to certain adjustments under the terms of the warrant transactions. The net proceeds from the offering were approximately $124,800,000 , after deducting fees and estimated offering expenses payable by the company and excluding the option by the purchasers to purchase an additional $20,000,000 aggregate principal amount of notes. Approximately $5,000,000 of the net proceeds from the offering were used to repurchase the company’s common shares from purchases of notes in the offering in privately negotiated transactions. A portion of the net proceeds from the offering were used to pay the cost of the convertible note hedge transactions (after such cost is partially offset by the proceeds to the company from the sale of the warrant transactions), which net cost was $13,520,000 . The company intends to use the remaining net proceeds from the offering for working capital and general corporate purposes, which may include funding portions of the company’s ongoing turnaround and addressing potential risks and contingencies described in the company’s Risk Factors as included in this Form 10-K.

Supplemental Guarantor Informat

Supplemental Guarantor Information	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Supplemental Guarantor Information	Supplemental Guarantor Information Effective February 12, 2007 , substantially all of the domestic subsidiaries (the “Guarantor Subsidiaries”) of the company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Convertible Senior Subordinated Debentures due 2027 (the “Debentures”) with an original aggregate principal amount of $135,000,000 . The majority of the company’s subsidiaries are not guaranteeing the indebtedness of the Debentures (the “Non-Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium and interest related to the Debentures and each of the Guarantor Subsidiaries are directly or indirectly100%-owned subsidiaries of the company. Specifically, the Debentures are guaranteed on an unsecured senior subordinated basis by all of the company's existing domestic subsidiaries (other than the company's captive insurance subsidiary and any receivables subsidiaries) and certain future direct and indirect 100% owned domestic subsidiaries. All of the guarantors are released and relieved of any liability under such guarantees upon the satisfaction and discharge of the indenture governing the debentures and the payment in full of the debentures. Additionally, in the event any subsidiary guarantor no longer guarantees any of the company's existing or future senior debt incurred in a public or private U.S. capital markets transaction, such guarantor shall be released and relieved of any liability which it has under the indenture governing the debentures. On February 16, 2016 , all of the company’s subsidiaries were released as guarantors of the Debentures, pursuant to the terms of the Indenture, dated as of February 12, 2007 , between the company and the trustee named therein. See "Subsequent Events". Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented. CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2015 Net sales $ 211,178 $ 402,108 $ 649,966 $ (120,914 ) $ 1,142,338 Cost of products sold 187,272 305,592 457,634 (120,984 ) 829,514 Gross Profit 23,906 96,516 192,332 70 312,824 Selling, general and administrative expenses 111,814 63,068 144,965 — 319,847 Charge related to restructuring activities 1,339 — 632 — 1,971 Income (loss) from equity investee 69,636 29,353 703 (99,692 ) — Interest expense (income)—net 3,011 428 (693 ) — 2,746 Earnings (Loss) from Continuing Operations Before Income Taxes (22,622 ) 62,373 48,131 (99,622 ) (11,740 ) Income taxes 3,568 — 11,142 — 14,710 Net Earnings (Loss) from Continuing Operations (26,190 ) 62,373 36,989 (99,622 ) (26,450 ) Net Earnings from Discontinued Operations — 260 — — 260 Net Earnings (Loss) (26,190 ) 62,633 36,989 (99,622 ) (26,190 ) Other Comprehensive Income (Loss), net of Tax (81,006 ) (15,037 ) (67,842 ) 82,879 (81,006 ) Comprehensive Income (Loss) $ (107,196 ) $ 47,596 $ (30,853 ) $ (16,743 ) $ (107,196 ) CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2014 Net sales $ 213,072 $ 413,067 $ 740,669 $ (96,645 ) $ 1,270,163 Cost of products sold 192,566 314,562 512,521 (96,874 ) 922,775 Gross Profit 20,506 98,505 228,148 229 347,388 Selling, general and administrative expenses 119,904 81,676 182,416 (83 ) 383,913 Charge related to restructuring activities 9,672 (1,326 ) 2,766 — 11,112 Asset write-downs to intangibles — 13,041 — — 13,041 Income (loss) from equity investee 53,536 35,208 280 (89,024 ) — Interest expense—net 175 2,114 243 — 2,532 Earnings (Loss) from Continuing Operations Before Income Taxes (55,709 ) 38,208 43,003 (88,712 ) (63,210 ) Income taxes 361 — 5,189 — 5,550 Net Earnings (Loss) from Continuing Operations (56,070 ) 38,208 37,814 (88,712 ) (68,760 ) Net Earnings from Discontinued Operations — 12,690 — — 12,690 Net Earnings (Loss) (56,070 ) 50,898 37,814 (88,712 ) (56,070 ) Other Comprehensive Income (Loss), net of Tax (53,537 ) (5,057 ) (50,058 ) 55,115 (53,537 ) Comprehensive Income (Loss) $ (109,607 ) $ 45,841 $ (12,244 ) $ (33,597 ) $ (109,607 ) CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2013 Net sales $ 241,871 $ 460,960 $ 720,978 $ (89,304 ) $ 1,334,505 Cost of products sold 211,896 338,650 506,308 (89,775 ) 967,079 Gross Profit 29,975 122,310 214,670 471 367,426 Selling, general and administrative expenses 123,377 93,731 177,530 2,694 397,332 Charge related to restructuring activities 6,356 79 2,901 — 9,336 Asset write-downs to intangibles and goodwill — 1,250 273 — 1,523 Income (loss) from equity investee 133,350 29,644 286 (163,280 ) — Interest (income) expense—net (1,661 ) 3,353 1,002 — 2,694 Earnings (Loss) from Continuing Operations Before Income Taxes 35,253 53,541 33,250 (165,503 ) (43,459 ) Income taxes (benefit) 2,202 (1,785 ) 10,458 — 10,875 Net Earnings (Loss) from Continuing Operations 33,051 55,326 22,792 (165,503 ) (54,334 ) Net Earnings from Discontinued Operations — 87,385 — — 87,385 Net Earnings (Loss) 33,051 142,711 22,792 (165,503 ) 33,051 Other Comprehensive Income (Loss), net of Tax 12,413 (2,309 ) 17,797 (15,488 ) 12,413 Comprehensive Income (Loss) $ 45,464 $ 140,402 $ 40,589 $ (180,991 ) $ 45,464 CONSOLIDATING CONDENSED BALANCE SHEETS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) December 31, 2015 Assets Current Assets Cash and cash equivalents $ 14,047 $ 314 $ 45,694 $ — $ 60,055 Trade receivables, net 43,534 20,020 70,101 — 133,655 Installment receivables, net — 361 784 — 1,145 Inventories, net 6,300 25,418 103,173 (2,084 ) 132,807 Intercompany advances, net 8,392 109 49,022 (57,523 ) — Other current assets 6,380 186 32,384 (4,491 ) 34,459 Total Current Assets 78,653 46,408 301,158 (64,098 ) 362,121 Investment in Subsidiaries 1,430,070 467,352 — (1,897,422 ) — Intercompany Advances, net 1,115,121 1,881,567 185,389 (3,182,077 ) — Other Assets 3,095 727 837 — 4,659 Intangibles 123 388 30,489 — 31,000 Property and Equipment, net 32,382 10,170 36,131 — 78,683 Goodwill — 12,142 349,538 — 361,680 Total Assets $ 2,659,444 $ 2,418,754 $ 903,542 $ (5,143,597 ) $ 838,143 Liabilities and Shareholders’ Equity Current Liabilities Accounts payable $ 38,395 $ 8,699 $ 58,514 $ — $ 105,608 Accrued expenses 31,061 20,940 74,910 (4,491 ) 122,420 Current taxes, payable and deferred 1,336 — 16,252 — 17,588 Intercompany advances, net 43,972 2,412 11,140 (57,524 ) — Short-term debt and current maturities of long-term obligations 880 275 873 — 2,028 Total Current Liabilities 115,644 32,326 161,689 (62,015 ) 247,644 Long-Term Debt 35,326 7,257 2,509 — 45,092 Other Long-Term Obligations 31,821 1,752 49,016 — 82,589 Intercompany Advances, net 2,013,835 1,116,834 51,407 (3,182,076 ) — Total Shareholders’ Equity 462,818 1,260,585 638,921 (1,899,506 ) 462,818 Total Liabilities and Shareholders’ Equity $ 2,659,444 $ 2,418,754 $ 903,542 $ (5,143,597 ) $ 838,143 CONSOLIDATING CONDENSED BALANCE SHEETS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) December 31, 2014 Assets Current Assets Cash and cash equivalents $ 7,340 $ 355 $ 31,236 $ — $ 38,931 Trade receivables, net 47,030 21,979 85,198 — 154,207 Installment receivables, net — 292 762 — 1,054 Inventories, net 25,021 25,784 107,139 (2,383 ) 155,561 Deferred income taxes — — 2,048 — 2,048 Intercompany advances, net 10,007 976 84,816 (95,799 ) — Other current assets 8,082 228 33,123 (4,635 ) 36,798 Assets held for sale - current 3,982 13,406 — — 17,388 Total Current Assets 101,462 63,020 344,322 (102,817 ) 405,987 Investment in Subsidiaries 1,409,482 491,541 — (1,901,023 ) — Intercompany Advances, net 1,049,235 1,685,366 184,652 (2,919,253 ) — Other Assets 16,955 657 1,441 — 19,053 Intangibles 286 393 37,334 — 38,013 Property and Equipment, net 29,632 7,209 42,818 — 79,659 Goodwill — 11,968 409,051 — 421,019 Total Assets $ 2,607,052 $ 2,260,154 $ 1,019,618 $ (4,923,093 ) $ 963,731 Liabilities and Shareholders’ Equity Current Liabilities Accounts payable $ 48,815 $ 6,363 $ 64,749 $ — $ 119,927 Accrued expenses 51,613 20,533 88,188 (4,635 ) 155,699 Current taxes, payable and deferred 1,632 — 11,002 — 12,634 Intercompany advances, net 81,141 1,738 12,921 (95,800 ) — Short-term debt and current maturities of long-term obligations — — 959 — 959 Liabilities held for sale - current 632 381 — — 1,013 Total Current Liabilities 183,833 29,015 177,819 (100,435 ) 290,232 Long-Term Debt 15,351 — 4,021 — 19,372 Other Long-Term Obligations 28,551 — 60,254 — 88,805 Intercompany Advances, net 1,813,995 1,051,170 54,088 (2,919,253 ) — Total Shareholders’ Equity 565,322 1,179,969 723,436 (1,903,405 ) 565,322 Total Liabilities and Shareholders’ Equity $ 2,607,052 $ 2,260,154 $ 1,019,618 $ (4,923,093 ) $ 963,731 CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2015 Net Cash Provided (Used) by Operating Activities $ (26,382 ) $ 2,125 $ 18,774 $ 105 $ (5,378 ) Investing Activities Purchases of property and equipment (464 ) (704 ) (6,354 ) — (7,522 ) Proceeds from sale of property and equipment 23,040 52 25 — 23,117 Proceeds from sale of businesses — 13,700 — — 13,700 Decrease in other long-term assets 14,488 — 515 — 15,003 Other — 5 178 (105 ) 78 Net Cash Provided (Used) for Investing Activities 37,064 13,053 (5,636 ) (105 ) 44,376 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 214,755 — 4,848 — 219,603 Payments on revolving lines of credit and long-term borrowings (217,589 ) (15,219 ) — — (232,808 ) Proceeds from exercise of equity awards 2,402 — — — 2,402 Payment of financing costs (1,954 ) — — — (1,954 ) Payment of dividends (1,589 ) — — — (1,589 ) Net Cash Used (Provided) by Financing Activities (3,975 ) (15,219 ) 4,848 — (14,346 ) Effect of exchange rate changes on cash — — (3,528 ) — (3,528 ) Increase (decrease) in cash and cash equivalents 6,707 (41 ) 14,458 — 21,124 Cash and cash equivalents at beginning of year 7,340 355 31,236 — 38,931 Cash and cash equivalents at end of year $ 14,047 $ 314 $ 45,694 $ — $ 60,055 CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2014 Net Cash (Used) Provided by Operating Activities $ (34,135 ) $ (511 ) $ 14,105 $ 29,433 $ 8,892 Investing Activities Purchases of property and equipment (2,256 ) (1,811 ) (8,260 ) — (12,327 ) Proceeds from sale of property and equipment — — 2,521 — 2,521 Proceeds from sale of businesses — 21,870 — — 21,870 Decrease in other long-term assets 20,926 — 23 — 20,949 Other 44,420 (14,393 ) (25 ) (29,433 ) 569 Net Cash Provided (Used) for Investing Activities 63,090 5,666 (5,741 ) (29,433 ) 33,582 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 255,658 — — — 255,658 Payments on revolving lines of credit and long-term borrowings (277,570 ) (5,113 ) (4,029 ) — (286,712 ) Proceeds from exercise of equity awards 480 — — — 480 Payment of dividends (1,584 ) — — — (1,584 ) Net Used by Financing Activities (23,016 ) (5,113 ) (4,029 ) — (32,158 ) Effect of exchange rate changes on cash — — (1,170 ) — (1,170 ) Increase in cash and cash equivalents 5,939 42 3,165 — 9,146 Cash and cash equivalents at beginning of year 1,401 313 28,071 — 29,785 Cash and cash equivalents at end of year $ 7,340 $ 355 $ 31,236 $ — $ 38,931 CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2013 Net Cash Provided (Used) by Operating Activities $ 11,566 $ (68,792 ) $ 1,891 $ 65,389 $ 10,054 Investing Activities Purchases of property and equipment (3,601 ) (4,020 ) (6,537 ) — (14,158 ) Proceeds from sale of property and equipment 4 13 868 — 885 Proceeds from sale of businesses — 187,552 — — 187,552 Decrease in other long-term assets 833 — 168 — 1,001 Other 181,195 (113,067 ) 20 (68,083 ) 65 Net Cash Provided (Used) for Investing Activities 178,431 70,478 (5,481 ) (68,083 ) 175,345 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 323,187 — 29,268 — 352,455 Payments on revolving lines of credit and long-term borrowings (516,488 ) (2,391 ) (26,995 ) — (545,874 ) Proceeds from exercise of equity awards 512 — — — 512 Payment of dividends (1,581 ) — (2,694 ) 2,694 (1,581 ) Net Cash (Used) Provided by Financing Activities (194,370 ) (2,391 ) (421 ) 2,694 (194,488 ) Effect of exchange rate changes on cash — — 83 — 83 Decrease in cash and cash equivalents (4,373 ) (705 ) (3,928 ) — (9,006 ) Cash and cash equivalents at beginning of year 5,774 1,018 31,999 — 38,791 Cash and cash equivalents at end of year $ 1,401 $ 313 $ 28,071 $ — $ 29,785

Interim Financial Information

Interim Financial Information	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Information	Interim Financial Information (unaudited) QUARTER ENDED (In thousands, except per share data) March 31, June 30, September 30, December 31, 2015 Net sales $ 289,024 $ 286,273 $ 283,776 $ 283,265 Gross profit 77,095 77,287 77,639 80,803 Earnings (loss) from continuing operations before income taxes (5,039 ) (6,492 ) (790 ) 581 Net loss from continuing operations (7,514 ) (8,217 ) (7,790 ) (2,929 ) Net earnings from discontinued operations 260 — — — Net loss (7,254 ) (8,217 ) (7,790 ) (2,929 ) Net loss per share from continuing operations—basic (0.23 ) (0.26 ) (0.24 ) (0.09 ) Net earnings per share from discontinued operations—basic 0.01 — — — Net loss per share—basic (0.23 ) (0.26 ) (0.24 ) (0.09 ) Loss per share from continuing operations—assuming dilution * (0.23 ) (0.26 ) (0.24 ) (0.09 ) Net earnings per share from discontinued operations—assuming dilution 0.01 — — — Net loss per share—assuming dilution * (0.23 ) (0.26 ) (0.24 ) (0.09 ) March 31, June 30, September 30, December 31, 2014 Net sales $ 304,501 $ 326,943 $ 320,520 $ 318,199 Gross profit 82,793 91,578 84,647 88,370 Loss from continuing operations before income taxes (16,870 ) (11,580 ) (26,375 ) (8,385 ) Net loss from continuing operations (18,895 ) (14,455 ) (28,725 ) (6,685 ) Net earnings (loss) from discontinued operations 919 842 13,629 (2,700 ) Net loss (17,976 ) (13,613 ) (15,096 ) (9,385 ) Net loss per share from continuing operations—basic (0.59 ) (0.45 ) (0.90 ) (0.21 ) Net earnings (loss) per share from discontinued operations—basic 0.03 0.03 0.43 (0.08 ) Net loss per share—basic (0.56 ) (0.43 ) (0.47 ) (0.29 ) Net loss per share from continuing operations—assuming dilution * (0.59 ) (0.45 ) (0.90 ) (0.21 ) Net earnings (loss) per share from discontinued operations—assuming dilution 0.03 0.03 0.42 (0.08 ) Net loss per share—assuming dilution * (0.56 ) (0.43 ) (0.47 ) (0.29 ) * Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss. The description of significant items affecting continuing operations for each quarter presented are detailed below. The company has classified Altimate as a discontinued operation for all periods presented. Loss and loss per share for the quarter ended March 31, 2015 reflects restructuring charges of $240,000 ( $240,000 after tax or $0.01 per share assuming dilution) and increased amortization expense related to the write-off of debt fees related to a debt amendment of $668,000 ( $668,000 after tax or $0.02 per share assuming dilution). Loss and loss per share for the quarter ended June 30, 2015 reflects restructuring charges of $689,000 ( $635,000 after tax or $0.02 per share assuming dilution). Loss and loss per share for the quarter ended September 30, 2015 reflects a tax expense impact as a result of goodwill deducted for tax purposes from the sale of the rentals business of $3,400,000 ( $0.11 per share assuming dilution). Loss and loss per share for the quarter ended December 31, 2015 reflects recall warranty expense reversal of $2,325,000 ( $2,325,000 after tax or $0.07 per share assuming dilution) and restructuring charges of $1,031,000 pre-tax ( $957,000 after tax or $0.03 per share assuming dilution). Loss and loss per share for the quarter ended March 31, 2014 reflects restructuring charges of $2,240,000 ( $1,811,000 after tax or $0.06 per share assuming dilution), incremental recall warranty expense of $2,237,000 ( $2,100,000 after tax or $0.07 per share assuming dilution) and increased amortization expense related to the write-off of debt fees related to a debt amendment of $1,070,000 ( $1,070,000 after tax or $0.03 per share assuming dilution). Loss and loss per share for the quarter ended June 30, 2014 reflects restructuring charges of $2,090,000 ( $1,711,000 after tax or $0.05 per share assuming dilution). Loss and loss per share for the quarter ended September 30, 2014 reflects restructuring charge of $4,077,000 ( $3,842,000 after tax or $0.12 per share assuming dilution), incremental recall warranty expense of $9,256,000 ( $8,701,000 after tax or $0.27 per share assuming dilution), intangible asset write-downs of $8,253,000 ( $8,253,000 after tax or $0.26 per share assuming dilution)and a positive impact of an intraperiod tax allocation associated with discontinued operations of $1,550,000 ( $0.05 per share assuming dilution). Loss and loss per share for the quarter ended December 31, 2014 reflects restructuring charges of $2,705,000 ( $2,732,000 after tax or $0.09 per share assuming dilution), asset write-downs for intangibles of $4,788,000 ( $4,788,000 after tax or $0.15 per share assuming dilution) and the positive impact of an intraperiod tax allocation associated with discontinued operations $2,700,000 ( $0.08 per share assuming dilution).

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	COL A. COL B. COL C. COL D. Balance At Beginning of Period Charged To Cost And Expenses Additions (Deductions) Describe Balance At End of Period (In thousands) Year Ended December 31, 2015 Deducted from asset accounts— Allowance for doubtful accounts $ 17,822 $ 754 $ (5,297 ) (A) $ 13,279 Inventory obsolescence reserve 17,617 5,054 (5,983 ) (B) 16,688 Tax valuation allowances 133,912 19,717 (1,657 ) (D) 151,972 Accrued warranty cost 30,738 9,899 (17,817 ) (B) 22,820 Accrued product liability 23,194 5,250 (10,735 ) (C) 17,709 Year Ended December 31, 2014 Deducted from asset accounts— Allowance for doubtful accounts $ 23,144 $ 1,765 $ (7,087 ) (A) $ 17,822 Inventory obsolescence reserve 15,135 5,993 (3,511 ) (B) 17,617 Tax valuation allowances 117,790 33,195 (17,073 ) (D) 133,912 Accrued warranty cost 27,393 26,097 (22,752 ) (B) 30,738 Accrued product liability 20,368 5,910 (3,084 ) (C) 23,194 Year Ended December 31, 2013 Deducted from asset accounts— Allowance for doubtful accounts $ 25,232 $ 3,684 $ (5,772 ) (A) $ 23,144 Inventory obsolescence reserve 13,085 5,310 (3,260 ) (B) 15,135 Tax valuation allowances 97,406 1,078 19,306 (D) 117,790 Accrued warranty cost 21,451 19,394 (13,452 ) (B) 27,393 Accrued product liability 20,334 7,039 (7,005 ) (C) 20,368 ________________________ Note (A)—Uncollectible accounts written off, net of recoveries. Note (B)—Amounts written off or payments incurred. Note (C)—Loss and loss adjustment. Note (D)—Other activity not affecting federal or foreign tax expense.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home based upon the company’s distribution channels, breadth of product line and net sales. The company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and continuing care markets.
Principles of Consolidation	Principles of Consolidation: The consolidated financial statements include the accounts of the company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the company as of December 31, 2015 and the results of its operations and changes in its cash flow for the years ended December 31, 2015 , 2014 and 2013 , respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a November 30 fiscal year end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the company’s financial statements. All significant intercompany transactions are eliminated.
Use of Estimates	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
Accounts Receivables	Accounts Receivable: The company records accounts receivable when product ships or services are provided to its unaffiliated customers, risk of loss is passed and title is transferred. The estimated allowance for uncollectible amounts is based primarily on management's evaluation of the financial condition of specific customers. The company records accounts receivable reserves for amounts that may become uncollectible in the future. The company writes off accounts receivable when it becomes apparent, based upon customer circumstances, that such amounts will not be collected and legal remedies are exhausted.
Inventories	Inventories: Inventories are stated at the lower of cost or market with cost determined by the first-in, first-out method. Market values are based on the lower of replacement cost or estimated net realizable value. Finished goods and work in process inventories include material, labor and manufacturing overhead costs. Inventories have been reduced by an allowance for excess and obsolete inventories. The estimated allowance is based on management’s review of inventories on hand compared to estimated future usage and sales.
Property and Equipment	Property and Equipment: Property and equipment are stated on the basis of cost. The company principally uses the straight-line method of depreciation for financial reporting purposes based on annual rates sufficient to amortize the cost of the assets over their estimated useful lives. Machinery and equipment as well as furniture and fixtures are generally depreciated using lives of 3 to 10 years, while buildings and improvements are depreciated using lives of 5 to 40 years. Accelerated methods of depreciation are used for federal income tax purposes. Expenditures for maintenance and repairs are charged to expense as incurred. Amortization of assets under capital leases is included in depreciation expense. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An asset would be considered impaired when the future net undiscounted cash flows generated by the asset are less than its carrying value. An impairment loss would be recognized based on the amount by which the carrying value of the asset exceeds its fair value.
Goodwill and Other Intangibles	Goodwill and Other Intangibles: In accordance with Intangibles—Goodwill and Other , ASC 350, goodwill and indefinite lived intangibles are subject to annual impairment testing. For purposes of the goodwill impairment test, the fair value of each reporting unit is estimated by forecasting cash flows and discounting those cash flows using appropriate discount rates. The fair values are then compared to the carrying value of the net assets of each reporting unit. Intangibles assets are also reviewed for impairment by estimating forecasted cash flows and discounting those cash flows as needed to calculate impairment amounts. During 2014, the company recognized intangible write-down charges of $13,041,000 comprised of a customer list impairment of $12,826,000 and a non-compete agreement impairment of $215,000 each recorded in the IPG segment. During 2013, the company recognized intangible write-down charges of $1,523,000 comprised of: trademarks with indefinite lives impairment of $568,000 , a trademark with a definite life impairment of $123,000 , customer list impairment of $442,000 and a developed technology impairment of $223,000 each recorded in the IPG segment and a customer list impairment of $167,000 recorded in the North America/HME segment.
Accrued Warranty Cost	Accrued Warranty Cost: Generally, the company’s products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sale to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the company’s warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. See Current Liabilities in the Notes to the Consolidated Financial Statements for a reconciliation of the changes in the warranty accrual.
Product Liability Cost	Product Liability Cost: The company is self-insured in North America for product liability exposures through its captive insurance company, Invatection Insurance Company, which currently has a policy year that runs from September 1 to August 31 and insures annual policy losses up to $10,000,000 per occurrence and $13,000,000 in the aggregate. The company also has additional layers of external insurance coverage, related to all lines of insurance coverage, insuring up to $75,000,000 in aggregate losses per policy year arising from individual claims anywhere in the world that exceed the captive insurance company policy limits or the limits of the company’s per country foreign liability limits, as applicable. There can be no assurance that Invacare’s current insurance levels will continue to be adequate or available at affordable rates. Product liability reserves are recorded for individual claims based upon historical experience, industry expertise and other indicators. Additional reserves, in excess of the specific individual case reserves, are provided for incurred but not reported claims based upon actuarial valuations at the time such valuations are conducted. Historical claims experience and other assumptions are taken into consideration by the company in estimating the ultimate reserves. For example, the actuarial analysis assumes that historical loss experience is an indicator of future experience, that the distribution of exposures by geographic area and nature of operations for ongoing operations is expected to be very similar to historical operations with no dramatic changes and that the government indices used to trend losses and exposures are appropriate. Estimates made are adjusted on a regular basis and can be impacted by actual loss awards and settlements on claims. While actuarial analysis is used to help determine adequate reserves, the company is responsible for the determination and recording of adequate reserves in accordance with accepted loss reserving standards and practices.
Revenue Recognition	Revenue Recognition: Invacare’s revenues are recognized when products are shipped or service provided to unaffiliated customers, risk of loss is passed and title is transferred. Revenue Recognition , ASC 605, provides guidance on the application of generally accepted accounting principles to selected revenue recognition issues. Shipping and handling costs are included in cost of goods sold. Sales are made only to customers with whom the company believes collection is reasonably assured based upon a credit analysis, which may include obtaining a credit application, a signed security agreement, personal guarantee and/or a cross corporate guarantee depending on the credit history of the customer. Credit lines are established for new customers after an evaluation of their credit report and/or other relevant financial information. Existing credit lines are regularly reviewed and adjusted with consideration given to any outstanding past due amounts. The company offers discounts and rebates, which are accounted for as reductions to revenue in the period in which the sale is recognized. Discounts offered include: cash discounts for prompt payment, base and trade discounts based on contract level for specific classes of customers. Volume discounts and rebates are given based on large purchases and the achievement of certain sales volumes. Product returns are accounted for as a reduction to reported sales with estimates recorded for anticipated returns at the time of sale. The company does not sell any goods on consignment. Distributed products sold by the company are accounted for in accordance with the revenue recognition guidance in ASC 605-45-05 . The company records distributed product sales gross as a principal since the company takes title to the products and has the risks of loss for collections, delivery and returns. Product sales that give rise to installment receivables are recorded at the time of sale when the risks and rewards of ownership are transferred. As such, interest income is recognized based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments, interest income is no longer recognized. All installment accounts are accounted for using the same methodology, regardless of duration of the installment agreements. The company has entered into an agreement with De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to Invacare customers.
Research and Development	Research and Development: Research and development costs are expensed as incurred and included in cost of products sold. The company’s annual expenditures for product development and engineering were approximately $18,677,000 , $23,149,000 and $24,075,000 for 2015 , 2014 and 2013 , respectively.
Advertising	Advertising: Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising expenses amounted to $9,203,000 , $13,463,000 and $15,026,000 for 2015 , 2014 and 2013 , respectively, the majority of which is incurred for advertising in the United States and Europe.
Income Taxes	Income Taxes: The company uses the liability method in measuring the provision for income taxes and recognizing deferred tax assets and liabilities on the balance sheet. The liability method requires that deferred income taxes reflect the tax consequences of currently enacted rates for differences between the tax and financial reporting bases of assets and liabilities. With the exception of two subsidiaries, foreign subsidiaries with undistributed earnings are considered to have such earnings indefinitely reinvested and, accordingly with the exception of the two subsidiaries, no deferred tax liability has been provided for future repatriation of $24,100,000 of unremitted earnings of these foreign subsidiaries. The amount of the unrecognized deferred tax liability for temporary differences related to investments in foreign subsidiaries that are permanently reinvested is not practically determinable. The company has recorded the deferred tax impact of the unremitted earnings of the two subsidiaries for which the earnings are not permanently reinvested.
Derivative Instruments	Derivative Instruments: Derivatives and Hedging, ASC 815, requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. The company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.
Foreign Currency Translation	Foreign Currency Translation: The functional currency of the company’s subsidiaries outside the United States is the applicable local currency. The assets and liabilities of the company’s foreign subsidiaries are translated into U.S. dollars at year-end exchange rates. Revenues and expenses are translated at monthly average exchange rates. Gains and losses resulting from translation of balance sheet items are included in accumulated other comprehensive earnings.
Net Earnings Per Share	Net Earnings Per Share: Basic earnings per share are computed based on the weighted-average number of Common Shares and Class B Common Shares outstanding during the year. Diluted earnings per share are computed based on the weighted-average number of Common Shares and Class B Common Shares outstanding plus the effects of dilutive stock options and awards outstanding during the year. Diluted earnings per share can potentially be impacted by the convertible notes issued in 2007 should the conditions be met to make the notes convertible or if average market price of company stock for the period exceeds the conversion price of $24.79 . For periods in which there was a net loss, loss per share assuming dilution utilized weighted average shares-basic.
Defined Benefit Plans	Defined Benefit Plans: The company’s benefit plans are accounted for in accordance with Compensation-Retirement Benefits , ASC 715 which requires plan sponsors to recognize the funded status of their defined benefit postretirement benefit plans in the consolidated balance sheet, measure the fair value of plan assets and benefit obligations as of the balance sheet date and to recognize changes in that funded status in the year in which the changes occur through comprehensive income.
Reclassifications	Reclassifications: In May 2015, the company's board of directors authorized the sale of the company's former rentals businesses. Accordingly, the rentals businesses were treated as held for sale. The company's December 31, 2014 Balance Sheet was restated to reflect this treatment. See Operations Held for Sale in the Notes to the Consolidated Financial Statements for a description of the impact on the consolidated balance sheet.
Recent Accounting Pronouncements	Recent Accounting Pronouncements: In April 2014, the FASB issued ASU 2014-08 changing the presentation of discontinued operations on the statements of income and other requirements for reporting discontinued operations. Under the new standard, a disposal of a component or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the component meets the criteria to be classified as held for sale or is disposed. The amendments in this update also require additional disclosures about discontinued operations and disposal of an individually significant component of an entity that does not qualify for discontinued operations. This standard must be prospectively applied to all reporting periods presented in financial reports issued after the effective date. Early adoption was permitted for disposals that were not reported in financial statements previously issued or available for issuance. The new accounting guidance was effective for interim and annual periods beginning after December 15, 2014. This standard can impact the presentation of the company's financial statements but does not affect the calculation of net income, comprehensive income or earnings per share. The company adopted ASU 2014-08 effective January 1, 2015 which impacted the company’s Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets and Statement of Cash Flows. Specifically, the disposal of the United States Rentals businesses, in the third quarter of 2015, was not deemed to be a discontinued operation. In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers." ASU 2014-09 requires a company to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. The guidance requires five steps to be applied: 1) identify the contract(s) with customers, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocate the transaction price to the performance obligation in the contract and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also requires both quantitative and qualitative disclosures, which are more comprehensive than existing revenue standards. The disclosures are intended to enable financial statement users to understand the nature, timing and uncertainty of revenue and the related cash flow. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospective with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new accounting guidance is effective for annual periods beginning after December 15, 2017, due to an approved one-year deferral, and early adoption is not permitted. The company is currently reviewing the impact of the adoption of ASU 2014-09 on the company's financial statements. In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 requires debt issuance costs to be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability, which is similar presentation of debt discounts or premiums. Debt issuance costs are currently reported on the balance sheet as assets and amortized as interest expense. ASU 2015-03 does not change the recognition and measurement guidance for debt issuance costs and requires retrospective application to all periods presented upon adoption. The new accounting guidance is effective for fiscal periods beginning after December 15, 2015 and early adoption is permitted. The company has determined the adoption of ASU 2015-03 will not have a material impact on the company's financial statements. In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory,” to simplify the subsequent measurement of inventory. Entities are now required to subsequently measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market. This update is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, and early adoption is permitted. The company is currently reviewing the impact of the adoption of ASU 2015-11 on the company's financial statements. In November 2015, the FASB issued ASU 2015-17, "Balance Sheet Classification of Deferred Taxes." ASU 2015-17 requires deferred tax assets and liabilities to be classified as noncurrent amounts on the balance sheet. The new accounting guidance is effective for fiscal periods beginning after December 15, 2016 and early adoption is permitted. The company adopted ASU 2015-17, on a prospective basis, effective October 1, 2015 and thus the company's deferred tax assets and liabilities have been classified as long-term in its Balance Sheet as of December 31, 2015. No prior periods were retrospectively adjusted. In February 2016, the FASB issued ASU 2016-02, "Leases." ASU 2016-02 requires lessees to put most leases on their balance sheet while recognizing expense in a manner similar to existing accounting. The new accounting guidance is effective for fiscal periods beginning after December 15, 2018 and early adoption is permitted. The company is currently reviewing the impact of the adoption of ASU 2016-02 on the company's financial statements.

Operations Held for Sale (Table

Operations Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	The assets and liabilities of the rentals businesses that were sold and shown as held for sale in the company's Consolidated Balance Sheets were comprised of the following (in thousands): July 2, December 31, Trade receivables, net $ 5,834 $ 6,207 Inventories, net 412 315 Other current assets 212 221 Property and equipment, net 4,126 5,896 Goodwill 4,518 4,692 Intangibles 40 57 Assets sold $ 15,142 $ 17,388 Accounts payable $ 410 $ 225 Accrued expenses and other short-term obligations 1,056 788 Liabilities sold $ 1,466 $ 1,013

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Altimate Medical, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	The assets and liabilities of Altimate were the following as of the date of the sale, August 29, 2014 , and as of December 31, 2013 (in thousands): August 29, Trade receivables, net $ 2,019 Inventories, net 1,954 Other current assets 246 Property and equipment, net 176 Other Intangibles 1,047 Assets sold $ 5,442 Accounts payable $ 425 Accrued expenses 316 Liabilities sold $ 741

Receivables (Tables)

Receivables (Tables)	12 Months Ended
	Dec. 31, 2015
Receivables [Abstract]
Schedule of Installment Receivables	Installment receivables as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Current Long- Term Total Current Long- Term Total Installment receivables $ 2,309 $ 2,318 $ 4,627 $ 2,692 $ 5,117 $ 7,809 Less: Unearned interest (42 ) — (42 ) (46 ) — (46 ) 2,267 2,318 4,585 2,646 5,117 7,763 Allowance for doubtful accounts (1,122 ) (1,670 ) (2,792 ) (1,592 ) (4,260 ) (5,852 ) $ 1,145 $ 648 $ 1,793 $ 1,054 $ 857 $ 1,911
Schedule of Installment Receivables Allowance for Doubtful Accounts	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands): 2015 2014 Balance as of January 1 $ 5,852 $ 6,039 Current period (benefit) provision (332 ) 796 Direct write-offs charged against the allowance (2,728 ) (983 ) Balance as of December 31 $ 2,792 $ 5,852
Schedule of Installment Receivables by Class	Installment receivables by class as of December 31, 2015 consist of the following (in thousands): Total Installment Receivables Unpaid Principal Balance Related Allowance for Doubtful Accounts Interest Income Recognized U.S. Impaired installment receivables with a related allowance recorded $ 3,618 $ 3,618 $ 2,729 $ — Canada Non-Impaired installment receivables with no related allowance recorded 946 904 — 52 Impaired installment receivables with a related allowance recorded 63 63 63 — Total Canadian installment receivables $ 1,009 $ 967 $ 63 $ 52 Total Non-Impaired installment receivables with no related allowance recorded 946 904 — 52 Impaired installment receivables with a related allowance recorded 3,681 3,681 2,792 — Total installment receivables $ 4,627 $ 4,585 $ 2,792 $ 52 Installment receivables by class as of December 31, 2014 consist of the following (in thousands): Total Installment Receivables Unpaid Principal Balance Related Allowance for Doubtful Accounts Interest Income Recognized U.S. Impaired installment receivables with a related allowance recorded $ 6,735 $ 6,735 $ 5,786 $ — Canada Non-Impaired installment receivables with no related allowance recorded 1,008 962 — 82 Impaired installment receivables with a related allowance recorded 66 66 66 — Total Canadian installment receivables $ 1,074 $ 1,028 $ 66 $ 82 Total Non-Impaired installment receivables with no related allowance recorded 1,008 962 — 82 Impaired installment receivables with a related allowance recorded 6,801 6,801 5,852 — Total installment receivables $ 7,809 $ 7,763 $ 5,852 $ 82
Schedule of Financing Receivables	Installment receivables by class as of December 31, 2015 consist of the following (in thousands): Total Installment Receivables Unpaid Principal Balance Related Allowance for Doubtful Accounts Interest Income Recognized U.S. Impaired installment receivables with a related allowance recorded $ 3,618 $ 3,618 $ 2,729 $ — Canada Non-Impaired installment receivables with no related allowance recorded 946 904 — 52 Impaired installment receivables with a related allowance recorded 63 63 63 — Total Canadian installment receivables $ 1,009 $ 967 $ 63 $ 52 Total Non-Impaired installment receivables with no related allowance recorded 946 904 — 52 Impaired installment receivables with a related allowance recorded 3,681 3,681 2,792 — Total installment receivables $ 4,627 $ 4,585 $ 2,792 $ 52 Installment receivables by class as of December 31, 2014 consist of the following (in thousands): Total Installment Receivables Unpaid Principal Balance Related Allowance for Doubtful Accounts Interest Income Recognized U.S. Impaired installment receivables with a related allowance recorded $ 6,735 $ 6,735 $ 5,786 $ — Canada Non-Impaired installment receivables with no related allowance recorded 1,008 962 — 82 Impaired installment receivables with a related allowance recorded 66 66 66 — Total Canadian installment receivables $ 1,074 $ 1,028 $ 66 $ 82 Total Non-Impaired installment receivables with no related allowance recorded 1,008 962 — 82 Impaired installment receivables with a related allowance recorded 6,801 6,801 5,852 — Total installment receivables $ 7,809 $ 7,763 $ 5,852 $ 82
Schedule of Aging of Installment Receivables	The aging of the company’s installment receivables was as follows as of December 31, 2015 and 2014 (in thousands): December 31, 2015 December 31, 2014 Total U.S. Canada Total U.S. Canada Current $ 908 $ — $ 908 $ 976 $ — $ 976 0-30 days past due 16 — 16 15 — 15 31-60 days past due 12 — 12 2 — 2 61-90 days past due 1 — 1 — — — 90+ days past due 3,690 3,618 72 6,816 6,735 81 $ 4,627 $ 3,618 $ 1,009 $ 7,809 $ 6,735 $ 1,074

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories, net of reserves, as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Finished goods $ 67,207 $ 85,828 Raw materials 54,005 57,509 Work in process 11,595 12,224 $ 132,807 $ 155,561

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Current Assets	Other current assets as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Value added tax receivables $ 18,031 $ 21,273 Recoverable income taxes 367 261 Derivatives (foreign currency forward contracts) 4,143 520 Prepaid insurance 2,538 2,713 Prepaid and other current assets 9,380 12,031 $ 34,459 $ 36,798

Other Long-Term Assets (Tables)

Other Long-Term Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets, Noncurrent	Other long-term assets as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Cash surrender value of life insurance policies $ 1,674 $ 15,765 Deferred financing fees 1,088 408 Investments 160 249 Long-term installment receivables 648 857 Long-term deferred taxes 908 613 Other 181 1,161 $ 4,659 $ 19,053

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Machinery and equipment $ 299,721 $ 318,286 Land, buildings and improvements 73,830 81,219 Furniture and fixtures 10,031 11,738 Leasehold improvements 11,966 14,517 395,548 425,760 Less allowance for depreciation (316,865 ) (346,101 ) $ 78,683 $ 79,659

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The carrying amount of goodwill by operating segment is as follows (in thousands): Institutional Products Group Europe Consolidated Balance at January 1, 2014 $ 31,615 $ 425,919 $ 457,534 Foreign currency translation adjustments (1,696 ) (34,819 ) (36,515 ) Balance at December 31, 2014 29,919 391,100 421,019 Foreign currency translation adjustments (2,763 ) (56,576 ) (59,339 ) Balance at December 31, 2015 $ 27,156 $ 334,524 $ 361,680

Intangibles (Tables)

Intangibles (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	The company’s intangibles consist of the following (in thousands): December 31, 2015 December 31, 2014 Historical Cost Accumulated Amortization Historical Cost Accumulated Amortization Customer lists $ 49,858 $ 45,019 $ 78,693 $ 71,343 Trademarks 24,524 — 28,314 — License agreements 1,098 1,098 1,290 1,290 Developed technology 7,405 5,921 8,297 6,340 Patents 5,959 5,843 6,102 5,804 Other 1,161 1,124 2,548 2,454 $ 90,005 $ 59,005 $ 125,244 $ 87,231
Schedule of Finite Lived Intangible Assets	The company’s intangibles consist of the following (in thousands): December 31, 2015 December 31, 2014 Historical Cost Accumulated Amortization Historical Cost Accumulated Amortization Customer lists $ 49,858 $ 45,019 $ 78,693 $ 71,343 Trademarks 24,524 — 28,314 — License agreements 1,098 1,098 1,290 1,290 Developed technology 7,405 5,921 8,297 6,340 Patents 5,959 5,843 6,102 5,804 Other 1,161 1,124 2,548 2,454 $ 90,005 $ 59,005 $ 125,244 $ 87,231

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses as of December 31, 2015 and 2014 consisted of accruals for the following (in thousands): 2015 2014 Salaries and wages $ 41,305 $ 40,850 Taxes other than income taxes, primarily Value Added Taxes 21,424 24,743 Warranty cost 22,820 30,738 Supplemental Executive Retirement Plan (SERP) 1,279 21,517 Freight 6,153 6,202 Professional 5,774 6,613 Product liability, current portion 3,127 4,334 Rebates 1,791 1,722 Insurance 695 1,266 Interest 872 1,068 Derivatives (foreign currency forward exchange contracts) 2,014 2,526 Severance 2,477 4,209 Other items, principally trade accruals 12,689 9,911 $ 122,420 $ 155,699
Accrued Warranty Costs	Changes in accrued warranty costs were as follows (in thousands): 2015 2014 Balance as of January 1 $ 30,738 $ 27,393 Warranties provided during the period 11,561 21,472 Settlements made during the period (17,817 ) (22,752 ) Changes in liability for pre-existing warranties during the period, including expirations (1,662 ) 4,625 Balance as of December 31 $ 22,820 $ 30,738

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Debt as of December 31, 2015 and 2014 consisted of the following (in thousands): 2015 2014 Senior secured revolving credit facility, due in October 2015 $ — $ 4,000 Convertible senior subordinated debentures at 4.125%, due in February 2027 12,147 11,351 Other notes and lease obligations 34,973 4,980 47,120 20,331 Less current maturities of long-term debt (2,028 ) (959 ) $ 45,092 $ 19,372
Schedule of Debt	The components of the company’s convertible debt as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Carrying amount of equity component $ 25,381 $ 25,381 Principal amount of liability component $ 13,350 $ 13,350 Unamortized discount (1,203 ) (1,999 ) Net carrying amount of liability component $ 12,147 $ 11,351

Other Long-Term Obligations (Ta

Other Long-Term Obligations (Tables)	12 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Schedule of Other Liabilities, Noncurrent	Other long-term obligations as of December 31, 2015 and 2014 consist of the following (in thousands): 2015 2014 Supplemental Executive Retirement Plan liability $ 4,930 $ 6,067 Product liability 14,582 18,860 Deferred income taxes 32,115 30,423 Deferred gain on sale leaseback 6,978 — Deferred compensation 4,167 5,667 Uncertain tax obligation including interest 4,467 15,160 Other 15,350 12,628 Total long-term obligations $ 82,589 $ 88,805

Leases and Commitments (Tables)

Leases and Commitments (Tables)	12 Months Ended
	Dec. 31, 2015
Leases [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum operating and capital lease commitments, as of December 31, 2015 , are as follows (in thousands): Capital Leases Operating Leases 2016 $ 3,375 $ 15,067 2017 3,375 8,804 2018 2,848 5,005 2019 2,671 2,378 2020 2,671 1,101 Thereafter 32,872 268 Total future minimum lease payments 47,812 $ 32,623 Amounts representing interest (12,839 ) Present value of minimum lease payments $ 34,973
Schedule of Future Minimum Lease Payments for Capital Leases	Future minimum operating and capital lease commitments, as of December 31, 2015 , are as follows (in thousands): Capital Leases Operating Leases 2016 $ 3,375 $ 15,067 2017 3,375 8,804 2018 2,848 5,005 2019 2,671 2,378 2020 2,671 1,101 Thereafter 32,872 268 Total future minimum lease payments 47,812 $ 32,623 Amounts representing interest (12,839 ) Present value of minimum lease payments $ 34,973

Equity Compensation (Tables)

Equity Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The amounts of equity-based compensation expense recognized as part of selling, general and administrative expenses were as follows (in thousands): 2015 2014 2013 Non-Qualified stock options $ 1,228 $ 3,356 $ 3,926 Restricted stock and restricted stock units 2,785 2,270 2,031 Performance shares and performance share units — — — Total stock-based compensation expense $ 4,013 $ 5,626 $ 5,957
Schedule of Unrecognized Compensation Cost, Nonvested Awards	As of December 31, 2015 , unrecognized compensation expense related to equity-based compensation arrangements granted under the company's 2013 Plan and previous plans, which is related to non-vested options and shares, was as follows (in thousands): 2015 2014 2013 Non-Qualified stock options $ 1,059 $ 2,600 $ 8,270 Restricted stock and restricted stock units 9,476 4,461 3,705 Performance shares and performance share units — — — Total stock-based compensation expense $ 10,535 $ 7,061 $ 11,975
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes information about stock option activity for the three years ended 2015 , 2014 and 2013 : 2015 Weighted Average Exercise Price 2014 Weighted Average Exercise Price 2013 Weighted Average Exercise Price Options outstanding at January 1 3,600,132 $ 22.74 4,533,782 $ 23.86 4,664,634 $ 26.21 Granted — 0.00 8,977 16.71 756,700 14.47 Exercised (172,218 ) 13.95 (33,810 ) 14.16 (30,166 ) 16.94 Canceled (485,131 ) 34.98 (908,817 ) 28.57 (857,386 ) 28.63 Options outstanding at December 31 2,942,783 $ 21.22 3,600,132 $ 22.74 4,533,782 $ 23.86 Options exercise price range at December 31 $ 13.37 to $ 13.37 to $ 13.35 to $ 33.36 $ 47.80 $ 47.80 Options exercisable at December 31 2,656,983 2,954,082 2,985,175 Shares available for grant at December 31* 2,659,562 3,654,426 4,460,337 ________________________ * Shares available for grant as of December 31, 2015 reduced by net restricted stock / unit and performance share / unit award activity of 1,110,740 shares and 681,058 shares, respectively.
Schedule of Share-based Compensation, Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2015 : Options Outstanding Options Exercisable Exercise Prices Number Outstanding At 12/31/15 Weighted Average Remaining Contractual Life Years Weighted Average Exercise Price Number Exercisable At 12/31/15 Weighted Average Exercise Price $ 13.37 – $20.00 778,159 6.7 $ 14.12 493,671 $ 14.11 $ 20.01 – $25.00 1,353,578 3.3 22.59 1,353,578 22.59 $ 25.01 – $30.00 783,738 3.7 25.55 783,738 25.55 $ 30.01 – $33.36 27,308 1.0 31.74 25,996 31.73 Total 2,942,783 4.3 $ 21.22 2,656,983 $ 21.98
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for awards granted in 2014 and 2013 as no options were granted in 2015: 2014 2013 Expected dividend yield 0.3 % 0.4 % Expected stock price volatility 36.8 % 38.2 % Risk-free interest rate 1.76 % 0.82 % Expected life in years 6.1 6.1 Forfeiture percentage 13.0 % 9.2 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes information about restricted shares and restricted share units (for non-U.S. recipients): 2015 Weighted Average Fair Value 2014 Weighted Average Fair Value 2013 Weighted Average Fair Value Stock / Units unvested at January 1 312,423 $ 17.91 264,878 $ 16.69 260,548 $ 19.15 Granted 480,839 19.09 218,276 19.36 114,700 14.49 Vested (56,976 ) 16.47 (93,140 ) 17.62 (97,445 ) 20.33 Canceled (94,781 ) 18.11 (77,591 ) 17.58 (12,925 ) 19.23 Stock / Units unvested at December 31 641,505 $ 18.89 312,423 $ 17.91 264,878 $ 16.69
Share-based Compensation, Performance Shares Award Unvested Activity	The following table summarizes information about performance shares and performance share units (for non-U.S. recipients): 2015 Weighted Average Fair Value 2014 Weighted Average Fair Value Shares / Units unvested at January 1 121,644 $ 20.05 — $ — Granted 114,257 18.95 152,800 20.05 Vested — — — — Canceled (37,500 ) 19.62 (31,156 ) 20.05 Shares / Units unvested at December 31 198,401 $ 19.50 121,644 $ 20.05

Accumulated Other Comprehensi53

Accumulated Other Comprehensive Income (Loss) by Component (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income ("OCI") during the year ended December 31, 2015 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2014 $ 86,236 $ (6,465 ) $ (7,601 ) $ (551 ) $ 71,619 OCI before reclassifications (91,980 ) 10,576 (2,292 ) 3,545 (80,151 ) Amount reclassified from accumulated OCI — — 136 (991 ) (855 ) Net current-period OCI (91,980 ) 10,576 (2,156 ) 2,554 (81,006 ) December 31, 2015 $ (5,744 ) $ 4,111 $ (9,757 ) $ 2,003 $ (9,387 ) Changes in OCI during the year ended December 31, 2014 were as follows (in thousands): Foreign Currency Long-Term Notes Defined Benefit Plans Derivatives Total December 31, 2013 $ 143,845 $ (12,566 ) $ (5,414 ) $ (709 ) $ 125,156 OCI before reclassifications (57,609 ) 6,101 (3,223 ) 562 (54,169 ) Amount reclassified from accumulated OCI — — 1,036 (404 ) 632 Net current-period OCI (57,609 ) 6,101 (2,187 ) 158 (53,537 ) December 31, 2014 $ 86,236 $ (6,465 ) $ (7,601 ) $ (551 ) $ 71,619
Schedule of Amounts Recognized in Other Comprehensive Income (Loss)	Reclassifications out of accumulated OCI for the year ended December 31, 2015 and December 31, 2014 were as follows (in thousands): Amount reclassified from OCI Affected Statement of Comprehensive (Income) Loss line 2015 2014 Defined Benefit Plans Service and interest costs $ 133 $ 1,045 Selling, General and Administrative Tax 3 (9 ) Income Taxes Total after tax $ 136 $ 1,036 Derivatives Foreign currency forward contracts hedging sales $ 2,778 $ 657 Net Sales Foreign currency forward contracts hedging purchases (3,890 ) (995 ) Cost of Products Sold Interest rate swaps — 12 Interest Expense Total before tax (1,112 ) (326 ) Tax 121 (78 ) Income Taxes Total after tax $ (991 ) $ (404 )

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Schedule of Capital Stock	Capital stock activity for 2015 , 2014 and 2013 consisted of the following (in thousands of shares): Common Stock Shares Class B Shares Treasury Shares January 1, 2013 Balance 33,952 1,085 (3,135 ) Exercise of stock options 30 — — Restricted stock awards 102 — (23 ) December 31, 2013 Balance 34,084 1,085 (3,158 ) Exercise of stock options 34 — — Restricted stock awards 101 — (29 ) December 31, 2014 Balance 34,219 1,085 (3,187 ) Conversion of Class B to Common 351 (351 ) — Exercise of stock options 172 — — Restricted stock awards 282 — (7 ) December 31, 2015 Balance 35,024 734 (3,194 )

Charges Related To Restructur55

Charges Related To Restructuring Activities (Tables)	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands): Severance Inventory Lease Terminations Other Total December 31, 2010 Balance $ — $ — $ — $ — $ — Charges North America/HME 4,755 — — 4 4,759 IPG 123 — — — 123 Europe 3,288 277 1,788 113 5,466 Asia/Pacific 186 — — — 186 Total 8,352 277 1,788 117 10,534 Payments North America/HME (1,663 ) — — (4 ) (1,667 ) IPG (52 ) — — — (52 ) Europe (1,546 ) (277 ) (1,714 ) (113 ) (3,650 ) Asia/Pacific (186 ) — — — (186 ) Total (3,447 ) (277 ) (1,714 ) (117 ) (5,555 ) December 31, 2011 Balance North America/HME 3,092 — — — 3,092 IPG 71 — — — 71 Europe 1,742 — 74 — 1,816 Asia/Pacific — — — — — Total 4,905 — 74 — 4,979 Charges North America/HME 4,242 — 5 — 4,247 IPG 35 — — — 35 Europe 817 — 53 1,223 2,093 Asia/Pacific 1,681 491 1,667 1,181 5,020 Total 6,775 491 1,725 2,404 11,395 Payments North America/HME (3,587 ) — (5 ) — (3,592 ) IPG (106 ) — — — (106 ) Europe (1,964 ) — (127 ) (1,223 ) (3,314 ) Asia/Pacific (812 ) (340 ) (42 ) (1,175 ) (2,369 ) Total (6,469 ) (340 ) (174 ) (2,398 ) (9,381 ) December 31, 2012 Balance North America/HME 3,747 — — — 3,747 Europe 595 — — — 595 Asia/Pacific 869 151 1,625 6 2,651 Total 5,211 151 1,625 6 6,993 Charges North America/HME 5,405 — 164 353 5,922 IPG 267 — — — 267 Europe 1,640 — — — 1,640 Asia/Pacific 970 — 534 3 1,507 Total 8,282 — 698 356 9,336 Payments North America/HME (6,347 ) — (164 ) (353 ) (6,864 ) IPG (175 ) — — — (175 ) Europe (1,146 ) — — — (1,146 ) Asia/Pacific (1,839 ) (151 ) (1,660 ) (9 ) (3,659 ) Total $ (9,507 ) $ (151 ) $ (1,824 ) $ (362 ) $ (11,844 ) Severance Inventory Lease Terminations Other Total December 31, 2013 Balance North America/HME $ 2,805 $ — $ — $ — $ 2,805 IPG 92 — — — 92 Europe 1,089 — — — 1,089 Asia/Pacific — — 499 — 499 Total 3,986 — 499 — 4,485 Charges North America/HME 4,404 — — — 4,404 IPG 1,163 — — 761 1,924 Europe 527 — — 525 1,052 Asia/Pacific 769 — (15 ) — 754 Other 2,978 — — — 2,978 Total 9,841 — (15 ) 1,286 11,112 Payments North America/HME (6,547 ) — — — (6,547 ) IPG (1,107 ) — — (761 ) (1,868 ) Europe (1,195 ) — — (525 ) (1,720 ) Asia/Pacific (769 ) — (227 ) — (996 ) Total (9,618 ) — (227 ) (1,286 ) (11,131 ) December 31, 2014 Balance North America/HME 662 — — — 662 IPG 148 — — — 148 Europe 421 — — — 421 Asia/Pacific — — 257 — 257 Other 2,978 — — — 2,978 Total 4,209 — 257 — 4,466 Charges North America/HME 1,069 — 292 — 1,361 IPG 73 — — — 73 Europe 510 — — — 510 Asia/Pacific 26 — 1 — 27 Total 1,678 — 293 — 1,971 Payments North America/HME (1,069 ) — (55 ) — (1,124 ) IPG (221 ) — — — (221 ) Europe (619 ) — — — (619 ) Asia/Pacific (26 ) — (258 ) — (284 ) Other (1,475 ) — — — (1,475 ) Total (3,410 ) — (313 ) — (3,723 ) December 31, 2015 Balance North America/HME 662 — 237 — 899 Europe 312 — — — 312 Other 1,503 — — — 1,503 Total $ 2,477 $ — $ 237 $ — $ 2,714

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Earnings (loss) from continuing operations before income taxes consist of the following (in thousands): 2015 2014 2013 Domestic $ (54,812 ) $ (104,776 ) $ (73,529 ) Foreign 43,072 41,566 30,070 $ (11,740 ) $ (63,210 ) $ (43,459 )
Schedule of Components of Income Tax Expense (Benefit)	The company has provided for income taxes (benefits) from continuing operations as follows (in thousands): 2015 2014 2013 Current: Federal $ (167 ) $ (7,105 ) $ (2,485 ) State (150 ) (63 ) 300 Foreign 11,439 15,105 11,043 11,122 7,937 8,858 Deferred: Federal 3,222 100 3,011 State 318 — — Foreign 48 (2,487 ) (994 ) 3,588 (2,387 ) 2,017 Income Taxes $ 14,710 $ 5,550 $ 10,875
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation to the effective income tax rate from the federal statutory rate is as follows: 2015 2014 2013 Statutory federal income tax rate (35.0 )% (35.0 )% (35.0 )% State and local income taxes, net of federal income tax benefit 0.9 (0.1 ) 0.5 Tax credits (61.8 ) (5.1 ) (22.8 ) Foreign taxes at less than the federal statutory rate (including tax holidays) (46.1 ) (10.7 ) (10.6 ) Federal and foreign valuation allowance 168.0 52.5 35.8 Withholding taxes 3.0 0.6 0.7 Compensation 0.6 0.1 0.5 Dividends 100.1 12.3 54.6 Life insurance (2.7 ) 4.1 (1.5 ) Foreign branch activity (8.1 ) (1.8 ) (1.8 ) Uncertain tax positions 6.7 1.2 1.3 Other, net (0.3 ) (9.3 ) 3.3 125.3 % 8.8 % 25.0 %
Schedule of Deferred Tax Assets and Liabilities	Significant components of deferred income tax assets and liabilities at December 31, 2015 and 2014 are as follows (in thousands): 2015 2014 Current deferred income tax assets (liabilities), net: Bad debt $ — $ 5,364 Warranty — 7,092 State and local taxes — 2,240 Other accrued expenses and reserves — 1,852 Inventory — 3,096 Compensation and benefits — 2,209 Product liability — 594 Valuation allowance — (22,084 ) Other, net — (732 ) $ — $ (369 ) Long-term deferred income tax assets (liabilities), net: Bad Debt $ 3,670 $ — Warranty 5,357 — Other accrued expenses and reserves 4,355 — Inventory 2,395 — Goodwill and intangibles (25,008 ) (21,915 ) Convertible debt (421 ) (700 ) Fixed assets (8,207 ) (10,431 ) Compensation and benefits 7,136 14,630 Loss and credit carryforwards 102,194 65,123 Product liability 4,107 4,919 State and local taxes 19,932 17,745 Valuation allowance (151,972 ) (111,828 ) Other, net 5,255 12,647 $ (31,207 ) $ (29,810 ) Net Deferred Income Taxes $ (31,207 ) $ (30,179 )
Summary of Deferred Tax Liability Not Recognized	A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands): 2015 2014 Balance at beginning of year $ 11,019 $ 10,833 Additions to: Positions taken during the current year 227 348 Positions taken during a prior year 270 418 Deductions due to: Exchange rate impact (1,197 ) (362 ) Positions taken during a prior year (527 ) — Lapse of statute of limitations (239 ) (218 ) Balance at end of year $ 9,553 $ 11,019

Net Earnings Per Common Share (

Net Earnings Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings (Loss) Per Share, Basic and Diluted	The following table sets forth the computation of basic and diluted net earnings (loss) per common share. 2015 2014 2013 (In thousands except per share data) Basic Average common shares outstanding 32,171 32,009 31,915 Net loss from continuing operations $ (26,450 ) $ (68,760 ) $ (54,334 ) Net earnings from discontinued operations $ 260 $ 12,690 $ 87,385 Net earnings (loss) $ (26,190 ) $ (56,070 ) $ 33,051 Net loss per common share from continuing operations $ (0.82 ) $ (2.15 ) $ (1.70 ) Net earnings per common share from discontinued operations $ 0.01 $ 0.40 $ 2.74 Net earnings (loss) per common share $ (0.81 ) $ (1.75 ) $ 1.04 Diluted Average common shares outstanding 32,171 32,009 31,915 Stock options and awards 512 188 128 Average common shares assuming dilution 32,683 32,197 32,043 Net loss from continuing operations $ (26,450 ) $ (68,760 ) $ (54,334 ) Net earnings from discontinued operations $ 260 $ 12,690 $ 87,385 Net earnings (loss) $ (26,190 ) $ (56,070 ) $ 33,051 Net loss per common share from continuing operations * $ (0.82 ) $ (2.15 ) $ (1.70 ) Net earnings per common share from discontinued operations $ 0.01 $ 0.39 $ 2.73 Net earnings (loss) per common share * $ (0.81 ) $ (1.75 ) $ 1.03 * Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss.

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	Foreign exchange forward contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD): December 31, 2015 December 31, 2014 Notional Amount Unrealized Net Gain (Loss) Notional Amount Unrealized Net Gain (Loss) USD / AUD $ 2,910 $ (83 ) $ 1,250 $ 65 USD / CAD 3,893 181 3,570 (63 ) USD / CHF — — 111 — USD / CNY 16,786 (282 ) — — USD / EUR 72,758 2,681 25,524 — USD / GBP 3,862 22 1,199 3 USD / NZD 4,893 37 7,018 (55 ) USD / SEK 5,128 39 594 1 USD / MXP 8,494 (284 ) 10,297 (657 ) EUR / AUD 669 (10 ) 452 5 EUR / CAD 1,283 (17 ) 580 (1 ) EUR / CHF 1,944 (17 ) 505 (2 ) EUR / DKK — — 643 (3 ) EUR / GBP 36,567 (424 ) 11,906 23 EUR / NOK 3,375 (55 ) 1,490 43 EUR / SEK 2,464 (42 ) 2,917 (9 ) EUR / NZD 3,609 476 7,074 60 GBP / AUD 830 (46 ) 656 22 GBP / CHF 463 (7 ) 331 (1 ) GBP / SEK 2,067 (1 ) 1,035 (2 ) AUD / CAD — — 1,538 30 AUD / CHF — — 93 1 AUD / NZD 352 8 537 19 AUD / SEK — — 61 (1 ) CAD / SEK — — 182 (1 ) CHF / DKK — — 269 (2 ) DKK / SEK 37,293 46 2,497 (44 ) NOK / CHF — — 66 2 NOK / SEK 3,524 (39 ) 1,547 19 $ 213,164 $ 2,183 $ 83,942 $ (548 )
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location	Foreign exchange forward contracts not qualifying or designated for hedge accounting treatment entered into in 2015 and 2014 , respectively, and outstanding were as follows (in thousands USD): December 31, 2015 December 31, 2014 Notional Amount Gain (Loss) Notional Amount Gain (Loss) AUD / USD $ 8,051 $ 337 $ 7,300 $ 117 CAD / USD 5,762 (4 ) 6,016 $ (6 ) CNY / USD 9,943 (441 ) 3,200 (14 ) EUR / USD 2,118 53 53,365 (1,585 ) DKK / USD 7,927 125 — — GBP / USD 4,526 (106 ) 5,592 18 NZD / USD — — 4,500 12 NOK / USD 1,838 (18 ) — — $ 40,165 $ (54 ) $ 79,973 $ (1,458 )
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location	The fair values of the company’s derivative instruments were as follows (in thousands): December 31, 2015 December 31, 2014 Assets Liabilities Assets Liabilities Derivatives designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts $ 3,626 $ 1,443 $ 373 $ 921 Derivatives not designated as hedging instruments under ASC 815 Foreign currency forward exchange contracts 517 571 147 1,605 Total derivatives $ 4,143 $ 2,014 $ 520 $ 2,526
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss)	The effect of derivative instruments on the Statement of Operations and Other Comprehensive Income (OCI) was as follows, net of tax (in thousands): Derivatives in ASC 815 cash flow hedge relationships Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion) Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion) Amount of Loss Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing) Year ended December 31, 2015 Foreign currency forward exchange contracts $ 3,545 $ 991 $ (11 ) Year ended December 31, 2014 Foreign currency forward exchange contracts $ 562 $ 416 $ (11 ) Interest rate swap contracts — (12 ) — $ 562 $ 404 $ (11 ) Derivatives not designated as hedging instruments under ASC 815 Amount of Gain (Loss) Recognized in Income on Derivatives Year ended December 31, 2015 Foreign currency forward contracts $ (54 ) Year ended December 31, 2014 Foreign currency forward contracts $ (1,458 )

Fair Values of Financial Instru

Fair Values of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides a summary of the company’s assets and liabilities that are measured on a recurring basis (in thousands). Basis for Fair Value Measurements at Reporting Date Quoted Prices in Active Markets for Identical Assets / (Liabilities) Significant Other Observable Inputs Significant Other Unobservable Inputs Total Level I Level II Level III December 31, 2015 : Forward Exchange Contracts—net $ 2,129 — $ 2,129 — December 31, 2014 : Forward Exchange Contracts—net $ (2,006 ) — $ (2,006 ) —
Fair Value, by Balance Sheet Grouping	The carrying amounts and fair values of the company’s financial instruments at December 31, 2015 and 2014 are as follows (in thousands): 2015 2014 Carrying Value Fair Value Carrying Value Fair Value Cash and cash equivalents $ 60,055 $ 60,055 $ 38,931 $ 38,931 Other investments 160 160 249 249 Installment receivables, net of reserves 1,793 1,793 1,911 1,911 Long-term debt (including current maturities of long-term debt) (47,120 ) (47,369 ) (20,331 ) (20,248 ) Forward contracts in other current assets 4,143 4,143 520 520 Forward contracts in accrued expenses (2,014 ) (2,014 ) (2,526 ) (2,526 )

Business Segments (Tables)

Business Segments (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The information by segment is as follows (in thousands): 2015 2014 2013 Revenues from external customers North America/HME $ 474,196 $ 507,867 $ 589,240 Institutional Products Group 87,137 102,796 112,290 Europe 536,463 610,555 583,143 Asia/Pacific 44,542 48,945 49,832 Consolidated $ 1,142,338 $ 1,270,163 $ 1,334,505 Intersegment revenues North America/HME $ 111,321 $ 84,247 $ 77,553 Institutional Products Group 997 6,711 5,304 Europe 9,958 8,938 8,272 Asia/Pacific 20,661 26,173 24,941 Consolidated $ 142,937 $ 126,069 $ 116,070 Depreciation and amortization North America/HME $ 8,775 $ 10,925 $ 12,149 Institutional Products Group 1,980 7,656 8,310 Europe 7,183 11,111 12,123 Asia/Pacific 1,463 2,406 3,073 All Other (1) 29 173 275 Discontinued Operations — 518 859 Consolidated $ 19,430 $ 32,789 $ 36,789 2015 2014 2013 Net interest expense (income) North America/HME $ 2,080 $ 348 $ (1,869 ) Institutional Products Group 1,028 2,244 3,656 Europe (444 ) (209 ) (53 ) Asia/Pacific 82 149 960 Consolidated $ 2,746 $ 2,532 $ 2,694 Earnings (loss) before income taxes from continuing operations North America/HME $ (32,866 ) $ (63,601 ) $ (50,506 ) Institutional Products Group 6,757 (10,961 ) 1,418 Europe 38,644 48,088 40,468 Asia/Pacific (3,521 ) (9,485 ) (13,258 ) All Other (1) (20,754 ) (27,251 ) (21,581 ) Consolidated $ (11,740 ) $ (63,210 ) $ (43,459 ) Assets North America/HME (2) $ 215,500 $ 218,877 $ 250,239 Institutional Products Group (3) 38,730 42,692 45,933 Europe 557,740 638,896 693,790 Asia/Pacific 24,421 30,231 31,034 All Other (1) 1,752 15,647 37,142 Assets Held for Sale (4) — 17,388 38,296 Consolidated $ 838,143 $ 963,731 $ 1,096,434 Long-lived assets North America/HME (2) $ 49,319 $ 44,727 $ 60,309 Institutional Products Group (3) 30,278 33,487 38,342 Europe 391,533 459,957 506,329 Asia/Pacific 3,140 4,046 5,238 All Other (1) 1,752 15,527 36,830 Consolidated $ 476,022 $ 557,744 $ 647,048 Expenditures for assets North America/HME $ 1,232 $ 2,960 $ 5,017 Institutional Products Group 212 1,232 3,308 Europe 5,058 6,708 4,809 Asia/Pacific 969 1,417 830 All Other (1) 51 — 50 Discontinued Operations — 10 144 Consolidated $ 7,522 $ 12,327 $ 14,158 ________________________ (1) Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments. (2) The 2013 North America/HME assets and long-lived assets include a decrease of $167,000 due to an intangible asset impairment write-off.
Revenue from External Customers by Products and Services	Net sales by product, are as follows (in thousands): 2015 2014 2013 North America/HME Lifestyle Products $ 222,944 $ 239,625 $ 267,934 Mobility and Seating 117,232 115,776 134,995 Respiratory Therapy 130,349 149,063 178,065 Other(1) 3,671 3,403 8,246 $ 474,196 $ 507,867 $ 589,240 Institutional Products Group Continuing Care $ 87,137 $ 102,796 $ 112,290 Europe Lifestyle Products $ 275,932 $ 322,370 $ 303,225 Mobility and Seating 208,730 228,163 216,152 Respiratory Therapy 36,373 40,661 40,885 Other(1) 15,428 19,361 22,881 $ 536,463 $ 610,555 $ 583,143 Asia/Pacific Mobility and Seating $ 25,655 $ 28,174 $ 26,737 Lifestyle Products 10,277 11,772 12,023 Continuing Care 3,115 3,956 2,785 Respiratory Therapy 807 1,286 1,290 Other(1) 4,688 3,757 6,997 $ 44,542 $ 48,945 $ 49,832 Total Consolidated $ 1,142,338 $ 1,270,163 $ 1,334,505 ________________________ (1) Includes various services, including repair services, equipment rentals and external contracting.

Supplemental Guarantor Inform61

Supplemental Guarantor Information (Tables)	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Financial Statements	CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2015 Net sales $ 211,178 $ 402,108 $ 649,966 $ (120,914 ) $ 1,142,338 Cost of products sold 187,272 305,592 457,634 (120,984 ) 829,514 Gross Profit 23,906 96,516 192,332 70 312,824 Selling, general and administrative expenses 111,814 63,068 144,965 — 319,847 Charge related to restructuring activities 1,339 — 632 — 1,971 Income (loss) from equity investee 69,636 29,353 703 (99,692 ) — Interest expense (income)—net 3,011 428 (693 ) — 2,746 Earnings (Loss) from Continuing Operations Before Income Taxes (22,622 ) 62,373 48,131 (99,622 ) (11,740 ) Income taxes 3,568 — 11,142 — 14,710 Net Earnings (Loss) from Continuing Operations (26,190 ) 62,373 36,989 (99,622 ) (26,450 ) Net Earnings from Discontinued Operations — 260 — — 260 Net Earnings (Loss) (26,190 ) 62,633 36,989 (99,622 ) (26,190 ) Other Comprehensive Income (Loss), net of Tax (81,006 ) (15,037 ) (67,842 ) 82,879 (81,006 ) Comprehensive Income (Loss) $ (107,196 ) $ 47,596 $ (30,853 ) $ (16,743 ) $ (107,196 ) CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2014 Net sales $ 213,072 $ 413,067 $ 740,669 $ (96,645 ) $ 1,270,163 Cost of products sold 192,566 314,562 512,521 (96,874 ) 922,775 Gross Profit 20,506 98,505 228,148 229 347,388 Selling, general and administrative expenses 119,904 81,676 182,416 (83 ) 383,913 Charge related to restructuring activities 9,672 (1,326 ) 2,766 — 11,112 Asset write-downs to intangibles — 13,041 — — 13,041 Income (loss) from equity investee 53,536 35,208 280 (89,024 ) — Interest expense—net 175 2,114 243 — 2,532 Earnings (Loss) from Continuing Operations Before Income Taxes (55,709 ) 38,208 43,003 (88,712 ) (63,210 ) Income taxes 361 — 5,189 — 5,550 Net Earnings (Loss) from Continuing Operations (56,070 ) 38,208 37,814 (88,712 ) (68,760 ) Net Earnings from Discontinued Operations — 12,690 — — 12,690 Net Earnings (Loss) (56,070 ) 50,898 37,814 (88,712 ) (56,070 ) Other Comprehensive Income (Loss), net of Tax (53,537 ) (5,057 ) (50,058 ) 55,115 (53,537 ) Comprehensive Income (Loss) $ (109,607 ) $ 45,841 $ (12,244 ) $ (33,597 ) $ (109,607 ) CONSOLIDATING CONDENSED STATEMENTS OF OPERATIONS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2013 Net sales $ 241,871 $ 460,960 $ 720,978 $ (89,304 ) $ 1,334,505 Cost of products sold 211,896 338,650 506,308 (89,775 ) 967,079 Gross Profit 29,975 122,310 214,670 471 367,426 Selling, general and administrative expenses 123,377 93,731 177,530 2,694 397,332 Charge related to restructuring activities 6,356 79 2,901 — 9,336 Asset write-downs to intangibles and goodwill — 1,250 273 — 1,523 Income (loss) from equity investee 133,350 29,644 286 (163,280 ) — Interest (income) expense—net (1,661 ) 3,353 1,002 — 2,694 Earnings (Loss) from Continuing Operations Before Income Taxes 35,253 53,541 33,250 (165,503 ) (43,459 ) Income taxes (benefit) 2,202 (1,785 ) 10,458 — 10,875 Net Earnings (Loss) from Continuing Operations 33,051 55,326 22,792 (165,503 ) (54,334 ) Net Earnings from Discontinued Operations — 87,385 — — 87,385 Net Earnings (Loss) 33,051 142,711 22,792 (165,503 ) 33,051 Other Comprehensive Income (Loss), net of Tax 12,413 (2,309 ) 17,797 (15,488 ) 12,413 Comprehensive Income (Loss) $ 45,464 $ 140,402 $ 40,589 $ (180,991 ) $ 45,464 CONSOLIDATING CONDENSED BALANCE SHEETS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) December 31, 2015 Assets Current Assets Cash and cash equivalents $ 14,047 $ 314 $ 45,694 $ — $ 60,055 Trade receivables, net 43,534 20,020 70,101 — 133,655 Installment receivables, net — 361 784 — 1,145 Inventories, net 6,300 25,418 103,173 (2,084 ) 132,807 Intercompany advances, net 8,392 109 49,022 (57,523 ) — Other current assets 6,380 186 32,384 (4,491 ) 34,459 Total Current Assets 78,653 46,408 301,158 (64,098 ) 362,121 Investment in Subsidiaries 1,430,070 467,352 — (1,897,422 ) — Intercompany Advances, net 1,115,121 1,881,567 185,389 (3,182,077 ) — Other Assets 3,095 727 837 — 4,659 Intangibles 123 388 30,489 — 31,000 Property and Equipment, net 32,382 10,170 36,131 — 78,683 Goodwill — 12,142 349,538 — 361,680 Total Assets $ 2,659,444 $ 2,418,754 $ 903,542 $ (5,143,597 ) $ 838,143 Liabilities and Shareholders’ Equity Current Liabilities Accounts payable $ 38,395 $ 8,699 $ 58,514 $ — $ 105,608 Accrued expenses 31,061 20,940 74,910 (4,491 ) 122,420 Current taxes, payable and deferred 1,336 — 16,252 — 17,588 Intercompany advances, net 43,972 2,412 11,140 (57,524 ) — Short-term debt and current maturities of long-term obligations 880 275 873 — 2,028 Total Current Liabilities 115,644 32,326 161,689 (62,015 ) 247,644 Long-Term Debt 35,326 7,257 2,509 — 45,092 Other Long-Term Obligations 31,821 1,752 49,016 — 82,589 Intercompany Advances, net 2,013,835 1,116,834 51,407 (3,182,076 ) — Total Shareholders’ Equity 462,818 1,260,585 638,921 (1,899,506 ) 462,818 Total Liabilities and Shareholders’ Equity $ 2,659,444 $ 2,418,754 $ 903,542 $ (5,143,597 ) $ 838,143 CONSOLIDATING CONDENSED BALANCE SHEETS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) December 31, 2014 Assets Current Assets Cash and cash equivalents $ 7,340 $ 355 $ 31,236 $ — $ 38,931 Trade receivables, net 47,030 21,979 85,198 — 154,207 Installment receivables, net — 292 762 — 1,054 Inventories, net 25,021 25,784 107,139 (2,383 ) 155,561 Deferred income taxes — — 2,048 — 2,048 Intercompany advances, net 10,007 976 84,816 (95,799 ) — Other current assets 8,082 228 33,123 (4,635 ) 36,798 Assets held for sale - current 3,982 13,406 — — 17,388 Total Current Assets 101,462 63,020 344,322 (102,817 ) 405,987 Investment in Subsidiaries 1,409,482 491,541 — (1,901,023 ) — Intercompany Advances, net 1,049,235 1,685,366 184,652 (2,919,253 ) — Other Assets 16,955 657 1,441 — 19,053 Intangibles 286 393 37,334 — 38,013 Property and Equipment, net 29,632 7,209 42,818 — 79,659 Goodwill — 11,968 409,051 — 421,019 Total Assets $ 2,607,052 $ 2,260,154 $ 1,019,618 $ (4,923,093 ) $ 963,731 Liabilities and Shareholders’ Equity Current Liabilities Accounts payable $ 48,815 $ 6,363 $ 64,749 $ — $ 119,927 Accrued expenses 51,613 20,533 88,188 (4,635 ) 155,699 Current taxes, payable and deferred 1,632 — 11,002 — 12,634 Intercompany advances, net 81,141 1,738 12,921 (95,800 ) — Short-term debt and current maturities of long-term obligations — — 959 — 959 Liabilities held for sale - current 632 381 — — 1,013 Total Current Liabilities 183,833 29,015 177,819 (100,435 ) 290,232 Long-Term Debt 15,351 — 4,021 — 19,372 Other Long-Term Obligations 28,551 — 60,254 — 88,805 Intercompany Advances, net 1,813,995 1,051,170 54,088 (2,919,253 ) — Total Shareholders’ Equity 565,322 1,179,969 723,436 (1,903,405 ) 565,322 Total Liabilities and Shareholders’ Equity $ 2,607,052 $ 2,260,154 $ 1,019,618 $ (4,923,093 ) $ 963,731 CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2015 Net Cash Provided (Used) by Operating Activities $ (26,382 ) $ 2,125 $ 18,774 $ 105 $ (5,378 ) Investing Activities Purchases of property and equipment (464 ) (704 ) (6,354 ) — (7,522 ) Proceeds from sale of property and equipment 23,040 52 25 — 23,117 Proceeds from sale of businesses — 13,700 — — 13,700 Decrease in other long-term assets 14,488 — 515 — 15,003 Other — 5 178 (105 ) 78 Net Cash Provided (Used) for Investing Activities 37,064 13,053 (5,636 ) (105 ) 44,376 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 214,755 — 4,848 — 219,603 Payments on revolving lines of credit and long-term borrowings (217,589 ) (15,219 ) — — (232,808 ) Proceeds from exercise of equity awards 2,402 — — — 2,402 Payment of financing costs (1,954 ) — — — (1,954 ) Payment of dividends (1,589 ) — — — (1,589 ) Net Cash Used (Provided) by Financing Activities (3,975 ) (15,219 ) 4,848 — (14,346 ) Effect of exchange rate changes on cash — — (3,528 ) — (3,528 ) Increase (decrease) in cash and cash equivalents 6,707 (41 ) 14,458 — 21,124 Cash and cash equivalents at beginning of year 7,340 355 31,236 — 38,931 Cash and cash equivalents at end of year $ 14,047 $ 314 $ 45,694 $ — $ 60,055 CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2014 Net Cash (Used) Provided by Operating Activities $ (34,135 ) $ (511 ) $ 14,105 $ 29,433 $ 8,892 Investing Activities Purchases of property and equipment (2,256 ) (1,811 ) (8,260 ) — (12,327 ) Proceeds from sale of property and equipment — — 2,521 — 2,521 Proceeds from sale of businesses — 21,870 — — 21,870 Decrease in other long-term assets 20,926 — 23 — 20,949 Other 44,420 (14,393 ) (25 ) (29,433 ) 569 Net Cash Provided (Used) for Investing Activities 63,090 5,666 (5,741 ) (29,433 ) 33,582 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 255,658 — — — 255,658 Payments on revolving lines of credit and long-term borrowings (277,570 ) (5,113 ) (4,029 ) — (286,712 ) Proceeds from exercise of equity awards 480 — — — 480 Payment of dividends (1,584 ) — — — (1,584 ) Net Used by Financing Activities (23,016 ) (5,113 ) (4,029 ) — (32,158 ) Effect of exchange rate changes on cash — — (1,170 ) — (1,170 ) Increase in cash and cash equivalents 5,939 42 3,165 — 9,146 Cash and cash equivalents at beginning of year 1,401 313 28,071 — 29,785 Cash and cash equivalents at end of year $ 7,340 $ 355 $ 31,236 $ — $ 38,931 CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS The Combined Guarantor Subsidiaries Combined Non-Guarantor Subsidiaries Eliminations Total (in thousands) Year ended December 31, 2013 Net Cash Provided (Used) by Operating Activities $ 11,566 $ (68,792 ) $ 1,891 $ 65,389 $ 10,054 Investing Activities Purchases of property and equipment (3,601 ) (4,020 ) (6,537 ) — (14,158 ) Proceeds from sale of property and equipment 4 13 868 — 885 Proceeds from sale of businesses — 187,552 — — 187,552 Decrease in other long-term assets 833 — 168 — 1,001 Other 181,195 (113,067 ) 20 (68,083 ) 65 Net Cash Provided (Used) for Investing Activities 178,431 70,478 (5,481 ) (68,083 ) 175,345 Financing Activities Proceeds from revolving lines of credit and long-term borrowings 323,187 — 29,268 — 352,455 Payments on revolving lines of credit and long-term borrowings (516,488 ) (2,391 ) (26,995 ) — (545,874 ) Proceeds from exercise of equity awards 512 — — — 512 Payment of dividends (1,581 ) — (2,694 ) 2,694 (1,581 ) Net Cash (Used) Provided by Financing Activities (194,370 ) (2,391 ) (421 ) 2,694 (194,488 ) Effect of exchange rate changes on cash — — 83 — 83 Decrease in cash and cash equivalents (4,373 ) (705 ) (3,928 ) — (9,006 ) Cash and cash equivalents at beginning of year 5,774 1,018 31,999 — 38,791 Cash and cash equivalents at end of year $ 1,401 $ 313 $ 28,071 $ — $ 29,785

Interim Financial Information (

Interim Financial Information (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Interim Financial Information (unaudited) QUARTER ENDED (In thousands, except per share data) March 31, June 30, September 30, December 31, 2015 Net sales $ 289,024 $ 286,273 $ 283,776 $ 283,265 Gross profit 77,095 77,287 77,639 80,803 Earnings (loss) from continuing operations before income taxes (5,039 ) (6,492 ) (790 ) 581 Net loss from continuing operations (7,514 ) (8,217 ) (7,790 ) (2,929 ) Net earnings from discontinued operations 260 — — — Net loss (7,254 ) (8,217 ) (7,790 ) (2,929 ) Net loss per share from continuing operations—basic (0.23 ) (0.26 ) (0.24 ) (0.09 ) Net earnings per share from discontinued operations—basic 0.01 — — — Net loss per share—basic (0.23 ) (0.26 ) (0.24 ) (0.09 ) Loss per share from continuing operations—assuming dilution * (0.23 ) (0.26 ) (0.24 ) (0.09 ) Net earnings per share from discontinued operations—assuming dilution 0.01 — — — Net loss per share—assuming dilution * (0.23 ) (0.26 ) (0.24 ) (0.09 ) March 31, June 30, September 30, December 31, 2014 Net sales $ 304,501 $ 326,943 $ 320,520 $ 318,199 Gross profit 82,793 91,578 84,647 88,370 Loss from continuing operations before income taxes (16,870 ) (11,580 ) (26,375 ) (8,385 ) Net loss from continuing operations (18,895 ) (14,455 ) (28,725 ) (6,685 ) Net earnings (loss) from discontinued operations 919 842 13,629 (2,700 ) Net loss (17,976 ) (13,613 ) (15,096 ) (9,385 ) Net loss per share from continuing operations—basic (0.59 ) (0.45 ) (0.90 ) (0.21 ) Net earnings (loss) per share from discontinued operations—basic 0.03 0.03 0.43 (0.08 ) Net loss per share—basic (0.56 ) (0.43 ) (0.47 ) (0.29 ) Net loss per share from continuing operations—assuming dilution * (0.59 ) (0.45 ) (0.90 ) (0.21 ) Net earnings (loss) per share from discontinued operations—assuming dilution 0.03 0.03 0.42 (0.08 ) Net loss per share—assuming dilution * (0.56 ) (0.43 ) (0.47 ) (0.29 ) * Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss.

Accounting Policies - Property

Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2015
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Furniture and fixtures | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Furniture and fixtures | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	10 years
Building and building improvements | Minimum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Building and building improvements | Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	40 years

Accounting Policies - Goodwill

Accounting Policies - Goodwill and Other Intangibles (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 4,788,000	$ 8,253,000		$ 1,523,000
Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets			$ 13,041,000	1,356,000
Trademarks | Institutional Products Group
Indefinite-lived Intangible Assets [Line Items]
Impairment of indefinite-lived intangible assets				568,000
Customer lists | Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets			12,826,000	442,000
Customer lists | North America/HME
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets				167,000
Developed technology | Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets				223,000
Noncompete Agreements | Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets			$ 215,000
Trademarks with definite life | Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets				$ 123,000

Accounting Policies - Product

Accounting Policies - Product Liability Cost (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Accounting Policies [Abstract]
Annual policy losses insured per occurence	$ 10,000,000
Annual policy losses, in aggregate	13,000,000
Annual policy losses, external insurance coverage, in aggregate	$ 75,000,000

Accounting Policies - Addition

Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2015USD ($)Facilities$ / shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Accounting Policies [Abstract]
Research and development expense	$ 18,677,000	$ 23,149,000	$ 24,075,000
Advertising expense	$ 9,203,000	$ 13,463,000	$ 15,026,000
Number of subsidiaries | Facilities	2
Unremitted earnings of foreign subsidiaries	$ 24,100,000
Convertible Subordinated Debt
Debt Conversion [Line Items]
Initial conversion price | $ / shares	$ 24.79

Operations Held for Sale (Detai

Operations Held for Sale (Details) - USD ($)	Jul. 02, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Liabilities			$ 0	$ 1,013,000
Rentals Businesses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Trade receivables, net	$ 5,834,000			6,207,000
Proceeds from sale of business	15,500,000
Proceeds from sale of Business, net	13,700,000
Gain on sale of businesses (pre-tax)		$ 24,000
Operations Held For Sale, Costs Incurred During the Period			1,792,000
Operations Held for Sale, Payment of Sale Costs			$ 1,244,000
Inventories, net	412,000			315,000
Other current assets	212,000			221,000
Property and equipment, net	4,126,000			5,896,000
Goodwill	4,518,000			4,692,000
Other Intangibles	40,000			57,000
Disposal Group, Including Discontinued Operation, Assets	15,142,000			17,388,000
Accounts payable	410,000			225,000
Accrued expenses	1,056,000			788,000
Disposal Group, Including Discontinued Operation, Liabilities	$ 1,466,000			$ 1,013,000

Discontinued Operations - Narr

Discontinued Operations - Narrative (Details) - USD ($)	Aug. 29, 2014	Aug. 06, 2013	Jan. 18, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Liabilities						$ 0	$ 1,013,000
Net earnings from discontinued operations						0	1,596,000	$ 6,442,000
Total expenses related to discontinued operations						8,801,000
Payments for expenses related to discontinued operations						$ 8,405,000
Invacare Supply Group
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses			$ 150,800,000
Gain on sale of businesses (pre-tax)								59,402,000
Net sales of discontinued operations								18,498,000
Net earnings from discontinued operations								402,000
Champion Manufacturing, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses		$ 45,000,000
Gain on sale of businesses (pre-tax)					$ 22,761,000
Net sales of discontinued operations								15,857,000
Net earnings from discontinued operations								3,156,000
Interest expense allocated to discontinued operations								449,000
Goodwill allocated to discontinued operations		$ 16,205,000
Altimate Medical, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Liabilities	$ 741,000
Trade receivables, net	2,019,000
Property and equipment, net	176,000
Proceeds from divestiture of businesses	23,000,000
Gain on sale of businesses (pre-tax)				$ 17,069,000
Net sales of discontinued operations							11,778,000	17,854,000
Net earnings from discontinued operations							2,796,000	5,118,000
Interest expense allocated to discontinued operations							$ 202,000	$ 323,000
Inventories, net	1,954,000
Disposal Group, Including Discontinued Operation, Assets	$ 5,442,000

Discontinued Operations - Asse

Discontinued Operations - Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Aug. 29, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Liabilities sold	$ 0	$ 1,013
Altimate Medical, Inc.
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Trade receivables, net			$ 2,019
Inventories, net			1,954
Other current assets			246
Property and equipment, net			176
Other Intangibles			1,047
Assets sold			5,442
Accounts payable			425
Accrued expenses			316
Liabilities sold			$ 741

Receivables - Narrative (Detai

Receivables - Narrative (Details)	12 Months Ended
	Dec. 31, 2015USD ($)payment	Dec. 31, 2014USD ($)
Receivables [Abstract]
Allowance for doubtful accounts receivable	$ 10,487,000	$ 11,970,000
Number of missed payments before delinquent | payment	3
Typical financing period	12 months
Credit amount requiring additional analysis	$ 250,000
Average period of adjudication	18 months
Installment receivable purchased from DLL	$ 936,000	$ 2,123,000

Receivables - Installment Rece

Receivables - Installment Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Receivables [Abstract]
Installment receivables, current	$ 2,309	$ 2,692
Installment receivables, long-term	2,318	5,117
Total Installment Receivables	4,627	7,809
Unearned interest, current	(42)	(46)
Unearned interest, long-term	0	0
Total Unearned Interest	42	46
Installment receivables net of unearned interest, current	2,267	2,646
Installment receivables net of unearned interest, long-term	2,318	5,117
Total installment receivables net of unearned interest	4,585	7,763
Allowance for doubtful accounts, current	(1,122)	(1,592)
Allowance for doubtful accounts, long-term	(1,670)	(4,260)
Allowance for doubtful accounts	(2,792)	(5,852)	$ (6,039)
Installment receivables, net	1,145	1,054
Installment receivables, long-term	648	857
Total installment receivables, net	$ 1,793	$ 1,911

Receivables - Rollforward of A

Receivables - Rollforward of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Allowance for Doubtful Accounts [Roll Forward]
Balance as of January 1	$ 5,852	$ 6,039
Current period (benefit) provision	(332)	796
Direct write-offs charged against the allowance	(2,728)	(983)
Balance as of December 31	$ 2,792	$ 5,852

Receivables - Installment Re73

Receivables - Installment Receivables by Class (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded	$ 946	$ 1,008
Impaired installment receivables with a related allowance recorded	3,681	6,801
Total installment receivables	4,627	7,809
Unpaid Principal Balance
Non-Impaired installment receivables with no related allowance recorded	904	962
Impaired installment receivables with a related allowance recorded	3,681	6,801
Total installment receivables	4,585	7,763
Related Allowance for Doubtful Accounts
Impaired installment receivables with a related allowance recorded	2,792	5,852
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded	52	82
Impaired installment receivables with a related allowance recorded	0	0
Total installment receivables	52	82
U.S.
Total Installment Receivables
Impaired installment receivables with a related allowance recorded	3,618	6,735
Unpaid Principal Balance
Impaired installment receivables with a related allowance recorded	3,618	6,735
Related Allowance for Doubtful Accounts
Impaired installment receivables with a related allowance recorded	2,729	5,786
Interest Income Recognized
Impaired installment receivables with a related allowance recorded	0	0
CANADA
Total Installment Receivables
Non-Impaired installment receivables with no related allowance recorded	946	1,008
Impaired installment receivables with a related allowance recorded	63	66
Total installment receivables	1,009	1,074
Unpaid Principal Balance
Non-Impaired installment receivables with no related allowance recorded	904	962
Impaired installment receivables with a related allowance recorded	63	66
Total installment receivables	967	1,028
Related Allowance for Doubtful Accounts
Impaired installment receivables with a related allowance recorded	63	66
Interest Income Recognized
Non-Impaired installment receivables with no related allowance recorded	52	82
Impaired installment receivables with a related allowance recorded	0	0
Total installment receivables	$ 52	$ 82

Receivables - Aging of Install

Receivables - Aging of Installment Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current	$ 908	$ 976
0-30 days past due	16	15
31-60 days past due	12	2
61-90 days past due	1	0
90 days past due	3,690	6,816
Total	4,627	7,809
U.S.
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current	0	0
0-30 days past due	0	0
31-60 days past due	0	0
61-90 days past due	0	0
90 days past due	3,618	6,735
Total	3,618	6,735
CANADA
Financing Receivable, Recorded Investment, Past Due [Line Items]
Current	908	976
0-30 days past due	16	15
31-60 days past due	12	2
61-90 days past due	1	0
90 days past due	72	81
Total	$ 1,009	$ 1,074

Inventories - (Details)

Inventories - (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 67,207	$ 85,828
Raw materials	54,005	57,509
Work in process	11,595	12,224
Inventory, Net	$ 132,807	$ 155,561

Other Current Assets - Compone

Other Current Assets - Components of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Value added tax receivables	$ 18,031	$ 21,273
Recoverable income taxes	367	261
Derivatives (foreign currency forward contracts)	4,143	520
Prepaid insurance	2,538	2,713
Prepaid and other current assets	9,380	12,031
Other current assets	$ 34,459	$ 36,798

Other Long-Term Assets - (Deta

Other Long-Term Assets - (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Cash surrender value of life insurance policies	$ 1,674	$ 15,765
Deferred financing fees	1,088	408
Investments	160	249
Long-term installment receivables	648	857
Long-term deferred taxes	908	613
Other	181	1,161
Other Assets	$ 4,659	$ 19,053

Other Long-Term Assets - Narra

Other Long-Term Assets - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Proceeds from sale of life insurance policies	$ 11,902,000	$ 21,338,000

Property And Equipment - (Deta

Property And Equipment - (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Asset Disposals, Pretax	$ 4,031,000
Property and equipment, gross	395,548,000	$ 425,760,000
Less allowance for depreciation	(316,865,000)	(346,101,000)
Property and equipment, net	78,683,000	79,659,000
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	299,721,000	318,286,000
Land, buildings and improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	73,830,000	81,219,000
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross	10,031,000	11,738,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 11,966,000	$ 14,517,000

Goodwill - (Details)

Goodwill - (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Beginning Balance	$ 421,019	$ 457,534
Foreign currency translation adjustments	(59,339)	(36,515)
Ending Balance	$ 361,680	$ 421,019	$ 457,534
Maturity of corporate debt with similar credit risk	20 years
US treasury bond maturity	20 years
Discounted cash flow, discount rate	9.41%	9.89%	10.00%
Institutional Products Group
Goodwill [Roll Forward]
Beginning Balance	$ 29,919	$ 31,615
Foreign currency translation adjustments	(2,763)	(1,696)
Ending Balance	$ 27,156	29,919	$ 31,615
Discounted cash flow sensitivity analysis discount rate rncrease	1.00%
Europe
Goodwill [Roll Forward]
Beginning Balance	$ 391,100	425,919
Foreign currency translation adjustments	(56,576)	(34,819)
Ending Balance	$ 334,524	$ 391,100	$ 425,919
Discounted cash flow sensitivity analysis discount rate rncrease	1.00%

Intangibles - Narrative (Detai

Intangibles - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets			$ 1,907,000	$ 20,358,000	$ 10,567,000
Impairment of intangible assets	$ 4,788,000	$ 8,253,000			1,523,000
Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets				13,041,000	1,356,000
Institutional Products Group | Customer lists
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets				12,826,000	442,000
Institutional Products Group | Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets				215,000
Institutional Products Group | Trademarks with definite life
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets					123,000
Institutional Products Group | Developed technology
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets					223,000
North America/HME | Customer lists
Finite-Lived Intangible Assets [Line Items]
Impairment of finite-lived intangible assets					167,000
Trademarks
Finite-Lived Intangible Assets [Line Items]
Historical Cost	$ 28,314,000		$ 24,524,000	$ 28,314,000
Trademarks | Institutional Products Group
Finite-Lived Intangible Assets [Line Items]
Impairment of indefinite-lived intangible assets					568,000
Impairment indefinite-lived intangible assets, net of tax					$ 496,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets			1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets			10 years
Weighted Average
Finite-Lived Intangible Assets [Line Items]
Useful life of intangible assets			5 years

Intangibles - Finite and Indef

Intangibles - Finite and Indefinite Lived Intangibles (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 90,005,000	$ 125,244,000
Accumulated Amortization	59,005,000	87,231,000
Customer lists
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	49,858,000	78,693,000
Accumulated Amortization	45,019,000	71,343,000
License agreements
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	1,098,000	1,290,000
Accumulated Amortization	1,098,000	1,290,000
Developed technology
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	7,405,000	8,297,000
Accumulated Amortization	5,921,000	6,340,000
Patents
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	5,959,000	6,102,000
Accumulated Amortization	5,843,000	5,804,000
Other
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	1,161,000	2,548,000
Accumulated Amortization	1,124,000	2,454,000
Trademarks
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Historical Cost	$ 24,524,000	$ 28,314,000

Intangibles - Finite-Lived Int

Intangibles - Finite-Lived Intangible Asset Future Amortization Expense (Details)	Dec. 31, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Future amortization expense, 2016	$ 1,626,000
Future amortization expense, 2017	1,549,000
Future amortization expense, 2018	1,530,000
Future amortization expense, 2019	992,000
Future amortization expense, 2020	$ 184,000

Accrued Expenses - Components

Accrued Expenses - Components of Current Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Payments for Deferred Compensation, Cash Based Arrangement	$ 21,126,000
Salaries and wages	41,305,000	$ 40,850,000
Taxes other than income taxes, primarily Value Added Taxes	21,424,000	24,743,000
Warranty cost	22,820,000	30,738,000	$ 27,393,000
Supplemental Executive Retirement Plan (SERP)	1,279,000	21,517,000
Freight	6,153,000	6,202,000
Professional	5,774,000	6,613,000
Product liability, current portion	3,127,000	4,334,000
Rebates	1,791,000	1,722,000
Insurance	695,000	1,266,000
Interest	872,000	1,068,000
Derivatives (foreign currency forward exchange contracts)	2,014,000	2,526,000
Severance	2,477,000	4,209,000
Other items, principally trade accruals	12,689,000	9,911,000
Accrued expenses	122,420,000	$ 155,699,000
Payments for Deferred Compensation Arrangement	$ 3,525,000

Accrued Expenses - Warranty Sc

Accrued Expenses - Warranty Schedule (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Product Liability Contingency [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)	$ (2,325,000)	$ 11,493,000	$ 7,264,000
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance as of January 1	30,738,000	27,393,000
Warranties provided during the period	11,561,000	21,472,000
Settlements made during the period	(17,817,000)	(22,752,000)
Changes in liability for pre-existing warranties during the period, including expirations	(1,662,000)	4,625,000
Balance as of December 31	22,820,000	30,738,000	27,393,000
Europe
Product Liability Contingency [Line Items]
Additional warranty expense related to recall		3,395,000
North America/HME
Product Liability Contingency [Line Items]
Additional warranty expense related to recall		3,164,000
Loss Contingency Accrual, Period Increase (Decrease)			2,625,000
North America [Member]
Product Liability Contingency [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)			$ 4,639,000
Field Action Under Review
Product Liability Contingency [Line Items]
Additional warranty expense related to recall	(2,000,000)	6,559,000
Warranty Related Sieve Bed Recall
Product Liability Contingency [Line Items]
Additional warranty expense related to recall	(250,000)	2,057,000
Warranty Related Recall
Product Liability Contingency [Line Items]
Additional warranty expense related to recall		2,877,000
Warranty Related Recall | North America/HME
Product Liability Contingency [Line Items]
Additional warranty expense related to recall	$ (75,000)	1,612,000
Warranty Related Recall | North America [Member]
Product Liability Contingency [Line Items]
Additional warranty expense related to recall		$ 1,265,000

Long-Term Debt - Debt (Details

Long-Term Debt - Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 47,120	$ 20,331
Less current maturities of long-term debt	(2,028)	(959)
Long-term debt of current maturities	45,092	19,372
Convertible Subordinated Debt | Convertible senior subordinated debentures at 4.125%, due in February 2027
Debt Instrument [Line Items]
Long-term debt	12,147	11,351
Other notes and lease obligations
Debt Instrument [Line Items]
Long-term debt	34,973	4,980
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Long-term debt	$ 0	$ 4,000

Long-Term Debt - Convertible D

Long-Term Debt - Convertible Debt (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term debt	$ 47,120,000	$ 20,331,000
Convertible senior subordinated debentures at 4.125%, due in February 2027 | Convertible Subordinated Debt
Debt Disclosure [Abstract]
Initial conversion price	$ 24.79
Debt Instrument [Line Items]
Interest rate (as a percent)	4.125%
Carrying amount of equity component	$ 25,381,000	25,381,000
Principal amount of liability component	13,350,000	13,350,000
Unamortized discount	(1,203,000)	(1,999,000)
Long-term debt	$ 12,147,000	$ 11,351,000

Long-Term Debt - Narrative (De

Long-Term Debt - Narrative (Details)	Jan. 16, 2015USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)sharesd$ / shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Feb. 16, 2016USD ($)	Apr. 22, 2015USD ($)	Feb. 17, 2007USD ($)
Debt Instrument [Line Items]
Write off of deferred debt issuance cost		$ 668,000	$ 1,070,000
Weighted average interest rate				3.83%	2.87%
Interest Paid				$ 2,753,000	$ 3,302,000	$ 4,046,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Year One				2,028,000
Year Two				2,169,000
Year Three				1,784,000
Year Four				1,632,000
Year Five				1,703,000
Convertible Subordinated Debt | Convertible senior subordinated debentures at 4.125%, due in February 2027
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount				1,203,000	1,999,000
Write off of deferred debt issuance cost				$ 668,000	1,070,000
Interest rate (as a percent)				4.125%
Principal amount of liability component				$ 13,350,000	13,350,000
Principal Amount									$ 135,000,000
Principal in excess of if-converted value				3,379,000
Conversion par amount				$ 1,000
Initial conversion price | $ / shares				$ 24.79
Conversion price premium				30.00%
Convertible debt, stock price trigger | $ / shares				$ 32.23
Conversion ratio				40.3323
Trading days common stock above conversion price | d				20
Period of consecutive trading days preceding the date on which the notice of conversion is given				30 days
Number of equity instruments upon conversion of convertible debt | shares				539,000
Effective Interest Rate				11.50%
Interest Expense				$ 796,000	710,000	633,000
Interest Paid				551,000	551,000	$ 551,000
Letters of Credit
Debt Instrument [Line Items]
Letters of credit outstanding				3,230,000	$ 7,063,000
Letters of Credit | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Borrowing capacity				5,000,000
Letters of Credit | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Borrowing capacity	$ 25,000,000
Swing Line Loans [Domain] | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Borrowing capacity				2,000,000
Amount Available to Invacare Limited and Invacare Poirier SAS [Domain] | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Borrowing capacity				15,000,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Debt issuance cost				1,954,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Borrowing capacity				$ 30,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Europe, Percent				85.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Availability Reserve, Minimum				$ 3,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger				$ 3,375,000
Line of Credit Facility, Covenant Feature, Dominion Trigger Maximum Percentage				12.50%
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn Balance	5 years			5 days
Line of Credit, Covenant Compliance, Interruption of Manufacturing Facilities Period				10 days
Line of Credit Facility, Current Borrowing Capacity				$ 21,528,000
Line of Credit Facility, Remaining Borrowing Capacity				$ 15,153,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent				11.25%
Line of Credit, Covenant Compliance, Required Undrawn Balance, Amount				$ 3,000,000
Remaining borrowing capacity				10,000,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Additional Long-Lived Asset Amount	$ 2,485,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Foreign, Percent	85.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Foreign, Percent	70.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Foreign, Liquidation Value, Percent	85.00%
Borrowing capacity	$ 100,000,000
Line of Credit Facility, Additional Borrowing Capacity	$ 25,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Trade Receivables, Domestic, Percent	85.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Domestic, Percent	70.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Liquidation Value, Percent	85.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Inventories, Liquidation Value, Amount	$ 4,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Property, Plant and Equipment, Liquidation Value, Percent	85.00%
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Availability Reserve, Minimum	$ 10,000,000
Line of Credit Facility, Covenant Feature, Dominion Trigger				11,250,000
Line of Credit Facility, Covenant Feature, Dominion Trigger for Five Consecutive Days				12,500,000
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn Balance	5 days
Line of Credit, Covenant Compliance, Interruption of Manufacturing Facilities Period	10 days
Line of Credit, Covenant Compliance, Single Acquisition Limit Maximum								$ 500,000
Line of Credit Facility, Current Borrowing Capacity				$ 38,230,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	11.25%
Line of Credit, Covenant Compliance, Required Undrawn Balance, Amount	$ 10,000,000
Base Rate | Revolving Credit Facility | Line of Credit | Credit Agreement
Debt Instrument [Line Items]
Basis spread on variable rate				0.25%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.375%
Maximum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.375%
Maximum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate				3.00%
Maximum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.75%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate				3.00%
Maximum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.75%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.25%
Minimum | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Minimum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate				2.50%
Minimum | Adjusted LIBOR | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (Europe Credit Agreement) [Member] [Domain]
Debt Instrument [Line Items]
Basis spread on variable rate				2.50%
Minimum | Base Rate | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.25%
Subsequent Event [Member] | Convertible Subordinated Debt | Convertible senior subordinated debentures at 4.125%, due in February 2027
Debt Instrument [Line Items]
Interest rate (as a percent)							4.125%
Subsequent Event [Member] | Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Debt Instrument [Line Items]
Borrowing capacity							$ 100,000,000
Line of Credit, Covenant Compliance, Maximum Borrowing Capacity, Availability Reserve, Minimum							$ 5,000,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent							20.00%
Line of Credit, Covenant Compliance, Required Undrawn Balance, Amount							$ 5,000,000

Other Long-Term Obligations -

Other Long-Term Obligations - (Details) - USD ($)	Dec. 31, 2015	Apr. 23, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Supplemental Executive Retirement Plan liability	$ 4,930,000		$ 6,067,000
Product liability	14,582,000		18,860,000
Deferred income taxes	32,115,000		30,423,000
Sale Leaseback Transaction, Deferred Gain, Gross	6,978,000	$ 7,414,000	0
Deferred compensation	4,167,000		5,667,000
Uncertain tax obligation including interest	4,467,000		15,160,000
Other	15,350,000		12,628,000
Total long-term obligations	$ 82,589,000		$ 88,805,000

Other Long-Term Obligations 90

Other Long-Term Obligations - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Apr. 23, 2015	Dec. 31, 2014
Income Tax Examination [Line Items]
Sale Leaseback Transaction, Deferred Gain, Gross	$ 6,978,000	$ 7,414,000	$ 0
Payments for Deferred Compensation Arrangement	3,525,000
Sale Leaseback Transaction, Current Period Gain Recognized	$ 171,000

Leases and Commitments - Narra

Leases and Commitments - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Leased Assets [Line Items]
Lease expense	$ 20,360,000	$ 23,568,000	$ 24,726,000
Buildings and equipment capitalized under capital leases	42,640,000	12,123,000
Accumulated amortization in connection with capital leases	$ 7,667,000	$ 7,143,000
Minimum
Operating Leased Assets [Line Items]
Lease term	1 year
Maximum
Operating Leased Assets [Line Items]
Lease term	20 years

Leases and Commitments - Futur

Leases and Commitments - Future Minimum Lease Commitments (Details) $ in Thousands	Dec. 31, 2015USD ($)
Capital Leases
Capital Leases - 2016	$ 3,375
Capital Leases - 2017	3,375
Capital Leases - 2018	2,848
Capital Leases - 2019	2,671
Capital Leases - 2020	2,671
Capital Leases - Thereafter	32,872
Total future minimum lease payments	47,812
Amounts representing interest	(12,839)
Present value of minimum lease payments	34,973
Operating Leases
Operating Leases - 2016	15,067
Operating Leases - 2017	8,804
Operating Leases - 2018	5,005
Operating Leases - 2019	2,378
Operating Leases - 2020	1,101
Operating Leases - Thereafter	268
Total future minimum lease payments	$ 32,623

Leases and Commitments - Sale

Leases and Commitments - Sale Leaseback Transactions (Details) - USD ($)	Apr. 23, 2015	Dec. 31, 2015	Dec. 31, 2014
Sale Leaseback Transaction [Line Items]
Sale Leaseback Transaction, Net Proceeds, Investing Activities		$ 23,000,000
Sale Leaseback Transaction, Annual Rental Payments		$ 2,275,000
Sale Leaseback Transaction, Lease Term		20 years
Sale Leaseback Transaction, Lease Terms		Each of the four lease agreements contains three 10-year renewals with the rent for each option term based on the greater of the then-current fair market rent for each property or the then- current rate and increasing annually by the applicable CPI. Under the terms of the lease agreements, the company is responsible for all taxes, insurance and utilities. The company is permitted to sublet the properties; however, the properties are currently being utilized exclusively by the company and there is no current subletting. The company is required to adequately maintain each of the properties and any leasehold improvements will be amortized over the lesser of the lives of the improvements or the remaining lease lives.
Sale Leaseback Transaction, Deferred Gain, Gross	$ 7,414,000	$ 6,978,000	$ 0
Sale Leaseback Transaction, Immediate Loss Recognized	257,000
Capital Lease Obligations	$ 32,339,000
Buildings and equipment capitalized under capital leases		$ 42,640,000	$ 12,123,000

Retirement and Benefit Plans -

Retirement and Benefit Plans - (Details)	12 Months Ended
	Dec. 31, 2015USD ($)planParticipantsTimesyr	Dec. 31, 2014USD ($)yr	Dec. 31, 2013USD ($)
Compensation and Retirement Disclosure [Abstract]
Company matching employee contributions	66.70%
Maximum percentage of matching contribution for total compensation	3.00%
Discretionary contributions, percentage of qualified wages	1.00%
Contribution expense	$ 2,573,000	$ 2,698,000	$ 3,126,000
Defined Benefit Plan Disclosure [Line Items]
Number of participants unaffected by plan conversion | Participants	3
Death benefit only plan, benefit payment as multiplier of final earnings | Times	1
Net periodic benefit (income) costs	$ 226,000
Death benefit only plan, benefit payment as multiplier of final earnings, current employee | Times	3
Proceeds from life insurance policies	$ 11,902,000	21,338,000
Accumulated other comprehensive income (loss)	9,757,000	7,601,000
Accumulated other comprehensive income, net change	$ 2,156,000
Supplemental Executive Retirement Plan
Defined Benefit Plan Disclosure [Line Items]
Interest credited for active participants (as a percent)	0.00%
Accumulated benefit obligation	$ 6,209,000	$ 27,548,000
Assumption, future salary increase rate	4.00%
Assumed discount rate	4.34%	3.95%
Retirement age | yr	67	67
Projected benefit obligation	$ 6,209,000	$ 27,548,000
Interest (benefit) cost	(42,000)	(377,000)	(236,000)
Net periodic benefit (income) costs	142,000	539,000	(14,000)
Benefit payments	21,517,000	394,000	398,000
Death Benefit Only Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit (income) costs	103,000	808,000	(259,000)
Service cost and accrual adjustments	$ 28,000	692,000	364,000
Switzerland | Foreign Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Number of plans | plan	2
Netherlands | Foreign Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Retirement age | yr	65
Europe | Foreign Postretirement Benefit Plan
Defined Benefit Plan Disclosure [Line Items]
Amounts recognized in other comprehensive income (loss)	$ 19,000	$ 220,000	$ 205,000

Equity Compensation - Narrativ

Equity Compensation - Narrative (Details)	12 Months Ended
	Dec. 31, 2015USD ($)votes$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	May. 16, 2013shares	Jul. 19, 2005$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock par value (in dollars per share) | $ / shares	$ 0.25
Stock option related treasury stock, shares acquired | shares	7,000	29,000	23,000
Right to purchase series A participating serial preferred purchase price per share | $ / shares					$ 180
Percentage of voting power to be acquired at which point rights become exercisable	30.00%
Percentage of the current market price per common share to be used as denominator of rights used to acquire common stock	50.00%
Number of securities called by each warrant or right | $ / shares	$ 0.001
Number of days following a public announcement of beneficial ownership acquisition	10 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase of treasury stock	$ 134,000	$ 471,000	$ 532,000
Expiration period	10 years
Unrecognized compensation expense, period for recognition	2 years
Award vesting percentage	25.00%
Weighted-average fair value of options granted | $ / shares		$ 6.23	$ 5.33
Weighted average remaining contractual term of options outstanding	4 years 3 months	5 years	5 years 9 months
Weighted-average remaining contractual term of options exercisable	4 years
Intrinsic value of exercises in period	$ 1,107,000	$ 101,000	$ 158,000
Intrinsic value of options outstanding	2,562,000
Intrinsic value of options exercisable	1,636,000
Cash received from exercise of stock options	2,413,000	480,000	512,000
Fair value of awards vested in period	$ 1,867,000	$ 3,436,000	$ 3,778,000
Award vesting period	4 years
Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Decrease of shares available for grant due to award activity | shares	1,110,740
Award vesting period	3 years
Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Decrease of shares available for grant due to award activity | shares	681,058
Award requisite service period	3 years
Performance achievement level, lower range	0.00%
Performance achievement level, upper range	150.00%
Performance achievement level, target range	100.00%
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized | shares				4,460,337
Weighted Average | Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	3 years
Class B Common Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Ratio of votes per share of Class B common stock to common stock | votes	10
Class B common shares dividend rate lower than common shares	10.00%
Cliff Vesting | Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years

Equity Compensation - Share-ba

Equity Compensation - Share-based Compensation Expense (Details) - Selling, general and administrative expense - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 4,013	$ 5,626	$ 5,957
Non-qualified stock options
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	1,228	3,356	3,926
Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	2,785	2,270	2,031
Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 0	$ 0	$ 0

Equity Compensation - Unrecogn

Equity Compensation - Unrecognized Compensation Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 10,535	$ 7,061	$ 11,975
Non-qualified stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	1,059	2,600	8,270
Restricted stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	9,476	4,461	3,705
Performance shares and performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 0	$ 0	$ 0

Equity Compensation - Options

Equity Compensation - Options Activity (Details) - $ / shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding at beginning of period (in shares)		3,600,132	4,533,782	4,664,634
Granted (in shares)		0	8,977	756,700
Excercised (in shares)		(172,218)	(33,810)	(30,166)
Canceled (in shares)		(485,131)	(908,817)	(857,386)
Options outstanding at end of period (in shares)		2,942,783	3,600,132	4,533,782
Weighted Average Exercise Price
Options outstanding at beginning of period - Weighted Average Exercise Price (in dollars per share)		$ 22.74	$ 23.86	$ 26.21
Granted - Weighted Average Exercise Price (in dollars per share)		0	16.71	14.47
Excercised - Weighted Average Exercise Price (in dollars per share)		13.95	14.16	16.94
Canceled - Weighted Average Exercise Price (in dollars per share)		34.98	28.57	28.63
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)		$ 21.22	$ 22.74	$ 23.86
Options exercisable at end of period (in shares)		2,656,983	2,954,082	2,985,175
Stock Options
Weighted Average Exercise Price
Options outstanding at end of period - Weighted Average Exercise Price (in dollars per share)		$ 21.22
Exercise price range, lower limit (in dollars per shares)		13.37	$ 13.37	$ 13.35
Exercise price range, upper limit (in dollars per shares)		$ 33.36	$ 47.80	$ 47.80
Options available for grant at end of period (in shares)	[1]	2,659,562	3,654,426	4,460,337
[1]	*Shares available for grant as of December 31, 2015 reduced by net restricted stock / unit and performance share / unit award activity of 1,110,740 shares and 681,058 shares, respectively.

Equity Compensation - Stock Op

Equity Compensation - Stock Options Outstanding by Exercise Price (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 21.22	$ 22.74	$ 23.86	$ 26.21
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per shares)	13.37	13.37	13.35
Exercise price range, upper limit (in dollars per shares)	$ 33.36	$ 47.80	$ 47.80
Options Outstanding - Number Outstanding at end of period (in shares)	2,942,783
Options Outstanding - Weighted Average Remaining Contractual Life	4 years 3 months
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 21.22
Options Exercisable - Number Exercisable at end of period (in shares)		2,656,983
Options Exercisable - Weighted Average Exercise Price (in dollars per share)		$ 21.98
Stock Options | $ 13.37 – $20.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per shares)	13.37
Exercise price range, upper limit (in dollars per shares)	$ 20
Options Outstanding - Number Outstanding at end of period (in shares)	778,159
Options Outstanding - Weighted Average Remaining Contractual Life	6 years 8 months
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 14.12
Options Exercisable - Number Exercisable at end of period (in shares)		493,671
Options Exercisable - Weighted Average Exercise Price (in dollars per share)		$ 14.11
Stock Options | $ 20.01 – $25.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per shares)	20.01
Exercise price range, upper limit (in dollars per shares)	$ 25
Options Outstanding - Number Outstanding at end of period (in shares)	1,353,578
Options Outstanding - Weighted Average Remaining Contractual Life	3 years 3 months
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 22.59
Options Exercisable - Number Exercisable at end of period (in shares)		1,353,578
Options Exercisable - Weighted Average Exercise Price (in dollars per share)		$ 22.59
Stock Options | $ 25.01 – $30.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per shares)	25.01
Exercise price range, upper limit (in dollars per shares)	$ 30
Options Outstanding - Number Outstanding at end of period (in shares)	783,738
Options Outstanding - Weighted Average Remaining Contractual Life	3 years 8 months
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 25.55
Options Exercisable - Number Exercisable at end of period (in shares)		783,738
Options Exercisable - Weighted Average Exercise Price (in dollars per share)		$ 25.55
Stock Options | $ 30.01 – $33.36
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower limit (in dollars per shares)	30.01
Exercise price range, upper limit (in dollars per shares)	$ 33.36
Options Outstanding - Number Outstanding at end of period (in shares)	27,308
Options Outstanding - Weighted Average Remaining Contractual Life	1 year
Options Outstanding - Weighted Average Exercise Price (in dollars per share)	$ 31.74
Options Exercisable - Number Exercisable at end of period (in shares)		25,996
Options Exercisable - Weighted Average Exercise Price (in dollars per share)		$ 31.73

Equity Compensation - Assumpti

Equity Compensation - Assumptions (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected dividend yield	0.00%	0.40%
Expected stock price volatility	36.80%	38.20%
Risk free interest rate	1.76%	0.82%
Expected life in years	6 years 1 month 6 days	6 years 1 month 6 days
Forfeiture percentage	13.00%	9.20%

Equity Compensation - Restrict

Equity Compensation - Restricted Stock Activity (Details) - Restricted stock and restricted stock units - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock / Units unvested at beginning of period (in shares)	312,423	264,878	260,548
Granted (in shares)	480,839	218,276	114,700
Vested (in shares)	(56,976)	(93,140)	(97,445)
Canceled (in shares)	(94,781)	(77,591)	(12,925)
Stock / Units unvested at end of period (in shares)	641,505	312,423	264,878
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock / Units unvested at beginning of period - Weighted Average Fair Value (in dollars per share)	$ 17.91	$ 16.69	$ 19.15
Granted - Weighted Average Fair Value (in dollars per share)	19.09	19.36	14.49
Vested - Weighted Average Fair Value (in dollars per share)	16.47	17.62	20.33
Canceled - Weighted Average Fair Value (in dollars per share)	18.11	17.58	19.23
Stock / Units unvested at end of period - Weighted Average Fair Value (in dollars per share)	$ 18.89	$ 17.91	$ 16.69

Equity Compensation - Performa

Equity Compensation - Performance Share Activity (Details) - Performance shares and performance share units - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Stock / Units unvested at beginning of period (in shares)	121,644	0
Granted (in shares)	114,257	152,800
Vested (in shares)	0	0
Canceled (in shares)	(37,500)	(31,156)
Stock / Units unvested at end of period (in shares)	198,401	121,644
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Stock / Units unvested at beginning of period - Weighted Average Fair Value (in dollars per share)	$ 20.05	$ 0
Granted - Weighted Average Fair Value (in dollars per share)	18.95	20.05
Vested - Weighted Average Fair Value (in dollars per share)	0	0
Canceled - Weighted Average Fair Value (in dollars per share)	19.62	20.05
Stock / Units unvested at end of period - Weighted Average Fair Value (in dollars per share)	$ 19.50	$ 20.05

Accumulated Other Comprehens103

Accumulated Other Comprehensive Income (Loss) by Component - Changes in Accumulated Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ 71,619	$ 125,156
OCI before reclassifications	(80,151)	(54,169)
Amount reclassified from accumulated OCI	(855)	632
Other Comprehensive Income (Loss)	(81,006)	(53,537)	$ 12,413
Ending balance	(9,387)	71,619	125,156
Foreign Currency
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	86,236	143,845
OCI before reclassifications	(91,980)	(57,609)
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	(91,980)	(57,609)
Ending balance	(5,744)	86,236	143,845
Long-Term Notes
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(6,465)	(12,566)
OCI before reclassifications	10,576	6,101
Amount reclassified from accumulated OCI	0	0
Other Comprehensive Income (Loss)	10,576	6,101
Ending balance	4,111	(6,465)	(12,566)
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(7,601)	(5,414)
OCI before reclassifications	(2,292)	(3,223)
Amount reclassified from accumulated OCI	136	1,036
Other Comprehensive Income (Loss)	(2,156)	(2,187)
Ending balance	(9,757)	(7,601)	(5,414)
Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(551)	(709)
OCI before reclassifications	3,545	562
Amount reclassified from accumulated OCI	(991)	(404)
Other Comprehensive Income (Loss)	2,554	158
Ending balance	$ 2,003	$ (551)	$ (709)

Accumulated Other Comprehens104

Accumulated Other Comprehensive Income (Loss) by Component - Reclassifications out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Net sales	$ 283,265	$ 283,776	$ 286,273	$ 289,024	$ 318,199	$ 320,520	$ 326,943	$ 304,501	$ 1,142,338	$ 1,270,163	$ 1,334,505
Cost of products sold									(829,514)	(922,775)	(967,079)
Selling, general and administrative expenses									(319,847)	(383,913)	(397,332)
Earnings before income taxes	581	(790)	(6,492)	(5,039)	(8,385)	(26,375)	(11,580)	(16,870)	(11,740)	(63,210)	(43,459)
Income taxes									(14,710)	(5,550)	(10,875)
Net Loss from Continuing Operations	$ (2,929)	$ (7,790)	$ (8,217)	$ (7,514)	$ (6,685)	$ (28,725)	$ (14,455)	$ (18,895)	(26,450)	(68,760)	$ (54,334)
Defined Benefit Plans | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Selling, general and administrative expenses									133	1,045
Income taxes									3	(9)
Net Loss from Continuing Operations									136	1,036
Derivatives | Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Earnings before income taxes									(1,112)	(326)
Income taxes									121	(78)
Net Loss from Continuing Operations									(991)	(404)
Derivatives | Reclassification out of Accumulated Other Comprehensive Income | Foreign exchange forward
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Net sales									2,778	657
Cost of products sold									(3,890)	(995)
Derivatives | Reclassification out of Accumulated Other Comprehensive Income | Interest rate swap
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Interest expense									$ 0	$ (12)

Capital Stock - (Details)

Capital Stock - (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Capital Stock [Roll Forward]
Treasury Shares, Beginning Balance	(3,187,000)	(3,158,000)	(3,135,000)
Exercise of stock options	172,218	33,810	30,166
Treasury Shares, Ending Balance	(3,194,000)	(3,187,000)	(3,158,000)
Number of stock awards canceled	94,781	77,591	12,925
Common Stock
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	351,000
Capital Stock [Roll Forward]
Common Stock, Beginning Balance	34,219,000	34,084,000	33,952,000
Exercise of stock options	172,000	34,000	30,000
Restricted stock awards	282,000	101,000	102,000
Common Stock, Ending Balance	35,024,000	34,219,000	34,084,000
Dividends declared (in dollars per share)	$ 0.05	$ 0.05	$ 0.05
Dividends paid (in dollars per share)	$ 0.05	$ 0.05	$ 0.05
Class B Common Shares
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	(351,000)
Capital Stock [Roll Forward]
Common Stock, Beginning Balance	1,085,000	1,085,000	1,085,000
Exercise of stock options	0	0	0
Restricted stock awards	0	0	0
Common Stock, Ending Balance	734,000	1,085,000	1,085,000
Dividends declared (in dollars per share)	$ 0.045	$ 0.045	$ 0.045
Dividends paid (in dollars per share)	$ 0.045	$ 0.045	$ 0.045
Treasury Shares
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities	0
Capital Stock [Roll Forward]
Exercise of stock options	0	0	0
Restricted stock awards	(7,000)	(29,000)	(23,000)

Charges Related To Restructu106

Charges Related To Restructuring Activities - (Details) - USD ($)	3 Months Ended							12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Reserve [Roll Forward]
Beginning Balance			$ 4,466,000				$ 4,485,000	$ 4,466,000	$ 4,485,000	$ 6,993,000	$ 4,979,000	$ 0
Charges	$ 1,031,000	$ 689,000	240,000	$ 2,705,000	$ 4,077,000	$ 2,090,000	2,240,000	1,971,000	11,112,000	9,336,000	11,395,000	10,534,000
Payments								(3,723,000)	(11,131,000)	(11,844,000)	(9,381,000)	(5,555,000)
Ending Balance	2,714,000			4,466,000				2,714,000	4,466,000	4,485,000	6,993,000	4,979,000
Severance
Restructuring Reserve [Roll Forward]
Beginning Balance			4,209,000				3,986,000	4,209,000	3,986,000	5,211,000	4,905,000	0
Charges								1,678,000	9,841,000	8,282,000	6,775,000	8,352,000
Payments								(3,410,000)	(9,618,000)	(9,507,000)	(6,469,000)	(3,447,000)
Ending Balance	2,477,000			4,209,000				2,477,000	4,209,000	3,986,000	5,211,000	4,905,000
Inventory
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	151,000	0	0
Charges								0	0	0	491,000	277,000
Payments								0	0	(151,000)	(340,000)	(277,000)
Ending Balance	0			0				0	0	0	151,000	0
Lease Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance			257,000				499,000	257,000	499,000	1,625,000	74,000	0
Charges								293,000	(15,000)	698,000	1,725,000	1,788,000
Payments								(313,000)	(227,000)	(1,824,000)	(174,000)	(1,714,000)
Ending Balance	237,000			257,000				237,000	257,000	499,000	1,625,000	74,000
Other
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	6,000	0	0
Charges								0	1,286,000	356,000	2,404,000	117,000
Payments								0	(1,286,000)	(362,000)	(2,398,000)	(117,000)
Ending Balance	0			0				0	0	0	6,000	0
North America/HME
Restructuring Reserve [Roll Forward]
Beginning Balance			662,000				2,805,000	662,000	2,805,000	3,747,000	3,092,000
Charges								1,361,000	4,404,000	5,922,000	4,247,000	4,759,000
Payments								(1,124,000)	(6,547,000)	(6,864,000)	(3,592,000)	(1,667,000)
Ending Balance	899,000			662,000				899,000	662,000	2,805,000	3,747,000	3,092,000
North America/HME | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance			662,000				2,805,000	662,000	2,805,000	3,747,000	3,092,000
Charges								1,069,000	4,404,000	5,405,000	4,242,000	4,755,000
Payments								(1,069,000)	(6,547,000)	(6,347,000)	(3,587,000)	(1,663,000)
Ending Balance	662,000			662,000				662,000	662,000	2,805,000	3,747,000	3,092,000
North America/HME | Inventory
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	0	0
Charges								0	0	0	0	0
Payments								0	0	0	0	0
Ending Balance	0			0				0	0	0	0	0
North America/HME | Lease Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	0	0
Charges								292,000	0	164,000	5,000	0
Payments								(55,000)	0	(164,000)	(5,000)	0
Ending Balance	237,000			0				237,000	0	0	0	0
North America/HME | Other
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	0	0
Charges								0	0	353,000	0	4,000
Payments								0	0	(353,000)	0	(4,000)
Ending Balance	0			0				0	0	0	0	0
IPG
Restructuring Reserve [Roll Forward]
Beginning Balance			148,000				92,000	148,000	92,000		71,000
Charges								73,000	1,924,000	267,000	35,000	123,000
Payments								(221,000)	(1,868,000)	(175,000)	(106,000)	(52,000)
Ending Balance				148,000					148,000	92,000		71,000
IPG | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance			148,000				92,000	148,000	92,000		71,000
Charges								73,000	1,163,000	267,000	35,000	123,000
Payments								(221,000)	(1,107,000)	(175,000)	(106,000)	(52,000)
Ending Balance				148,000					148,000	92,000		71,000
IPG | Inventory
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0		0
Charges								0	0	0	0	0
Payments								0	0	0	0	0
Ending Balance				0					0	0		0
IPG | Lease Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0		0
Charges								0	0	0	0	0
Payments								0	0	0	0	0
Ending Balance				0					0	0		0
IPG | Other
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0		0
Charges								0	761,000	0	0	0
Payments								0	(761,000)	0	0	0
Ending Balance				0					0	0		0
Europe
Restructuring Reserve [Roll Forward]
Beginning Balance			421,000				1,089,000	421,000	1,089,000	595,000	1,816,000
Charges								510,000	1,052,000	1,640,000	2,093,000	5,466,000
Payments								(619,000)	(1,720,000)	(1,146,000)	(3,314,000)	(3,650,000)
Ending Balance	312,000			421,000				312,000	421,000	1,089,000	595,000	1,816,000
Europe | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance			421,000				1,089,000	421,000	1,089,000	595,000	1,742,000
Charges								510,000	527,000	1,640,000	817,000	3,288,000
Payments								(619,000)	(1,195,000)	(1,146,000)	(1,964,000)	(1,546,000)
Ending Balance	312,000			421,000				312,000	421,000	1,089,000	595,000	1,742,000
Europe | Inventory
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	0	0
Charges								0	0	0	0	277,000
Payments								0	0	0	0	(277,000)
Ending Balance	0			0				0	0	0	0	0
Europe | Lease Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	0	74,000
Charges								0	0	0	53,000	1,788,000
Payments								0	0	0	(127,000)	(1,714,000)
Ending Balance	0			0				0	0	0	0	74,000
Europe | Other
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	0	0
Charges								0	525,000	0	1,223,000	113,000
Payments								0	(525,000)	0	(1,223,000)	(113,000)
Ending Balance	0			0				0	0	0	0	0
Asia/Pacific
Restructuring Reserve [Roll Forward]
Beginning Balance			257,000				499,000	257,000	499,000	2,651,000	0
Charges								27,000	754,000	1,507,000	5,020,000	186,000
Payments								(284,000)	(996,000)	(3,659,000)	(2,369,000)	(186,000)
Ending Balance				257,000					257,000	499,000	2,651,000	0
Asia/Pacific | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	869,000	0
Charges								26,000	769,000	970,000	1,681,000	186,000
Payments								(26,000)	(769,000)	(1,839,000)	(812,000)	(186,000)
Ending Balance				0					0	0	869,000	0
Asia/Pacific | Inventory
Restructuring Reserve [Roll Forward]
Beginning Balance			0				0	0	0	151,000	0
Charges								0	0	0	491,000	0
Payments								0	0	(151,000)	(340,000)	0
Ending Balance				0					0	0	151,000	0
Asia/Pacific | Lease Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance			257,000				499,000	257,000	499,000	1,625,000	0
Charges								1,000	(15,000)	534,000	1,667,000	0
Payments								(258,000)	(227,000)	(1,660,000)	(42,000)	0
Ending Balance				257,000					257,000	499,000	1,625,000	0
Asia/Pacific | Other
Restructuring Reserve [Roll Forward]
Beginning Balance			0				$ 0	0	0	6,000	0
Charges								0	0	3,000	1,181,000	0
Payments								0	0	(9,000)	(1,175,000)	0
Ending Balance				0					0	$ 0	$ 6,000	$ 0
Other
Restructuring Reserve [Roll Forward]
Beginning Balance			2,978,000					2,978,000
Charges									2,978,000
Payments								(1,475,000)
Ending Balance	1,503,000			2,978,000				1,503,000	2,978,000
Other | Severance
Restructuring Reserve [Roll Forward]
Beginning Balance			2,978,000					2,978,000
Charges									2,978,000
Payments								(1,475,000)
Ending Balance	1,503,000			2,978,000				1,503,000	2,978,000
Other | Inventory
Restructuring Reserve [Roll Forward]
Beginning Balance			0					0
Charges									0
Payments								0
Ending Balance	0			0				0	0
Other | Lease Terminations
Restructuring Reserve [Roll Forward]
Beginning Balance			0					0
Charges									0
Payments								0
Ending Balance	0			0				0	0
Other | Other
Restructuring Reserve [Roll Forward]
Beginning Balance			$ 0					0
Charges									0
Payments								0
Ending Balance	$ 0			$ 0				$ 0	$ 0

Charges Related To Restructu107

Charges Related To Restructuring Activities - Narrative (Details) - USD ($)	3 Months Ended							12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]
Charges	$ 1,031,000	$ 689,000	$ 240,000	$ 2,705,000	$ 4,077,000	$ 2,090,000	$ 2,240,000	$ 1,971,000	$ 11,112,000	$ 9,336,000	$ 11,395,000	$ 10,534,000
Payments								$ (3,723,000)	(11,131,000)	(11,844,000)	(9,381,000)	(5,555,000)
Expected payout period								12 months
Severance
Restructuring Cost and Reserve [Line Items]
Charges								$ 1,678,000	9,841,000	8,282,000	6,775,000	8,352,000
Payments								(3,410,000)	(9,618,000)	(9,507,000)	(6,469,000)	(3,447,000)
Lease Terminations
Restructuring Cost and Reserve [Line Items]
Charges								293,000	(15,000)	698,000	1,725,000	1,788,000
Payments								(313,000)	(227,000)	(1,824,000)	(174,000)	(1,714,000)
Other
Restructuring Cost and Reserve [Line Items]
Charges								0	1,286,000	356,000	2,404,000	117,000
Payments								0	(1,286,000)	(362,000)	(2,398,000)	(117,000)
Inventory
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	491,000	277,000
Payments								0	0	(151,000)	(340,000)	(277,000)
Europe
Restructuring Cost and Reserve [Line Items]
Charges								510,000	1,052,000	1,640,000	2,093,000	5,466,000
Payments								(619,000)	(1,720,000)	(1,146,000)	(3,314,000)	(3,650,000)
Europe | Severance
Restructuring Cost and Reserve [Line Items]
Charges								510,000	527,000	1,640,000	817,000	3,288,000
Payments								(619,000)	(1,195,000)	(1,146,000)	(1,964,000)	(1,546,000)
Europe | Lease Terminations
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	53,000	1,788,000
Payments								0	0	0	(127,000)	(1,714,000)
Europe | Other
Restructuring Cost and Reserve [Line Items]
Charges								0	525,000	0	1,223,000	113,000
Payments								0	(525,000)	0	(1,223,000)	(113,000)
Europe | Inventory
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	0	277,000
Payments								0	0	0	0	(277,000)
Asia/Pacific
Restructuring Cost and Reserve [Line Items]
Charges								27,000	754,000	1,507,000	5,020,000	186,000
Payments								(284,000)	(996,000)	(3,659,000)	(2,369,000)	(186,000)
Asia/Pacific | Severance
Restructuring Cost and Reserve [Line Items]
Charges								26,000	769,000	970,000	1,681,000	186,000
Payments								(26,000)	(769,000)	(1,839,000)	(812,000)	(186,000)
Asia/Pacific | Lease Terminations
Restructuring Cost and Reserve [Line Items]
Charges								1,000	(15,000)	534,000	1,667,000	0
Payments								(258,000)	(227,000)	(1,660,000)	(42,000)	0
Asia/Pacific | Other
Restructuring Cost and Reserve [Line Items]
Charges								0	0	3,000	1,181,000	0
Payments								0	0	(9,000)	(1,175,000)	0
Asia/Pacific | Inventory
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	491,000	0
Payments								0	0	(151,000)	(340,000)	0
North America/HME
Restructuring Cost and Reserve [Line Items]
Charges								1,361,000	4,404,000	5,922,000	4,247,000	4,759,000
Payments								(1,124,000)	(6,547,000)	(6,864,000)	(3,592,000)	(1,667,000)
North America/HME | Severance
Restructuring Cost and Reserve [Line Items]
Charges								1,069,000	4,404,000	5,405,000	4,242,000	4,755,000
Payments								(1,069,000)	(6,547,000)	(6,347,000)	(3,587,000)	(1,663,000)
North America/HME | Lease Terminations
Restructuring Cost and Reserve [Line Items]
Charges								292,000	0	164,000	5,000	0
Payments								(55,000)	0	(164,000)	(5,000)	0
North America/HME | Other
Restructuring Cost and Reserve [Line Items]
Charges								0	0	353,000	0	4,000
Payments								0	0	(353,000)	0	(4,000)
North America/HME | Inventory
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	0	0
Payments								0	0	0	0	0
Other
Restructuring Cost and Reserve [Line Items]
Charges									2,978,000
Payments								(1,475,000)
Other | Severance
Restructuring Cost and Reserve [Line Items]
Charges									2,978,000
Payments								(1,475,000)
Other | Lease Terminations
Restructuring Cost and Reserve [Line Items]
Charges									0
Payments								0
Other | Other
Restructuring Cost and Reserve [Line Items]
Charges									0
Payments								0
Other | Inventory
Restructuring Cost and Reserve [Line Items]
Charges									0
Payments								0
Institutional Products Group
Restructuring Cost and Reserve [Line Items]
Charges								73,000	1,924,000	267,000	35,000	123,000
Payments								(221,000)	(1,868,000)	(175,000)	(106,000)	(52,000)
Institutional Products Group | Severance
Restructuring Cost and Reserve [Line Items]
Charges								73,000	1,163,000	267,000	35,000	123,000
Payments								(221,000)	(1,107,000)	(175,000)	(106,000)	(52,000)
Institutional Products Group | Lease Terminations
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	0	0
Payments								0	0	0	0	0
Institutional Products Group | Other
Restructuring Cost and Reserve [Line Items]
Charges								0	761,000	0	0	0
Payments								0	(761,000)	0	0	0
Institutional Products Group | Inventory
Restructuring Cost and Reserve [Line Items]
Charges								0	0	0	0	0
Payments								$ 0	$ 0	$ 0	$ 0	$ 0

Income Taxes - Income Before I

Income Taxes - Income Before Income Tax (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Domestic									$ (54,812)	$ (104,776)	$ (73,529)
Foreign									43,072	41,566	30,070
Earnings before income taxes	$ 581	$ (790)	$ (6,492)	$ (5,039)	$ (8,385)	$ (26,375)	$ (11,580)	$ (16,870)	$ (11,740)	$ (63,210)	$ (43,459)

Income Taxes - Income Tax Expe

Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$ (167)	$ (7,105)	$ (2,485)
State	(150)	(63)	300
Foreign	11,439	15,105	11,043
Current Income Tax Expense (Benefit)	11,122	7,937	8,858
Deferred:
Federal	3,222	100	3,011
State	318	0	0
Foreign	48	(2,487)	(994)
Deferred Income Tax Expense (Benefit)	3,588	(2,387)	2,017
Income Taxes	$ 14,710	$ 5,550	$ 10,875

Income Taxes - Rate Reconcilia

Income Taxes - Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate	(35.00%)	(35.00%)	(35.00%)
State and local income taxes, net of federal income tax benefit	0.90%	(0.10%)	0.50%
Tax credits	(61.80%)	(5.10%)	(22.80%)
Foreign taxes at less than the federal statutory rate (including tax holidays)	(46.10%)	(10.70%)	(10.60%)
Federal and foreign valuation allowance	168.00%	52.50%	35.80%
Withholding taxes	3.00%	0.60%	0.70%
Compensation	0.60%	0.10%	0.50%
Dividends	100.10%	12.30%	54.60%
Life insurance	(2.70%)	4.10%	(1.50%)
Foreign branch activity	(8.10%)	(1.80%)	(1.80%)
Uncertain tax positions	6.70%	1.20%	1.30%
Other, net	(0.30%)	(9.30%)	3.30%
Effective Income Tax Rate, Continuing Operations	125.30%	8.80%	25.00%

Income Taxes - Components of D

Income Taxes - Components of Deferred Income Tax (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current deferred income tax assets (liabilities), net:
Bad debt	$ 0	$ 5,364,000
Warranty	0	7,092,000
State and local taxes	0	2,240,000
Other accrued expenses and reserves	0	1,852,000
Inventory	0	(3,096,000)
Compensation and benefits	0	2,209,000
Product liability	0	594,000
Valuation allowance	0	(22,084,000)
Other, net	0	(732,000)
Deferred Tax Liabilities, Net, Current	0	(369,000)
Long-term deferred income tax assets (liabilities), net:
Bad debt	3,670,000	0
Warranty	5,357,000	0
Other accrued expenses and reserves	4,355,000	0
Inventory	2,395,000	0
Goodwill and intangibles	(25,008,000)	(21,915,000)
Convertible debt	(421,000)	(700,000)
Fixed assets	(8,207,000)	(10,431,000)
Compensation and benefits	7,136,000	14,630,000
Loss and credit carryforwards	102,194,000	65,123,000
Product liability	4,107,000	4,919,000
State and local taxes	19,932,000	17,745,000
Valuation allowance	(151,972,000)	(111,828,000)
Other, net	5,255,000	12,647,000
Deferred tax assets (Liabilities), net, noncurrent	(31,207,000)	(29,810,000)
Net Deferred Income Taxes	$ 31,207,000	$ 30,179,000

Income Taxes - Unrecognized Ta

Income Taxes - Unrecognized Tax Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$ 11,019	$ 10,833
Additions to:
Positions taken during the current year	227	348
Positions taken during a prior year	270	418
Deductions due to:
Exchange rate impact	(1,197)	(362)
Positions taken during a prior year	(527)	0
Lapse of statute of limitations	(239)	(218)
Balance at end of year	$ 9,553	$ 11,019

Income Taxes - (Narrative) (De

Income Taxes - (Narrative) (Details) - USD ($)	3 Months Ended			12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Tax Credit Carryforward [Line Items]
Tax benefit from intra-period allocation	$ (3,400,000)	$ 2,700,000	$ (1,550,000)	$ 140,000	$ 7,175,000	$ 3,455,000
Income taxes (benefit)				14,710,000	5,550,000	10,875,000
Deferred tax assets, gross		137,511,000		154,401,000	137,511,000
Deferred tax liabilities		33,778,000		33,636,000	33,778,000
Deferred tax assets, valuation allowance		133,912,000		151,972,000	133,912,000
Income Taxes Paid, Net				7,966,000	6,384,000	6,349,000
Domestic state and local tax loss carryforwards				563,000,000
Federal tax credit carryforwards				38,520,000
Unrecognized tax benefits, excluding interest and penalties		10,030,000		8,366,000	10,030,000
Expected Foreign Tax Payments Pursuant to Payment Plan, Current				9,100,000
Unrecognized tax benefits that would impact effective tax rate		10,030,000		8,366,000	10,030,000
Income tax penalties and interest expense				(315,000)	(500,000)	$ (676,000)
Income tax penalties and interest accrued		$ 5,130,000		5,440,000	$ 5,130,000
Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign				61,330,000
Tax Year 2014 to 2017 | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration				206,000,000
Tax year 2018 to 2027 | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration				191,000,000
Tax Year 2014 to 2018 | Domestic tax authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards				4,169,000
Tax Year 2019 to 2022 | Domestic tax authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards				32,522,000
Tax Year 2028 and Thereafter | State and Local Jurisdiction [Member]
Tax Credit Carryforward [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration				166,000,000
Tax Year 2031 | Domestic tax authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards				1,582,000
Indefinite | Domestic tax authority
Tax Credit Carryforward [Line Items]
Tax credit carryforwards				247,000
Loss Carryforwards | Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Deferred tax assets, valuation allowance				$ 61,330,000

Net Earnings (Loss) Per Comm114

Net Earnings (Loss) Per Common Share - Computation of Basic and Diluted Net Earnings Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Net Earnings (loss) per Share—Basic:
Average common shares outstanding									32,171		32,009		31,915
Net Loss from Continuing Operations	$ (2,929)	$ (7,790)	$ (8,217)	$ (7,514)	$ (6,685)	$ (28,725)	$ (14,455)	$ (18,895)	$ (26,450)		$ (68,760)		$ (54,334)
Total Net Earnings from Discontinued Operations	0	0	0	260	(2,700)	13,629	842	919	260		12,690		87,385
Net Earnings (loss)	$ (2,929)	$ (7,790)	$ (8,217)	$ (7,254)	$ (9,385)	$ (15,096)	$ (13,613)	$ (17,976)	$ (26,190)		$ (56,070)		$ 33,051
Net loss from continuing operations - Basic (in dollars per share)	$ (0.09)	$ (0.24)	$ (0.26)	$ (0.23)	$ (0.21)	$ (0.90)	$ (0.45)	$ (0.59)	$ (0.82)		$ (2.15)		$ (1.70)
Net earnings (loss) from discontinued operations - Basic (in dollars per share	0	0	0	0.01	(0.08)	0.43	0.03	0.03	0.01		0.40		2.74
Net earnings per common share	$ (0.09)	$ (0.24)	$ (0.26)	$ (0.23)	$ (0.29)	$ (0.47)	$ (0.43)	$ (0.56)	$ (0.81)		$ (1.75)		$ 1.04
Diluted
Average common shares outstanding									32,171		32,009		31,915
Stock options and awards									512		188		128
Average common shares assuming dilution									32,683		32,197		32,043
Net Loss from Continuing Operations	$ (2,929)	$ (7,790)	$ (8,217)	$ (7,514)	$ (6,685)	$ (28,725)	$ (14,455)	$ (18,895)	$ (26,450)		$ (68,760)		$ (54,334)
Total Net Earnings from Discontinued Operations	0	0	0	260	(2,700)	13,629	842	919	260		12,690		87,385
Net Earnings (loss)	$ (2,929)	$ (7,790)	$ (8,217)	$ (7,254)	$ (9,385)	$ (15,096)	$ (13,613)	$ (17,976)	$ (26,190)		$ (56,070)		$ 33,051
Net loss from continuing operations assuming dilution (in dollars per share)	$ (0.09)	$ (0.24)	$ (0.26)	$ (0.23)	$ (0.21)	$ (0.90)	$ (0.45)	$ (0.59)	$ (0.82)	[1]	$ (2.15)	[1]	$ (1.70)	[1]
Net earnings (loss) from discontinued operations assuming dilution (in dollars per share)	0	0	0	0.01	(0.08)	0.42	0.03	0.03	0.01		0.39		2.73
Net Earnings (loss) per Share - Assuming Dilution (in dollars per share)	$ (0.09)	$ (0.24)	$ (0.26)	$ (0.23)	$ (0.29)	$ (0.47)	$ (0.43)	$ (0.56)	$ (0.81)	[1]	$ (1.75)	[1]	$ 1.03	[1]
[1]	Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss.

Net Earnings (Loss) Per Comm115

Net Earnings (Loss) Per Common Share - Narrative (Details) - Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,479,912	2,857,590	4,307,458
Average exercise price	$ 18.51	$ 41.87	$ 41.87
Fair value stock price	$ 25.24	$ 16.95	$ 16.48

Concentration Of Credit Risk -

Concentration Of Credit Risk - (Details)	12 Months Ended
	Dec. 31, 2015USD ($)Customer
Net Sales | Customer Concentration Risk
Concentration Risk [Line Items]
Number of Customers Used For Concentration Risk Disclosure | Customer	10
Concentration risk, percentage	16.40%
Maximum percent of revenue from single customer	3.30%
Payment Guarantee
Concentration Risk [Line Items]
Retained recourse obligation	$ 6,089,000
Total contracts	39,510,000
Other Long-Term Obligations | Payment Guarantee
Concentration Risk [Line Items]
Guarantee obligation at carrying value	$ 109,000

Derivatives - Notional Amounts

Derivatives - Notional Amounts - Designated as Hedges (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	$ 40,165,000	$ 79,973,000
Gain (Loss)	(54,000)	(1,458,000)
Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	213,164,000	83,942,000
Unrealized Gain (Loss)	2,183,000	(548,000)
Foreign exchange forward
Derivative [Line Items]
Gain (Loss)	1,112,000	338,000	$ (271,000)
Foreign exchange forward | Not Designated as Hedging Instrument
Derivative [Line Items]
Gain (Loss)	(54,000)	(1,458,000)
USD / AUD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	2,910,000	1,250,000
Unrealized Gain (Loss)	(83,000)	65,000
USD / CAD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	3,893,000	3,570,000
Unrealized Gain (Loss)	181,000	(63,000)
USD / CHF | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	111,000
Unrealized Gain (Loss)	0	0
USD / CNY | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	16,786,000	0
Unrealized Gain (Loss)	(282,000)	0
USD / EUR | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	72,758,000	25,524,000
Unrealized Gain (Loss)	2,681,000	0
USD / GBP | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	3,862,000	1,199,000
Unrealized Gain (Loss)	22,000	3,000
USD / NZD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	4,893,000	7,018,000
Unrealized Gain (Loss)	37,000	(55,000)
USD / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	5,128,000	594,000
Unrealized Gain (Loss)	39,000	1,000
USD / MXP | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	8,494,000	10,297,000
Unrealized Gain (Loss)	(284,000)	(657,000)
EUR / AUD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	669,000	452,000
Unrealized Gain (Loss)	(10,000)	5,000
EUR / CAD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	1,283,000	580,000
Unrealized Gain (Loss)	(17,000)	(1,000)
EUR / CHF | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	1,944,000	505,000
Unrealized Gain (Loss)	(17,000)	(2,000)
EUR / DKK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	643,000
Unrealized Gain (Loss)	0	(3,000)
EUR / GBP | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	36,567,000	11,906,000
Unrealized Gain (Loss)	(424,000)	23,000
EUR / NOK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	3,375,000	1,490,000
Unrealized Gain (Loss)	(55,000)	43,000
EUR / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	2,464,000	2,917,000
Unrealized Gain (Loss)	(42,000)	(9,000)
EUR / NZD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	3,609,000	7,074,000
Unrealized Gain (Loss)	476,000	60,000
GBP / AUD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	830,000	656,000
Unrealized Gain (Loss)	(46,000)	22,000
GBP / CHF | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	463,000	331,000
Unrealized Gain (Loss)	(7,000)	(1,000)
GBP / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	2,067,000	1,035,000
Unrealized Gain (Loss)	(1,000)	(2,000)
AUD / CAD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	1,538,000
Unrealized Gain (Loss)	0	30,000
AUD / CHF | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	93,000
Unrealized Gain (Loss)	0	1,000
AUD / NZD | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	352,000	537,000
Unrealized Gain (Loss)	8,000	19,000
AUD / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	61,000
Unrealized Gain (Loss)	0	(1,000)
CAD / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	182,000
Unrealized Gain (Loss)	0	(1,000)
CHF / DKK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	269,000
Unrealized Gain (Loss)	0	(2,000)
DKK / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	37,293,000	2,497,000
Unrealized Gain (Loss)	46,000	(44,000)
NOK / CHF | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	66,000
Unrealized Gain (Loss)	0	2,000
NOK / SEK | Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	3,524,000	1,547,000
Unrealized Gain (Loss)	$ (39,000)	$ 19,000

Derivatives - Notional Amou118

Derivatives - Notional Amounts - Not Designated as Hedges (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	$ 40,165,000	$ 79,973,000
Gain (Loss)	(54,000)	(1,458,000)
Foreign exchange forward
Derivative [Line Items]
Gain (Loss)	1,112,000	338,000	$ (271,000)
Foreign exchange forward | Not Designated as Hedging Instrument
Derivative [Line Items]
Gain (Loss)	(54,000)	(1,458,000)
AUD / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	8,051,000	7,300,000
Gain (Loss)	337,000	117,000
CAD / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	5,762,000	6,016,000
Gain (Loss)	(4,000)	(6,000)
CNY / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	9,943,000	3,200,000
Gain (Loss)	(441,000)	(14,000)
EUR / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	2,118,000	53,365,000
Gain (Loss)	53,000	(1,585,000)
DKK / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	7,927,000	0
Gain (Loss)	125,000	0
GBP / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	4,526,000	5,592,000
Gain (Loss)	(106,000)	18,000
NZD / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	0	4,500,000
Gain (Loss)	0	12,000
NOK / USD | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional Amount	1,838,000	0
Gain (Loss)	$ (18,000)	$ 0

Derivatives - Balance Sheet Lo

Derivatives - Balance Sheet Location (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Current Assets
Derivatives, Fair Value [Line Items]
Assets	$ 4,143	$ 520
Other Current Assets | Foreign exchange forward | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	3,626	373
Other Current Assets | Foreign exchange forward | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Assets	517	147
Accrued Expenses
Derivatives, Fair Value [Line Items]
Liabilities	2,014	2,526
Accrued Expenses | Foreign exchange forward | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities	1,443	921
Accrued Expenses | Foreign exchange forward | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Liabilities	$ 571	$ 1,605

Derivatives - Gain (Loss) in S

Derivatives - Gain (Loss) in Statement of Finacial Position (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)		$ 562,000
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		404,000
Amount of Loss Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)		(11,000)
Amount of Gain (Loss) Recognized in Income on Derivatives	$ 1,112,000	338,000	$ (271,000)
Foreign exchange forward
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income on Derivatives	1,112,000	338,000	$ (271,000)
Foreign exchange forward | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)	3,545,000	562,000
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	991,000	416,000
Amount of Loss Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)	(11,000)	(11,000)
Interest rate swap | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)		0
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)		(12,000)
Amount of Loss Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)		0
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income on Derivatives	(54,000)	(1,458,000)
Not Designated as Hedging Instrument | Foreign exchange forward
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in Income on Derivatives	$ (54,000)	$ (1,458,000)

Derivatives - Narrative (Detai

Derivatives - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Minimum
Derivative [Line Items]
Percentage of forcasted transactions with currency rate exposure	50.00%
Maximum
Derivative [Line Items]
Percentage of forcasted transactions with currency rate exposure	90.00%
Foreign exchange forward
Derivative [Line Items]
Notional amount of derivatives, matured during period	$ 136,818,000	$ 157,121,000
Gain (Loss)	1,112,000	338,000	$ (271,000)
Interest expense | Interest rate swap
Derivative [Line Items]
Loss on derivative		12,000	337,000
Selling, general and administrative expense | Foreign exchange forward
Derivative [Line Items]
Gain on derivative			(370,000)
Loss on derivative	54,000	1,458,000
Cash Flow Hedging
Derivative [Line Items]
Gain (Loss)	1,112,000	338,000	$ (271,000)
Cash Flow Hedging | Net sales
Derivative [Line Items]
Loss on derivative	2,778,000	657,000
Cash Flow Hedging | Cost of products sold
Derivative [Line Items]
Gain on derivative	$ (3,890,000)	$ (995,000)

Fair Values of Financial Ins122

Fair Values of Financial Instruments - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Foreign exchange forward - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 2,129	$ (2,006)
Quoted Prices in Active Markets for Identical Assets / (Liabilities) - Level I
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	0	0
Significant Other Observable Inputs - Level II
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	2,129	(2,006)
Significant Other Unobservable Inputs - Level III
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets (liabilities), at fair value, net	$ 0	$ 0

Fair Values of Financial Ins123

Fair Values of Financial Instruments - Details of Book Value and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	$ 60,055	$ 38,931
Other investments	160	249
Installment receivables, net of reserves	1,793	1,911
Long-term debt (including current maturities of long-term debt)	(47,120)	(20,331)
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and cash equivalents	60,055	38,931
Other investments	160	249
Installment receivables, net of reserves	1,793	1,911
Long-term debt (including current maturities of long-term debt)	(47,369)	(20,248)
Foreign exchange forward | Other Current Assets | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets	4,143	520
Foreign exchange forward | Other Current Assets | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative assets	4,143	520
Foreign exchange forward | Accrued Expenses | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	(2,014)	(2,526)
Foreign exchange forward | Accrued Expenses | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liabilities	$ (2,014)	$ (2,526)

Fair Values of Financial Ins124

Fair Values of Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maturity of corporate debt with similar credit risk			20 years
US treasury bond maturity			20 years
Discounted cash flow, discount rate			9.41%	9.89%	10.00%
Impairment of intangible assets	$ 4,788,000	$ 8,253,000			$ 1,523,000
Discounted cash flow, discount rate premium			1.00%
Institutional Products Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets				$ 13,041,000	1,356,000
Discounted cash flow sensitivity analysis discount rate rncrease			1.00%
Europe
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discounted cash flow sensitivity analysis discount rate rncrease			1.00%
Customer lists | Institutional Products Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets				12,826,000	442,000
Customer lists | North America/HME
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets					167,000
Noncompete Agreements | Institutional Products Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets				215,000
Trademarks with definite life | Institutional Products Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets					123,000
Developed technology | Institutional Products Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of finite-lived intangible assets					223,000
Trademarks | Institutional Products Group
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of indefinite-lived intangible assets					568,000
Impairment indefinite-lived intangible assets, net of tax					496,000
Foreign exchange forward
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss)			$ 1,112,000	$ 338,000	$ (271,000)

Business Segments - (Narrative

Business Segments - (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Institutional Products Group
Segment Reporting Information [Line Items]
Impairment of finite-lived intangible assets	$ 13,041,000	$ 1,356,000
Customer lists | Institutional Products Group
Segment Reporting Information [Line Items]
Impairment of finite-lived intangible assets	$ 12,826,000	442,000
Customer lists | North America/HME
Segment Reporting Information [Line Items]
Impairment of finite-lived intangible assets		$ 167,000
Customer Concentration Risk | Net Sales
Segment Reporting Information [Line Items]
Maximum percent of revenue from single customer			3.30%

Business Segments - (Informati

Business Segments - (Information by Segment) (Details) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net sales		$ 283,265	$ 283,776	$ 286,273	$ 289,024	$ 318,199	$ 320,520	$ 326,943	$ 304,501	$ 1,142,338	$ 1,270,163	$ 1,334,505
Depreciation and amortization										19,430	32,789	36,789
Net interest expense (income)										2,746	2,532	2,694
Earnings (loss) before income taxes										(11,740)	(63,210)	(43,459)
Assets		838,143				963,731				838,143	963,731	1,096,434
Long-lived assets		476,022				557,744				476,022	557,744	647,048
Expenditures for assets										7,522	12,327	14,158
North America/HME
Segment Reporting Information [Line Items]
Depreciation and amortization										8,775	10,925	12,149
Net interest expense (income)										2,080	348	(1,869)
Earnings (loss) before income taxes										(32,866)	(63,601)	(50,506)
Assets		215,500				218,877				215,500	218,877	250,239
Long-lived assets		49,319				44,727				49,319	44,727	60,309
Expenditures for assets										1,232	2,960	5,017
Institutional Products Group
Segment Reporting Information [Line Items]
Depreciation and amortization										1,980	7,656	8,310
Net interest expense (income)										1,028	2,244	3,656
Earnings (loss) before income taxes										6,757	(10,961)	1,418
Assets		38,730				42,692				38,730	42,692	45,933
Long-lived assets		30,278				33,487				30,278	33,487	38,342
Expenditures for assets										212	1,232	3,308
Europe
Segment Reporting Information [Line Items]
Depreciation and amortization										7,183	11,111	12,123
Net interest expense (income)										(444)	(209)	(53)
Earnings (loss) before income taxes										38,644	48,088	40,468
Assets		557,740				638,896				557,740	638,896	693,790
Long-lived assets		391,533				459,957				391,533	459,957	506,329
Expenditures for assets										5,058	6,708	4,809
Asia/Pacific
Segment Reporting Information [Line Items]
Depreciation and amortization										1,463	2,406	3,073
Net interest expense (income)										82	149	960
Earnings (loss) before income taxes										(3,521)	(9,485)	(13,258)
Assets		24,421				30,231				24,421	30,231	31,034
Long-lived assets		3,140				4,046				3,140	4,046	5,238
Expenditures for assets										969	1,417	830
All Other
Segment Reporting Information [Line Items]
Depreciation and amortization	[1]									29	173	275
Earnings (loss) before income taxes	[1]									(20,754)	(27,251)	(21,581)
Assets		1,752				15,647				1,752	15,647	37,142
Long-lived assets		1,752				15,527				1,752	15,527	36,830
Expenditures for assets										51	0	50
Discontinued Operations
Segment Reporting Information [Line Items]
Depreciation and amortization										0	518	859
Assets		$ 0				$ 17,388				0	17,388	38,296
Expenditures for assets										0	10	144
Operating Segments | North America/HME
Segment Reporting Information [Line Items]
Net sales										474,196	507,867	589,240
Operating Segments | Institutional Products Group
Segment Reporting Information [Line Items]
Net sales										87,137	102,796	112,290
Operating Segments | Europe
Segment Reporting Information [Line Items]
Net sales										536,463	610,555	583,143
Operating Segments | Asia/Pacific
Segment Reporting Information [Line Items]
Net sales										44,542	48,945	49,832
Intersegment Eliminations
Segment Reporting Information [Line Items]
Net sales										142,937	126,069	116,070
Intersegment Eliminations | North America/HME
Segment Reporting Information [Line Items]
Net sales										111,321	84,247	77,553
Intersegment Eliminations | Institutional Products Group
Segment Reporting Information [Line Items]
Net sales										997	6,711	5,304
Intersegment Eliminations | Europe
Segment Reporting Information [Line Items]
Net sales										9,958	8,938	8,272
Intersegment Eliminations | Asia/Pacific
Segment Reporting Information [Line Items]
Net sales										$ 20,661	$ 26,173	$ 24,941
[1]	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Business Segments - (Net Sales

Business Segments - (Net Sales by Product) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue from External Customer [Line Items]
Net sales by product		$ 1,142,338	$ 1,270,163	$ 1,334,505
North America/HME
Revenue from External Customer [Line Items]
Net sales by product		474,196	507,867	589,240
Institutional Products Group | Continuing Care
Revenue from External Customer [Line Items]
Net sales by product		87,137	102,796	112,290
Europe
Revenue from External Customer [Line Items]
Net sales by product		536,463	610,555	583,143
Asia/Pacific
Revenue from External Customer [Line Items]
Net sales by product		44,542	48,945	49,832
Operating Segments | North America/HME | Lifestyle Products
Revenue from External Customer [Line Items]
Net sales by product		222,944	239,625	267,934
Operating Segments | North America/HME | Mobility and Seating
Revenue from External Customer [Line Items]
Net sales by product		117,232	115,776	134,995
Operating Segments | North America/HME | Respiratory Therapy
Revenue from External Customer [Line Items]
Net sales by product		130,349	149,063	178,065
Operating Segments | North America/HME | Other Products and Services
Revenue from External Customer [Line Items]
Net sales by product	[1]	3,671	3,403	8,246
Operating Segments | Europe | Lifestyle Products
Revenue from External Customer [Line Items]
Net sales by product		275,932	322,370	303,225
Operating Segments | Europe | Mobility and Seating
Revenue from External Customer [Line Items]
Net sales by product		208,730	228,163	216,152
Operating Segments | Europe | Respiratory Therapy
Revenue from External Customer [Line Items]
Net sales by product		36,373	40,661	40,885
Operating Segments | Europe | Other Products and Services
Revenue from External Customer [Line Items]
Net sales by product	[1]	15,428	19,361	22,881
Operating Segments | Asia/Pacific | Lifestyle Products
Revenue from External Customer [Line Items]
Net sales by product		10,277	11,772	12,023
Operating Segments | Asia/Pacific | Mobility and Seating
Revenue from External Customer [Line Items]
Net sales by product		25,655	28,174	26,737
Operating Segments | Asia/Pacific | Respiratory Therapy
Revenue from External Customer [Line Items]
Net sales by product		807	1,286	1,290
Operating Segments | Asia/Pacific | Continuing Care
Revenue from External Customer [Line Items]
Net sales by product		3,115	3,956	2,785
Operating Segments | Asia/Pacific | Other Products and Services
Revenue from External Customer [Line Items]
Net sales by product	[1]	$ 4,688	$ 3,757	$ 6,997
[1]	Includes various services, including repair services, equipment rentals and external contracting.

Contingencies - (Details)

Contingencies - (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Loss Contingencies [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)	$ (2,325,000)	$ 11,493,000	$ 7,264,000
Europe
Loss Contingencies [Line Items]
Additional warranty expense related to recall		3,395,000
North America/HME
Loss Contingencies [Line Items]
Additional warranty expense related to recall		3,164,000
Loss Contingency Accrual, Period Increase (Decrease)			2,625,000
Asia/Pacific
Loss Contingencies [Line Items]
Loss Contingency Accrual, Period Increase (Decrease)			$ 4,639,000
Field Action Under Review
Loss Contingencies [Line Items]
Additional warranty expense related to recall	(2,000,000)	6,559,000
Warranty Related Sieve Bed Recall
Loss Contingencies [Line Items]
Additional warranty expense related to recall	(250,000)	2,057,000
Warranty Related Recall
Loss Contingencies [Line Items]
Additional warranty expense related to recall		2,877,000
Warranty Related Recall | North America/HME
Loss Contingencies [Line Items]
Additional warranty expense related to recall	$ (75,000)	1,612,000
Warranty Related Recall | Asia/Pacific
Loss Contingencies [Line Items]
Additional warranty expense related to recall		$ 1,265,000

Subsequent Event Subsequent Eve

Subsequent Event Subsequent Event (Details)	Feb. 16, 2016USD ($)$ / shares$ / unitshares	Dec. 31, 2015USD ($)$ / shares	Apr. 22, 2015USD ($)	Jan. 16, 2015USD ($)	Dec. 31, 2014USD ($)
Convertible Subordinated Debt | Convertible senior subordinated debentures at 4.125%, due in February 2027
Subsequent Event [Line Items]
Interest rate (as a percent)		4.125%
Initial conversion price | $ / shares		$ 24.79
Principal amount of liability component		$ 13,350,000			$ 13,350,000
Convertible Subordinated Debt | Convertible senior subordinated debentures at 4.125%, due in February 2027 | Subsequent Event [Member]
Subsequent Event [Line Items]
Interest rate (as a percent)	4.125%
Convertible Subordinated Debt | Convertible Senior Subordinated Debentures at 5.00% February 2021 [Domain] | Subsequent Event [Member]
Subsequent Event [Line Items]
Interest rate (as a percent)	5.00%
Debt Instrument, Convertible, Percentage of Principal Required to be Repurchased Upon the Occurrence of Certain Fundamental Changes	100.00%
Convertible Common Stock, Shares Issued upon Conversion | shares	60.0492
Debt Instrument, Convertible, Conversion Ratio Principal Amount	$ 1,000
Initial conversion price | $ / shares	$ 16.65
Derivative, Price Risk Option Strike Price | $ / unit	22.4175
Line of Credit, Covenant Compliance, Single Acquisition Limit Maximum	$ 30,000,000
Principal amount of liability component	130,000,000
Convertible Debt, Net Proceeds	124,800,000
Convertible Debt, Option to Purchase Solely to Cover Over-Allotments, Amount	20,000,000
Convertible Debt, Hedge Transaction Cost, net	$ 13,520,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member]
Subsequent Event [Line Items]
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent				11.25%
Borrowing capacity				$ 100,000,000
Line of Credit, Covenant Compliance, Maximum Capital Expenditure, Amount				20,000,000
Line of Credit, Covenant Compliance, Single Acquisition Limit Maximum			$ 500,000
Line of Credit, Covenant Compliance, Aggregate Amount of Permitted Dispositions, Amount				20,000,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Amount				$ 10,000,000
Revolving Credit Facility | Line of Credit | Revolving Credit and Security Agreement (New Credit Agreement) [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Line of Credit, Covenant Compliance, Required Undrawn Balance, Minimum, Percent	20.00%
Borrowing capacity	$ 100,000,000
Line of Credit, Covenant Compliance, Consecutive Business Days for Undrawn Balance	30 days
Line of Credit, Covenant Compliance, Common Stock Repurchase, Amount	$ 5,000,000
Line of Credit, Covenant Compliance, Maximum Capital Expenditure, Amount	35,000,000
Line of Credit, Covenant Compliance, Aggregate Amount of Permitted Dispositions, Amount	25,000,000
Line of Credit, Covenant Compliance, Required Undrawn Balance, Amount	$ 5,000,000

Supplemental Guarantor Infor130

Supplemental Guarantor Information - Consolidating Condensed Statements of Operations (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Feb. 17, 2007
Condensed Financial Statements, Captions [Line Items]
Net sales	$ 283,265,000	$ 283,776,000	$ 286,273,000	$ 289,024,000	$ 318,199,000	$ 320,520,000	$ 326,943,000	$ 304,501,000	$ 1,142,338,000	$ 1,270,163,000	$ 1,334,505,000
Cost of products sold									829,514,000	922,775,000	967,079,000
Gross Profit	80,803,000	77,639,000	77,287,000	77,095,000	88,370,000	84,647,000	91,578,000	82,793,000	312,824,000	347,388,000	367,426,000
Selling, general and administrative expenses									319,847,000	383,913,000	397,332,000
Charges related to restructuring activities									1,971,000	11,112,000	9,336,000
Asset write-downs to intangibles and goodwill									0	13,041,000	1,523,000
Income (loss) from equity investee									0	0	0
Interest expense, net									2,746,000	2,532,000	2,694,000
Earnings before income taxes	581,000	(790,000)	(6,492,000)	(5,039,000)	(8,385,000)	(26,375,000)	(11,580,000)	(16,870,000)	(11,740,000)	(63,210,000)	(43,459,000)
Income taxes (benefit)									14,710,000	5,550,000	10,875,000
Net Loss from Continuing Operations	(2,929,000)	(7,790,000)	(8,217,000)	(7,514,000)	(6,685,000)	(28,725,000)	(14,455,000)	(18,895,000)	(26,450,000)	(68,760,000)	(54,334,000)
Net Earnings from Discontinued Operations	0	0	0	260,000	(2,700,000)	13,629,000	842,000	919,000	260,000	12,690,000	87,385,000
Net Earnings (loss)	$ (2,929,000)	$ (7,790,000)	$ (8,217,000)	$ (7,254,000)	$ (9,385,000)	$ (15,096,000)	$ (13,613,000)	$ (17,976,000)	(26,190,000)	(56,070,000)	33,051,000
Other Comprehensive Income (Loss), net of Tax									(81,006,000)	(53,537,000)	12,413,000
Comprehensive Income (Loss)									(107,196,000)	(109,607,000)	45,464,000
The Company (Parent)
Condensed Financial Statements, Captions [Line Items]
Net sales									211,178,000	213,072,000	241,871,000
Cost of products sold									187,272,000	192,566,000	211,896,000
Gross Profit									23,906,000	20,506,000	29,975,000
Selling, general and administrative expenses									111,814,000	119,904,000	123,377,000
Charges related to restructuring activities									1,339,000	9,672,000	6,356,000
Asset write-downs to intangibles and goodwill										0	0
Income (loss) from equity investee									69,636,000	53,536,000	133,350,000
Interest expense, net									3,011,000	175,000	(1,661,000)
Earnings before income taxes									(22,622,000)	(55,709,000)	35,253,000
Income taxes (benefit)									3,568,000	361,000	2,202,000
Net Loss from Continuing Operations									(26,190,000)	(56,070,000)	33,051,000
Net Earnings from Discontinued Operations									0	0	0
Net Earnings (loss)									(26,190,000)	(56,070,000)	33,051,000
Other Comprehensive Income (Loss), net of Tax									(81,006,000)	(53,537,000)	12,413,000
Comprehensive Income (Loss)									(107,196,000)	(109,607,000)	45,464,000
Combined Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net sales									402,108,000	413,067,000	460,960,000
Cost of products sold									305,592,000	314,562,000	338,650,000
Gross Profit									96,516,000	98,505,000	122,310,000
Selling, general and administrative expenses									63,068,000	81,676,000	93,731,000
Charges related to restructuring activities									0	(1,326,000)	79,000
Asset write-downs to intangibles and goodwill										13,041,000	1,250,000
Income (loss) from equity investee									29,353,000	35,208,000	29,644,000
Interest expense, net									428,000	2,114,000	3,353,000
Earnings before income taxes									62,373,000	38,208,000	53,541,000
Income taxes (benefit)									0	0	(1,785,000)
Net Loss from Continuing Operations									62,373,000	38,208,000	55,326,000
Net Earnings from Discontinued Operations									260,000	12,690,000	87,385,000
Net Earnings (loss)									62,633,000	50,898,000	142,711,000
Other Comprehensive Income (Loss), net of Tax									(15,037,000)	(5,057,000)	(2,309,000)
Comprehensive Income (Loss)									47,596,000	45,841,000	140,402,000
Combined Non-Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net sales									649,966,000	740,669,000	720,978,000
Cost of products sold									457,634,000	512,521,000	506,308,000
Gross Profit									192,332,000	228,148,000	214,670,000
Selling, general and administrative expenses									144,965,000	182,416,000	177,530,000
Charges related to restructuring activities									632,000	2,766,000	2,901,000
Asset write-downs to intangibles and goodwill										0	273,000
Income (loss) from equity investee									703,000	280,000	286,000
Interest expense, net									(693,000)	243,000	1,002,000
Earnings before income taxes									48,131,000	43,003,000	33,250,000
Income taxes (benefit)									11,142,000	5,189,000	10,458,000
Net Loss from Continuing Operations									36,989,000	37,814,000	22,792,000
Net Earnings from Discontinued Operations									0	0	0
Net Earnings (loss)									36,989,000	37,814,000	22,792,000
Other Comprehensive Income (Loss), net of Tax									(67,842,000)	(50,058,000)	17,797,000
Comprehensive Income (Loss)									(30,853,000)	(12,244,000)	40,589,000
Eliminations
Condensed Financial Statements, Captions [Line Items]
Net sales									(120,914,000)	(96,645,000)	(89,304,000)
Cost of products sold									(120,984,000)	(96,874,000)	(89,775,000)
Gross Profit									70,000	229,000	471,000
Selling, general and administrative expenses									0	(83,000)	2,694,000
Charges related to restructuring activities									0	0	0
Asset write-downs to intangibles and goodwill										0	0
Income (loss) from equity investee									(99,692,000)	(89,024,000)	(163,280,000)
Interest expense, net									0	0	0
Earnings before income taxes									(99,622,000)	(88,712,000)	(165,503,000)
Income taxes (benefit)									0	0	0
Net Loss from Continuing Operations									(99,622,000)	(88,712,000)	(165,503,000)
Net Earnings from Discontinued Operations									0	0	0
Net Earnings (loss)									(99,622,000)	(88,712,000)	(165,503,000)
Other Comprehensive Income (Loss), net of Tax									82,879,000	55,115,000	(15,488,000)
Comprehensive Income (Loss)									$ (16,743,000)	$ (33,597,000)	$ (180,991,000)
Convertible Senior Subordinated Debentures February 2027 | Convertible Subordinated Debt
Condensed Financial Statements, Captions [Line Items]
Interest rate (as a percent)	4.125%								4.125%
Principal Amount												$ 135,000,000

Supplemental Guarantor Infor131

Supplemental Guarantor Information - Consolidating Condensed Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 60,055	$ 38,931	$ 29,785	$ 38,791
Trade receivables, net	133,655	154,207
Installment receivables, net	1,145	1,054
Inventories, net	132,807	155,561
Deferred income taxes	0	2,048
Intercompany advance	0	0
Other current assets	34,459	36,798
Disposal Group, Including Discontinued Operation, Assets, Current	0	17,388
Total Current Assets	362,121	405,987
Investment in subsidiaries	0	0
Intercompany advances, net	0	0
Other Assets	4,659	19,053
Intangibles	31,000	38,013
Property and Equipment, net	78,683	79,659
Goodwill	361,680	421,019	457,534
Total Assets	838,143	963,731	1,096,434
Current Liabilities
Accounts payable	105,608	119,927
Accrued expenses	122,420	155,699
Current taxes, payable and deferred	17,588	12,634
Intercompany advances, net	0	0
Short-term debt and current maturities of long-term obligations	2,028	959
Disposal Group, Including Discontinued Operation, Liabilities	0	1,013
Total Current Liabilities	247,644	290,232
Long-Term Debt	45,092	19,372
Other Long-Term Obligations	82,589	88,805
Inercompany advances, net	0	0
Total Shareholders’ Equity	462,818	565,322	670,809	620,989
Total Liabilities and Shareholders’ Equity	838,143	963,731
The Company (Parent)
Current Assets
Cash and cash equivalents	14,047	7,340	1,401	5,774
Trade receivables, net	43,534	47,030
Installment receivables, net	0	0
Inventories, net	6,300	25,021
Deferred income taxes		0
Intercompany advance	8,392	10,007
Other current assets	6,380	8,082
Disposal Group, Including Discontinued Operation, Assets, Current		3,982
Total Current Assets	78,653	101,462
Investment in subsidiaries	1,430,070	1,409,482
Intercompany advances, net	1,115,121	1,049,235
Other Assets	3,095	16,955
Intangibles	123	286
Property and Equipment, net	32,382	29,632
Goodwill	0	0
Total Assets	2,659,444	2,607,052
Current Liabilities
Accounts payable	38,395	48,815
Accrued expenses	31,061	51,613
Current taxes, payable and deferred	1,336	1,632
Intercompany advances, net	43,972	81,141
Short-term debt and current maturities of long-term obligations	880	0
Disposal Group, Including Discontinued Operation, Liabilities		632
Total Current Liabilities	115,644	183,833
Long-Term Debt	35,326	15,351
Other Long-Term Obligations	31,821	28,551
Inercompany advances, net	2,013,835	1,813,995
Total Shareholders’ Equity	462,818	565,322
Total Liabilities and Shareholders’ Equity	2,659,444	2,607,052
Combined Guarantor Subsidiaries
Current Assets
Cash and cash equivalents	314	355	313	1,018
Trade receivables, net	20,020	21,979
Installment receivables, net	361	292
Inventories, net	25,418	25,784
Deferred income taxes		0
Intercompany advance	109	976
Other current assets	186	228
Disposal Group, Including Discontinued Operation, Assets, Current		13,406
Total Current Assets	46,408	63,020
Investment in subsidiaries	467,352	491,541
Intercompany advances, net	1,881,567	1,685,366
Other Assets	727	657
Intangibles	388	393
Property and Equipment, net	10,170	7,209
Goodwill	12,142	11,968
Total Assets	2,418,754	2,260,154
Current Liabilities
Accounts payable	8,699	6,363
Accrued expenses	20,940	20,533
Current taxes, payable and deferred	0	0
Intercompany advances, net	2,412	1,738
Short-term debt and current maturities of long-term obligations	275	0
Disposal Group, Including Discontinued Operation, Liabilities		381
Total Current Liabilities	32,326	29,015
Long-Term Debt	7,257	0
Other Long-Term Obligations	1,752	0
Inercompany advances, net	1,116,834	1,051,170
Total Shareholders’ Equity	1,260,585	1,179,969
Total Liabilities and Shareholders’ Equity	2,418,754	2,260,154
Combined Non-Guarantor Subsidiaries
Current Assets
Cash and cash equivalents	45,694	31,236	28,071	31,999
Trade receivables, net	70,101	85,198
Installment receivables, net	784	762
Inventories, net	103,173	107,139
Deferred income taxes		2,048
Intercompany advance	49,022	84,816
Other current assets	32,384	33,123
Disposal Group, Including Discontinued Operation, Assets, Current		0
Total Current Assets	301,158	344,322
Investment in subsidiaries	0	0
Intercompany advances, net	185,389	184,652
Other Assets	837	1,441
Intangibles	30,489	37,334
Property and Equipment, net	36,131	42,818
Goodwill	349,538	409,051
Total Assets	903,542	1,019,618
Current Liabilities
Accounts payable	58,514	64,749
Accrued expenses	74,910	88,188
Current taxes, payable and deferred	16,252	11,002
Intercompany advances, net	11,140	12,921
Short-term debt and current maturities of long-term obligations	873	959
Disposal Group, Including Discontinued Operation, Liabilities		0
Total Current Liabilities	161,689	177,819
Long-Term Debt	2,509	4,021
Other Long-Term Obligations	49,016	60,254
Inercompany advances, net	51,407	54,088
Total Shareholders’ Equity	638,921	723,436
Total Liabilities and Shareholders’ Equity	903,542	1,019,618
Eliminations
Current Assets
Cash and cash equivalents	0	0	$ 0	$ 0
Trade receivables, net	0	0
Installment receivables, net	0	0
Inventories, net	(2,084)	(2,383)
Deferred income taxes		0
Intercompany advance	(57,523)	(95,799)
Other current assets	(4,491)	(4,635)
Disposal Group, Including Discontinued Operation, Assets, Current		0
Total Current Assets	(64,098)	(102,817)
Investment in subsidiaries	(1,897,422)	(1,901,023)
Intercompany advances, net	(3,182,077)	(2,919,253)
Other Assets	0	0
Intangibles	0	0
Property and Equipment, net	0	0
Goodwill	0	0
Total Assets	(5,143,597)	(4,923,093)
Current Liabilities
Accounts payable	0	0
Accrued expenses	(4,491)	(4,635)
Current taxes, payable and deferred	0	0
Intercompany advances, net	(57,524)	(95,800)
Short-term debt and current maturities of long-term obligations	0	0
Disposal Group, Including Discontinued Operation, Liabilities		0
Total Current Liabilities	(62,015)	(100,435)
Long-Term Debt	0	0
Other Long-Term Obligations	0	0
Inercompany advances, net	(3,182,076)	(2,919,253)
Total Shareholders’ Equity	(1,899,506)	(1,903,405)
Total Liabilities and Shareholders’ Equity	$ (5,143,597)	$ (4,923,093)
Convertible Subordinated Debt | Convertible senior subordinated debentures at 4.125%, due in February 2027
Condensed Financial Statements, Captions [Line Items]
Interest rate (as a percent)	4.125%

Supplemental Guarantor Infor132

Supplemental Guarantor Information - Consolidating Condensed Statement of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Condensed Financial Statements, Captions [Line Items]
Net Cash Provided (Used) by Operating Activities	$ (5,378)	$ 8,892	$ 10,054
Investing Activities
Purchases of property and equipment	(7,522)	(12,327)	(14,158)
Proceeds from sale of property and equipment	23,117	2,521	885
Proceeds from sale of businesses	13,700	21,870	187,552
Other long-term assets	15,003	20,949	1,001
Other	78	569	65
Net Cash Provided for Investing Activities	44,376	33,582	175,345
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	219,603	255,658	352,455
Payments on revolving lines of credit and long-term borrowings	(232,808)	(286,712)	(545,874)
Proceeds from exercise of equity awards	2,402	480	512
Payments of Financing Costs	(1,954)	0	0
Payment of dividends	(1,589)	(1,584)	(1,581)
Net Cash Used by Financing Activities	(14,346)	(32,158)	(194,488)
Effect of exchange rate changes on cash	(3,528)	(1,170)	83
Increase (decrease) in cash and cash equivalents	21,124	9,146	(9,006)
Cash and cash equivalents at beginning of year	38,931	29,785	38,791
Cash and cash equivalents at end of year	60,055	38,931	29,785
The Company (Parent)
Condensed Financial Statements, Captions [Line Items]
Net Cash Provided (Used) by Operating Activities	(26,382)	(34,135)	11,566
Investing Activities
Purchases of property and equipment	(464)	(2,256)	(3,601)
Proceeds from sale of property and equipment	23,040	0	4
Proceeds from sale of businesses	0	0	0
Other long-term assets	14,488	20,926	833
Other	0	44,420	181,195
Net Cash Provided for Investing Activities	37,064	63,090	178,431
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	214,755	255,658	323,187
Payments on revolving lines of credit and long-term borrowings	(217,589)	(277,570)	(516,488)
Proceeds from exercise of equity awards	2,402	480	512
Payments of Financing Costs	(1,954)
Payment of dividends	(1,589)	(1,584)	(1,581)
Net Cash Used by Financing Activities	(3,975)	(23,016)	(194,370)
Effect of exchange rate changes on cash	0	0	0
Increase (decrease) in cash and cash equivalents	6,707	5,939	(4,373)
Cash and cash equivalents at beginning of year	7,340	1,401	5,774
Cash and cash equivalents at end of year	14,047	7,340	1,401
Combined Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net Cash Provided (Used) by Operating Activities	2,125	(511)	(68,792)
Investing Activities
Purchases of property and equipment	(704)	(1,811)	(4,020)
Proceeds from sale of property and equipment	52	0	13
Proceeds from sale of businesses	13,700	21,870	187,552
Other long-term assets	0	0	0
Other	5	(14,393)	(113,067)
Net Cash Provided for Investing Activities	13,053	5,666	70,478
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	0	0	0
Payments on revolving lines of credit and long-term borrowings	(15,219)	(5,113)	(2,391)
Proceeds from exercise of equity awards	0	0	0
Payments of Financing Costs	0
Payment of dividends	0	0	0
Net Cash Used by Financing Activities	(15,219)	(5,113)	(2,391)
Effect of exchange rate changes on cash	0	0	0
Increase (decrease) in cash and cash equivalents	(41)	42	(705)
Cash and cash equivalents at beginning of year	355	313	1,018
Cash and cash equivalents at end of year	314	355	313
Combined Non-Guarantor Subsidiaries
Condensed Financial Statements, Captions [Line Items]
Net Cash Provided (Used) by Operating Activities	18,774	14,105	1,891
Investing Activities
Purchases of property and equipment	(6,354)	(8,260)	(6,537)
Proceeds from sale of property and equipment	25	2,521	868
Proceeds from sale of businesses	0	0	0
Other long-term assets	515	23	168
Other	178	(25)	20
Net Cash Provided for Investing Activities	(5,636)	(5,741)	(5,481)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	4,848	0	29,268
Payments on revolving lines of credit and long-term borrowings	0	(4,029)	(26,995)
Proceeds from exercise of equity awards	0	0	0
Payments of Financing Costs	0
Payment of dividends	0	0	(2,694)
Net Cash Used by Financing Activities	4,848	(4,029)	(421)
Effect of exchange rate changes on cash	(3,528)	(1,170)	83
Increase (decrease) in cash and cash equivalents	14,458	3,165	(3,928)
Cash and cash equivalents at beginning of year	31,236	28,071	31,999
Cash and cash equivalents at end of year	45,694	31,236	28,071
Eliminations
Condensed Financial Statements, Captions [Line Items]
Net Cash Provided (Used) by Operating Activities	105	29,433	65,389
Investing Activities
Purchases of property and equipment	0	0	0
Proceeds from sale of property and equipment	0	0	0
Proceeds from sale of businesses	0	0	0
Other long-term assets	0	0	0
Other	(105)	(29,433)	(68,083)
Net Cash Provided for Investing Activities	(105)	(29,433)	(68,083)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	0	0	0
Payments on revolving lines of credit and long-term borrowings	0	0	0
Proceeds from exercise of equity awards	0	0	0
Payments of Financing Costs	0
Payment of dividends	0	0	2,694
Net Cash Used by Financing Activities	0	0	2,694
Effect of exchange rate changes on cash	0	0	0
Increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents at beginning of year	0	0	0
Cash and cash equivalents at end of year	$ 0	$ 0	$ 0

Interim Financial Information

Interim Financial Information - (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 283,265	$ 283,776	$ 286,273	$ 289,024	$ 318,199	$ 320,520	$ 326,943	$ 304,501	$ 1,142,338		$ 1,270,163		$ 1,334,505
Gross profit	80,803	77,639	77,287	77,095	88,370	84,647	91,578	82,793	312,824		347,388		367,426
Earnings before income taxes	581	(790)	(6,492)	(5,039)	(8,385)	(26,375)	(11,580)	(16,870)	(11,740)		(63,210)		(43,459)
Net Loss from Continuing Operations	(2,929)	(7,790)	(8,217)	(7,514)	(6,685)	(28,725)	(14,455)	(18,895)	(26,450)		(68,760)		(54,334)
Net Earnings from Discontinued Operations	0	0	0	260	(2,700)	13,629	842	919	260		12,690		87,385
Net earnings (loss)	$ (2,929)	$ (7,790)	$ (8,217)	$ (7,254)	$ (9,385)	$ (15,096)	$ (13,613)	$ (17,976)	$ (26,190)		$ (56,070)		$ 33,051
Net loss from continuing operations - Basic (in dollars per share)	$ (0.09)	$ (0.24)	$ (0.26)	$ (0.23)	$ (0.21)	$ (0.90)	$ (0.45)	$ (0.59)	$ (0.82)		$ (2.15)		$ (1.70)
Net earnings (loss) from discontinued operations - Basic (in dollars per share	0	0	0	0.01	(0.08)	0.43	0.03	0.03	0.01		0.40		2.74
Net earnings (loss) per share - basic	(0.09)	(0.24)	(0.26)	(0.23)	(0.29)	(0.47)	(0.43)	(0.56)	(0.81)		(1.75)		1.04
Net loss from continuing operations assuming dilution (in dollars per share)	(0.09)	(0.24)	(0.26)	(0.23)	(0.21)	(0.90)	(0.45)	(0.59)	(0.82)	[1]	(2.15)	[1]	(1.70)	[1]
Net earnings (loss) from discontinued operations assuming dilution (in dollars per share)	0	0	0	0.01	(0.08)	0.42	0.03	0.03	0.01		0.39		2.73
Net Earnings (loss) per Share - Assuming Dilution (in dollars per share)	$ (0.09)	$ (0.24)	$ (0.26)	$ (0.23)	$ (0.29)	$ (0.47)	$ (0.43)	$ (0.56)	$ (0.81)	[1]	$ (1.75)	[1]	$ 1.03	[1]
[1]	Net earnings (loss) per share assuming dilution calculated utilizing weighted average shares outstanding - basic in periods in which there is a net loss.

Interim Financial Informatio134

Interim Financial Information - Narrative (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]
Loss Contingency Accrual, Net of Tax	$ (2,325,000)								$ (2,325,000)
Loss Contingency Accrual, Net of Tax, Per Diluted Share	$ (0.07)
Charges	$ 1,031,000		$ 689,000	$ 240,000	$ 2,705,000	$ 4,077,000	$ 2,090,000	$ 2,240,000	1,971,000	$ 11,112,000	$ 9,336,000	$ 11,395,000	$ 10,534,000
Restructuring charges, net of tax	$ 957,000		$ 635,000	$ 240,000	$ 2,732,000	$ 3,842,000	$ 1,711,000	$ 1,811,000
Restructuring charges, net of tax, per diluted share	$ 0.03		$ 0.02	$ 0.01	$ 0.09	$ 0.12	$ 0.05	$ 0.06
Product warranty expense						$ 9,256,000		$ 2,237,000
Product warranty expense, net of tax						$ 8,701,000		$ 2,100,000
Product warranty expense, net of tax, per diluted share						$ 0.27		$ 0.07
Write off of debt fees				$ 668,000				$ 1,070,000
Write off of debt fees, net of tax				$ 668,000				$ 1,070,000
Write off of debt fees per diluted share				$ 0.02				$ 0.03
Tax benefit (expense) from intra-period allocation		$ 3,400,000			$ (2,700,000)	$ 1,550,000			(140,000)	(7,175,000)	(3,455,000)
Tax benefit (expense) from intra-period allocation per diluted share		$ 0.11			$ (0.08)	$ 0.05
Loss Contingency Accrual, Period Increase (Decrease)									$ (2,325,000)	$ 11,493,000	7,264,000
Impairment of intangible assets					$ 4,788,000	$ 8,253,000					$ 1,523,000
Impairment of intangible assets, net of tax					$ 4,788,000	$ 8,253,000
Valuation tax expense per diluted share					$ 0.15	$ 0.26

Schedule II - Valuation and 135

Schedule II - Valuation and Qualifying Accounts - (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period		$ 17,822	$ 23,144	$ 25,232
Charged To Cost And Expenses		754	1,765	3,684
Additions (Deductions) Describe	[1]	(5,297)	(7,087)	(5,772)
Balance At End of Period		13,279	17,822	23,144
Inventory obsolescense reserve [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period		17,617	15,135	13,085
Charged To Cost And Expenses		5,054	5,993	5,310
Additions (Deductions) Describe	[2]	(5,983)	(3,511)	(3,260)
Balance At End of Period		16,688	17,617	15,135
Tax valuation allowances [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period		133,912	117,790	97,406
Charged To Cost And Expenses		19,717	33,195	1,078
Additions (Deductions) Describe	[3]	(1,657)	(17,073)	19,306
Balance At End of Period		151,972	133,912	117,790
Accrued warranty cost [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period		30,738	27,393	21,451
Charged To Cost And Expenses		9,899	26,097	19,394
Additions (Deductions) Describe	[2]	(17,817)	(22,752)	(13,452)
Balance At End of Period		22,820	30,738	27,393
Accrued product liability [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance At Beginning of Period		23,194	20,368	20,334
Charged To Cost And Expenses		5,250	5,910	7,039
Additions (Deductions) Describe	[4]	(10,735)	(3,084)	(7,005)
Balance At End of Period		$ 17,709	$ 23,194	$ 20,368
[1]	Uncollectible accounts written off, net of recoveries.
[2]	Amounts written off or payments incurred.
[3]	Other activity not affecting federal or foreign tax expense.
[4]	Loss and loss adjustment.